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1 Summary 
The identification of previously unknown targets as well as the development of efficacious 
inhibitors for known targets are key factors to make more patients benefit from tumor 
therapy. For instance, the role of two-pore channel 2 (TPC2), one of the few cation 
channels localized on endolysosomal membranes, in cancer remains poorly understood. 
Here, we report that TPC2 knockout reduces proliferation of liver cancer cells in vitro, 
affects their energy metabolism and successfully abrogates tumor growth in vivo. 
Concurrently, we have identified novel, simplified analogues of the alkaloid tetrandrine 
(SG-005 and SG-094) as potent TPC2 inhibitors by screening a library of 
benzyltetrahydroisoquinoline derivatives using cell proliferation assays, endolysosomal 
patch clamp and calcium imaging. Removal of dispensable substructures of the lead 
molecule tetrandrine increases antiproliferative properties against several cancer cell lines 
and impairs proangiogenic signaling of endothelial cells to a greater extent than 
tetrandrine. Simultaneously, toxic effects on non-cancerous cells are reduced, allowing in 
vivo administration and revealing the first TPC2 inhibitor with antitumor efficacy in mice 
(SG-094). Hence, our study unveils TPC2 as valid target for cancer therapy and provides 
novel, easily accessible tetrandrine analogues as promising option for effective 
pharmacological interference. 
Furthermore, in-depth studies were conducted to investigate a postulated mechanism of 
metabolic toxification of tetrandrine. A combined medicinal chemistry and cell biology 
approach showed that a reduction of the toxicity of tetrandrine cannot be achieved by 
replacing or eliminating the hypothesized metabolically instable functional group, clearly 
indicating that the proposed pathway is not the primary cause for the in vitro toxicity of 
tetrandrine and related alkaloids. 
Moreover, we have uncovered that the simplified tetrandrine congeners SG-005 and SG-
094 additionally inhibit P-glycoprotein (P-gp), a drug efflux pump associated with multidrug 
resistance and treatment failure in tumor therapy. Since no approved molecules targeting 
P-gp are currently available, SG-005 and SG-094 might represent promising candidates 
to treat drug-resistant cancers owing to their favorable drug-like properties. Generally, the 
dual mode of action of isoquinoline-based TPC2/P-gp antagonists is mentioned here for 
the first time. Based on this, the known third-generation P-gp inhibitor elacridar was 
exemplarily studied for its potential to block TPC2, revealing another potent TPC2 blocker 
and thereby challenging the assumption of elacridar specifically acting on efflux pumps. 
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Hence, on the one hand, a new lead structure (elacridar) for the development of 
prospective TPC2 blockers is provided. On the other hand, hints for common structural 
motifs on TPC2 and P-gp are given, which can facilitate the search for additional TPC2 
antagonists.    
We further uncovered that TPC2 and P-gp do not only share mutual small molecule 
inhibitors, but also seem to be functionally connected. This is reflected by the higher 
sensitivity of TPC2-deficient, drug-resistant leukemia cells to vincristine, opening the stage 
for further studying the implication of TPC2 in processes related to (P-gp-mediated) 
chemoresistance.    
Summarizing, this work clearly illustrates that the endolysosomal cation channel TPC2 is 
a suitable target for tumor therapy. Additionally, synthetically accessible, potent TPC2 
blockers were developed as promising preclinical candidates, making TPC2 a druggable 
protein target. Further, an implication of TPC2 and blockers of this channel in 
chemoresistance was uncovered, both by TPC2 promoting chemoresistance as well as 
by the dual action of isoquinolines on TPC2 and the drug efflux pump P-gp.      
 
Figure 1 I Targeting TPC2 and P-gp in cancer – the project at a glance 
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Histone deacetylase 6 (HDAC6) is another protein that has gained attention as target for 
tumor therapy. HDAC6 is primarily located to the cytoplasm, where it deacetylates several 
non-histone proteins and thereby alters critical cancer-related pathways. Selective 
targeting of HDAC6 is aimed to reduce the toxicity associated with pan-HDAC inhibition 
and, along this line, we have developed and characterized potent and selective HDAC6 
inhibitors (KV-46, KV-70, KV-181) with a phenothiazine system as cap group and a 
benzhydroxamic acid moiety as zinc-binding group. In accordance with effects of specific 
HDAC6 inhibition, KV-46, KV-70 and KV-181 are relatively non-toxic to healthy liver cells 
and moderately effective at reducing cancer cell proliferation and inducing apoptosis. 
Further, KV-46, KV-70 and KV-181 exposure increases the expression of critical protein 
markers of the unfolded protein response and the immune response, suggesting a 
potential benefit of combining HDAC6 inhibitors with proteasome inhibitors or 
immunomodulatory agents.  
 
Figure 2 I Characterization of HDAC6 inhibitors in cancer – the project at a glance  
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2 Introduction 
2.1 The need for identification of novel, druggable targets in cancer 
With an estimated number of 9.6 million deaths worldwide in 20181, cancer-related 
mortality represents a major health problem to date. Huge efforts have been made to 
identify suitable targets for cancer therapy and 109 protein targets could be addressed by 
85 protein-targeted oncology drugs in 20172. On the contrary, around 600 cancer drivers 
have been discovered, but a majority thereof lacks detailed biological investigation or 
remains to be targeted by antitumor agents2, 3. The need for the identification and 
validation of novel, druggable targets in cancer provided the rationale for this study. In the 
first part, benzylisoquinolines were utilized to block two-pore channel 2, a largely unknown 
target in cancer, but also to inhibit P-glycoprotein, a more established protein target. In the 
second part, benzhydroxamic acids were studied as subtype-selective inhibitors of histone 
deacetylase 6, a target with great potential in chemotherapy.      
2.2 Endolysosomal two-pore channel 2 as novel target for cancer therapy 
Two-pore channels (TPCs) are cation channels that span membranes of acidic vesicles 
of the endolysosomal (EL) system. EL ion channels are not targeted by anticancer drugs 
to date. Comprehensive information about structures of TPCs have long been scarce and 
reports about the ions they conduct were conflicting4. Very recent advantages, however, 
provided the first detailed view of an animal TPC5 and novel insights into the underlying 
mechanisms for ion selectivity6, respectively. There are two subtypes of TPCs in primates, 
TPC1 and TPC24. By cyro-electron microscopy, She et al.5 have resolved the structure of 
mouse TPC1, comprising two subunits, each of which consisting of two transmembrane 
domains, 6-TMI and 6-TMII (Figure 3). Opening of the channel is suggested to be 
mediated by cooperation between the two transmembrane domains. Binding of the 
endogenous agonist, the phosphoinositide PI(3,5)P2, to arginine residues of 6-TMI 
induces conformational changes to the pore, whereas 6-TMII acts as voltage sensor to 
finalize channel opening5. In contrast, opening of the other TPC subtype, TPC2, is not 
modulated by voltage changes4. The structure of TPC2 has not been resolved yet, but a 
recent report by Gerndt and coworkers6 improved the understanding of its ion permeability. 
It was shown that TPC2 conducts different ions (Na+, Ca2+) depending on its activation 
with either nicotinic acid adenine dinucleotide phosphate (NAADP) or PI(3,5)P2, leading 
to different effects on exocytosis and lysosomal pH6.  
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Figure 3 I Structure of murine TPC1. TPC1 consists of two subunits and each subunit has two 
transmembrane domains (6-TMI, 6-TMII) that are connected by a cytoplasmic linker. One TPC1 subunit is 
depicted here. Activation of the channel is facilitated by binding of the phosphoinositide PI(3,5)P2 (blue) to 
arginine residues (red) in 6-TMI and voltage sensing in 6-TMII by arginine residues (purple), resulting in ion 
passage from the vesicle interior. The figure was adapted from Patel et al.4.     
Aberrant TPC2 function is linked to several diseases, including Parkinson’s diseases, fatty 
liver disease, viral infections, diabetes and cardiac dysfunction7. Furthermore, high gene 
expression of TPC2 was correlated with poor survival probability of prostate cancer 
patients8 and there is growing evidence that TPCs are necessary for sustaining cancer 
hallmarks9, 10. Therefore, TPC2 might serve as an innovative target for antitumor drugs. In 
particular, silencing of TPC2, predominantly found on lysosomal membranes11, reduced 
migration and adhesion of invasive tumor cells12. The EL system facilitates trafficking of 
integrins and the disturbance of this recycling process impaired cancer cell migration in 
vitro and metastasis in vivo12. Furthermore, vessel formation, a fundamental step for 
vascularization of solid tumors, was reduced in TPC2, but not in TPC1 knockout mice13. 
Whether TPCs, especially TPC2, are involved in other cancer hallmarks, such as 
sustained proliferation and deregulated cellular energetics14, however, remains largely 
unknown and was therefore investigated in the context of this study.  
In the past years, several efforts have been made in the search for pharmacological 
inhibitors of TPCs, illustrating the increasing importance of the ion channels as novel drug 
targets. The NAADP antagonist and indirect TPC2 blocker trans-Ned-19 (Ned-19) reduced 
NAADP-induced Ca2+ release and was able to prevent the activation of the 
VEGFR2/NAADP/TPC2/Ca2+ signaling pathway13, as well as cancer cell migration12, but 
required high micromolar doses (≥ 100 µM)12, 13. Similarly, high concentrations (≥ 500 µM) 
of the direct TPC2 inhibitor naringenin were necessary to affect VEGF-evoked tube 
formation15. Furthermore, naringenin treatment bears the risk of undesired drug-drug 
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interactions due to inhibition of cytochrome P450 (CYP) enzymes, including CYP1A216 
and CYP3A417, 18, and can lead to QTc prolongation through acting on cardiac hERG 
channels19, 20.  Penny and coworkers21 recently extended the limited number of 
compounds directly inhibiting TPC2 with the dopamine receptor antagonist fluphenazine 
and the selective estrogen receptor modulator (SERM) raloxifene. The first-generation 
antipsychotic drug fluphenazine, however, can cause serious extrapyramidal side 
effects22, and raloxifene, used for treatment and prevention of osteoporosis, is approved 
for postmenopausal women only23. Consequently, there is an emerging need for the 
development of inhibitors with drug-like properties and antitumor efficacy, and, 
concurrently, to unravel the involvement of TPC2 in cancer.  
Tetrandrine, an alkaloid isolated from Stephania tetrandra, was recently shown to 
effectively inhibit cancer cell migration12 and infections with Ebola24, MERS-CoV25 and 
SARS-CoV-226 viruses via directly acting on TPCs and thereby represents a promising 
lead structure for the development of TPC2 blockers. However, its poor solubility requires 
acidification of the injection solution before in vivo application24, 27 and its toxicity in animal 
models27, 28 are serious drawbacks of this compound. In addition, tetrandrine can only be 
obtained by extraction of plants or by complex chemical synthesis that involves 20 steps 
to gain enantiomerically pure tetrandrine 29, or 12 steps to obtain racemic tetrandrine30. 
We aimed to overcome the outlined drawbacks by chemical simplification, substitution and 
derivatization of tetrandrine. 
2.3 Successful inhibition of the efflux transporter P-glycoprotein – an unmet 
need in tumor therapy 
Pharmacological activities of tetrandrine are diverse and not limited to modulation of TPCs. 
These include, among many others, antihypertensive31, anti-inflammatory32 and multidrug 
resistance reversing33, 34 effects by blocking L-Type Ca2+ channels31, proinflammatory 
cytokine production32 and the permeability-glycoprotein (P-glycoprotein, P-gp, ABCB1A)33, 
34, 35. Most importantly, tetrandrine has advanced into early phase clinical studies as P-gp 
inhibitor under the brand name CBT-1® (CBA Research, Inc.)35. Although three clinical 
studies have either been completed or were announced (NCT00437749, NCT00972205, 
NCT03002805)36, no study results were published since 2012 (NCT00972205)35. 
Therefore, the current development stage of the molecule as P-gp inhibitor remains 
unclear and the reasons for the failure of its clinical progress are somewhat speculative. 
P-gp acts as an efflux pump that is capable of decreasing influx of cytostatic agents into 
tumor cells in an adenosine 5’-triphosphate (ATP)-dependent manner37. Overexpression 
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of P-gp is regarded as a major contributor to treatment failure in chemotherapy and the 
phenomenon of multidrug resistance (MDR)38. Generally, the development of efficacious 
P-gp inhibitors remains a high unmet need in clinics since no such approved drugs are 
available39. In the last two decades, huge efforts have been made by both academia and 
industry in the search for P-gp inhibitors that can be used to overcome drug resistance in 
chemotherapy. With respect to their specificity and affinity, P-gp inhibitors can be divided 
into three generations.  
The clinical use of first-generation inhibitors, approved drugs that exert inhibitory P-gp 
activity, such as verapamil, cyclosporine A and tamoxifen, is restricted by their dose-
related toxicity to achieve the desired effect40. The affinity of second-generation inhibitors, 
including valspodar, an analogue of cyclosporine A, and dexverapamil, the D-isomer of 
verapamil, to P-gp could be improved, but their non-specific interaction with CYP enzymes 
represents a major drawback due to potential drug-drug interactions with antitumor 
agents. In contrast, third-generation inhibitors have a high affinity to P-gp and do not 
interact with CYP enzymes39. Of them, elacridar was tested in clinical phase I41, 42 and 
tariquidar, laniquidar and zosuquidar have entered clinical phase II and III studies as add-
on therapeutic for the treatment of newly diagnosed and/or refractory malignancies 
(NCT00048633, NCT00046930, NCT00028873)36, 39. Even though a plethora of in vitro 
and in vivo data underlined effective P-gp blockade by third-generation inhibitors and, in 
turn, successful sensitization of drug-resistant cells and tumors, these molecules have 
failed in clinical studies43, 44. Yet, the underlying reasons have not been completely 
understood. Poor pharmacokinetic properties of lipophilic third-generation P-gp inhibitors, 
undesired interactions with efflux transporters of the kidney, intestine, brain etc. leading to 
enforced accumulation of cytostatics in those organs and adverse events as well as the 
presence of P-gp-independent resistance mechanisms are hypothesized to play a role39, 
43. Consequently, translatability of P-gp blockade into clinical practice remains a major 
problem to be solved.  
Recently, natural compounds, including bisbenzylisoquinoline alkaloids, have gained 
attention as P-gp inhibitors with tetrandrine being the most prominent representative37, 38. 
Therefore, we aimed to test tetrandrine-derived TPC2 blockers and related 
benzylisoquinoline alkaloids additionally for their potential to inhibit P-gp and to reverse 
chemoresistance.  
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2.4 Targeting lysosomal ion channels as potential strategy to overcome 
chemoresistance in cancer  
P-gp is a membrane-bound protein, usually embedded in the plasma membrane, actively 
transporting cargo into the extracellular space. Recently, lysosomal overexpression of P-
gp has been reported in chemoresistant cells. Mechanistically, it is hypothesized that P-
gp is incorporated into lysosomal membranes during trafficking and recycling events, 
rather than being redistributed after de-novo synthesis45, 46, 47. Thus, lysosomal P-gp can 
contribute to the so-called drug safe house effect. In particular, the acidity of lysosomes 
facilitates luminal accumulation of cytostatic weak bases, leads to their protonation and 
reduces their ability to pass the lysosomal membrane, causing lysosomal drug 
sequestration. Cytostatics enter the lysosome either by passive diffusion along the pH 
gradient or may be actively transported across the membrane by inward turned P-gp drug 
efflux pumps embedded in the lysosomal membrane45, 46. Consequently, localization of P-
gp to lysosomal membranes can mediate drug resistance.  
Since protein trafficking is dependent on proper function of EL membrane-integrated 
proteins, such as ion channels9, 12, 48, targeting of those proteins might present a successful 
strategy to sensitize drug-resistant cells towards antitumor agents. In that context, 
knockdown or inhibition of acid sphingomyelinase und V-ATPase, which are responsible 
for hydrolysis of sphingomyelin and lysosomal acidification, respectively, were shown to 
overcome chemoresistance49, 50. If blockade of lysosomal ion channels, namely TPC2, 
increases the sensitivity of drug-resistant cancer cells towards cytostatics, is unknown to 
date and was investigated in this study. 
The concept of targeting lysosomes in general as well as lysosomal proteins in particular 
might represent a promising option to overcome chemoresistance in cancer therapy. It 
was reviewed as part of this work and published in the journal Frontiers in Oncology – 
Section Molecular and Cellular Oncology (Frontiers Media) in 202051.   
2.5 Histone Deacetylase 6 - an emerging drug target in cancer therapy 
Cancer hallmark characteristics, such as proliferation and migration that were introduced 
in chapter 2.2, are the consequences of genetic alterations, but also epigenetic 
mechanisms play a crucial role52. Since epigenetic changes, such as DNA methylation 
and histone modifications, are potentially reversible, reverting those alterations represents 
an opportunity for pharmacological intervention in tumor therapy.  
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Posttranslational modifications of lysines on histones include acetylation, catalyzed by 
histone acetylases (HATs), and deacetylation, catalyzed by histone deacetylases 
(HDACs)52. There are 18 HDAC members which can be classified into class I (HDAC1, 2, 
3, 8), class II (HDAC4, 5, 6, 7, 9, 10) and class IV (HDAC11) HDACs53. Whereas the 
substrates of most zinc-dependent HDACs are histones, the HDAC6 isozyme is unique in 
that it is predominantly localized in the cytoplasm and as a result mainly deacetylates non-
histone proteins as α-tubulin in microtubules54, the heat shock protein 90 (HSP90) 
chaperone55 and cortactin56, among others. By formation of complexes with its partner 
proteins, HDAC6 regulates many important cellular processes such as cell motility, cell 
spreading, misfolded protein degradation, transcription, cell proliferation and death, and 
stress or immune response57. In consequence, misregulation of HDAC6 activity is 
associated with a variety of human diseases, which highlights it as a potential therapeutic 
target. HDAC6 is implicated in various neurodegenerative disorders, including 
Alzheimer’s, Parkinson’s, and Huntington’s diseases58 as well as autoimmune and 
inflammatory disorders59. Moreover, high expression levels of HDAC6 seem to play a 
crucial role in the pathogenesis of cancer, for instance, as found in acute myeloid and 
myeloblastic leukemia, as well as in breast and ovarian cancer60.  
Until now, all approved HDAC inhibitors for cancer treatment target multiple HDACs. Their 
poor selectivity, however, can dose-dependently cause serious side effects53, 61, which 
might limit their clinical use in oncology and beyond. Therefore, the development of 
inhibitors for the particular isoform of interest is of great relevance, and selective inhibition 
of HDAC6 may lead to fewer severe side effects62. 
Various selective HDAC6 inhibitors have emerged over the years, mainly containing a 
hydroxamic acid as zinc-binding group (ZBG) (Figure 4). For instance, tubastatin A, a γ-
carboline-based hydroxamic acid with a benzylic linker, was developed utilizing a 
structure-based drug design combined with homology modeling and displays high potency 
on HDAC6 with an IC50 of 15 nM and over 1000-fold selectivity over HDAC163. Tubastatin 
A showed neuroprotective effects without adverse toxicity and in recent preclinical tests in 
animal models, it reduced stroke-induced brain infarction and functional deficits64 as well 
as reverted cognitive impairment in Alzheimer’s disease transgenic mice65. Ricolinostat, 
another potent but less selective inhibitor with at least 10-fold selectivity for HDAC6 
relative to class I HDACs, possesses favorable characteristics for drug development. In 
combination with the proteasome inhibitor bortezomib, ricolinostat showed synergistic 
anti-multiple myeloma activity in vitro66. Ricolinostat is the first HDAC6 inhibitor with 
reduced class I activity that has entered clinical trials and it is currently investigated in 
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patients with relapsed or refractory multiple myeloma in combination with lenalidomide 
and dexamethasone as well as with bortezomib and dexamethasone67, 68. 
A large number of HDAC inhibitors share common structural features, including the ZBG, 
the linker, and the cap group (Figure 4). A key point to gain subtype selectivity is the 
capping motif, which interacts with the surface of the wide basin surrounding the binding 
pocket of the enzyme69. On the basis of the knowledge of the structural parameters 
essential for selective HDAC6 inhibitor activity, we chose to investigate and characterize 
new hydroxamate-based HDAC6 inhibitors that might gain the desired isoenzyme 
selectivity by their capping motif (lead structure: KV-46, Figure 4).  
 
Figure 4 I Structures of known HDAC6 inhibitors (tubastatin A, ricolinostat) and the novel 
hydroxamate-based lead structure KV46. The general structure of these inhibitors consists of a cap group 
(in red), a linker (in green) and a zinc-binding group (ZBG, in blue). 
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2.6 Aims of the study 
This study’s main objectives were, on the one hand, to explore the suitability of TPC2 as 
target for tumor therapy and, concurrently, we aimed to develop efficacious TPC2 
blockers. On the other hand, novel inhibitors of known, cancer-related targets, namely P-
gp and HDAC6, should be identified and investigated.    
 
Part I: TPC2, P-gp and tetrahydroisoquinolines 
1. Elucidation of the role of the lysosomal ion channel TPC2 as suitable target for 
tumor therapy by studying the impact of genetic TPC2 knockout on proliferation, 
tumor growth and energy metabolism  
2. Development of synthetically accessible TPC2 inhibitors with improved drug-like 
properties by simplification of the bisbenzylisoquinoline alkaloid tetrandrine 
3. Studies on CYP3A4-mediated toxification of tetrandrine 
4. Testing of advanced TPC2 blocker candidates for their potential to inhibit the efflux 
pump P-gp and to reverse chemoresistance 
5. Determination of potential chemosensitizing effects of genetic TPC2 knockout on 
multidrug resistant leukemia cells 
6. Biological characterization of the isoquinoline-benzylisoquinoline alkaloid 
muraricine 
Part II: HDAC6 inhibitors 
1. Functional characterization of the HDAC6 inhibitors KV-46, KV-70 and KV-181 
(phenothiazine-based benzhydroxamic acids) in tumor cells concerning 
proliferation and apoptosis 
2. Analysis of toxicity of KV-46, KV-70 and KV-181 to hepatocyte-like cells 
3. Studies on the influence of KV-46, KV-70 and KV-181 on markers of the unfolded 
protein response and immune checkpoints 
  
Introduction 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
  
Materials and Methods 
14 
 
3 Materials and Methods 
3.1 Materials 
3.1.1 Compounds 
Compound Producer/source 
berbamine dihydrochloride Sigma-Aldrich, Taufkirchen, Germany 
cepharanthine Carbosynth, Compton, Berkshire, UK 
dauricine Carbosynth, Compton, Berkshire, UK 
elacridar Sellekchem, Houston, USA 
KV compounds 
Katharina Vögerl (Prof. Bracher, LMU 
Munich) 
oxyacanthine abcr, Karlsruhe, Germany 
rac-muraricine (muraricine) Ramona Schütz (Prof. Bracher, LMU Munich) 
rac-naringenin (naringenin) Sigma-Aldrich, Taufkirchen, Germany 
RMS compounds Ramona Schütz (Prof. Bracher, LMU Munich) 
SG compounds Susanne Gerndt (Prof. Bracher, LMU Munich) 
sorafenib Enzo Life Sciences, Farmingdale, USA 
tetrandrine Prof. Peter Pachaly 
TPCA1-N Susanne Gerndt (Prof. Bracher, LMU Munich) 
TPCA1-P Susanne Gerndt (Prof. Bracher, LMU Munich) 
trans-Ned-19 (Ned-19) Tocris Bioscience, Bristol, UK 
vincristine Adipogen Corporation, San Diego, USA 
Z compounds Prof. Meinhart Zenk 
Table 1 I Compounds 
3.1.2 Reagents: Biochemicals, kits, inhibitors and cell culture reagents 
Reagent Producer 
Amaxa Nucleofector Kit C Lonza, Basel, Switzerland 
ATP (25 mM) Lucigen, Wisconsin, USA 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford reagent Roti® Quant Bio-Rad, Munich, Germany 
Calcein-AM Biomol GmbH, Hamburg, Germany 
CellTiter-Blue® reagent Promega, Mannheim, Germany 
CellTiter-Glo® reagent Promega, Mannheim, Germany 
CellTrace™ CFSE Reagent Thermo Fisher, Waltham, USA 
Collagen G Biochrom AG, Berlin, Germany 
Complete® Roche Diagnostics, Penzberg, Germany 
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Reagent Producer 
Corning® Cell-TakTM Cell and Tissue 
Adhesive  
Corning Inc., Corning, USA 
CYP3A4 P450-GloTM assay Promega, Mannheim, Germany 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen, Germany 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
PAA Laboratories, Pasching, Austria 
Dulbecco’s Modified Eagle Medium 
(DMEM) 5030-10X1L Powder 
Sigma-Aldrich, Taufkirchen, Germany 
EGCM Kit enhanced PELO Biotech GmbH, Martinsried, Germany 
Ethylendiaminetetraacetic acid (EDTA) Sigma Aldrich, Taufkirchen, Germany 
FastAPTM Thermosensitive Alkaline 
Phosphatase and buffers 
Thermo Fisher, Waltham, USA 
FastDigest restriction enzymes and 
buffer 
Thermo Fisher, Waltham, USA 
Fetal calf serum (FCS) Biochrom AG, Berlin, Germany 
G418 powder Sigma-Aldrich, Taufkirchen, Germany 
GlutaMAXTM Supplement Life Technologies, Eugene, USA 
Glycerol Applichem¸ Darmstadt, Germany 
HepaRG™ Maintenance/Metabolism 
Medium Supplement (5X) 
Life Technologies, Eugene, USA 
HepaRG™ Thaw, Plate, & General 
Purpose Medium Supplement (5X) 
Life Technologies, Eugene, USA 
High-Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, Waltham, USA 
ibidiTreat µ-slides Ibidi GmbH, Munich, Germany 
JC-1 Thermo Fisher, Waltham, USA 
L-Glutamine Sigma-Aldrich, Taufkirchen, Germany 
LipofectamineTM 3000 transfection 
reagent 
Thermo Fisher, Waltham, USA 
Live Cell Imaging Solution Life Technologies, Eugene, USA 
LysoTracker-RedTM DND-99 Thermo Fisher, Waltham, USA 
MicroAmp® Fast Optical 96-Well 
Reaction Plate, 0.1 mL 
Applied Biosystems, Waltham, USA 
MicroAmp® Optical Adhesive Film Applied Biosystems, Waltham, USA 
Millipore Express® PLUS membrane 
filter (0.22 µM) 
Merck Millipore, Darmstadt, Germany 
MitoTracker™ Green FM  Thermo Fisher, Waltham, USA 
Nitrocellulose membrane (0.2 µM) 
Hybond-ECLTM, Amersham Bioscience, 
Freiburg, Germany 
Non-fat dry milk powder Carl Roth, Karlsruhe, Germany 
Page Ruler™ Prestained Protein 
Ladder 
Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
peqGOLD agarose, universal VWR international, Radnor, USA 
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Reagent Producer 
Phenymethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Taufkirchen, Germany 
Phusion Green Hot Start II High-Fidelity 
Polymerase 
Thermo Fisher, Waltham, USA 
PlasmidSafe buffer (10X) Lucigen, Wisconsin, USA 
PlasmidSafe Exonuclease Lucigen, Wisconsin, USA 
Polyacrylamide Carl Roth, Karlsruhe, Germany 
Poly-D-lysine hydrobromide (mol wt 
70,000-150,000) 
Sigma-Aldrich, Taufkirchen, Germany 
Polyvinylidene difluoride (PVDF) 
membrane (0.2 µM) 
Hybond-ECLTM, Amersham Bioscience, 
Freiburg, Germany 
PowerUp™ SYBR® Green Master Mix Applied Biosystems, Waltham, USA 
Primers metabion, Planegg, Germany 
Puromycin Sigma-Aldrich, Taufkirchen, Germany 
Q5® High-Fidelity DNA Polymerase New England Biolabs, Ipswich, USA 
QIAGEN Minprep and Maxiprep kits QIAGEN, Hilden, Germany 
RNeasy® Mini Kit (250) QIAGEN, Hilden, Germany 
RPMI 1640 PAN Biotech, Aidenbach, Germany 
RPMI 1640 without phenol red PAN Biotech, Aidenbach, Germany 
Seahorse XF Glycolysis Stress Test Kit Agilent Technologies, Santa Clara, USA 
Seahorse XFe96 FluxPaks (inc. mini) Agilent Technologies, Santa Clara, USA 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodium fluoride (NaF) Merck, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) ICN, Biomedicals, Aurora, OH, USA 
Sodiumdodecylsulfate (SDS) Carl Roth, Karlsruhe, Germany 
T4 DNA ligase and ligation buffer Thermo Fisher, Waltham, USA 
T7 DNA Endonuclease I and buffers New England Biolabs, Ipswich, USA 
Tris Base Sigma-Aldrich, Taufkirchen, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween 20 Sigma-Aldrich, Taufkirchen, Germany 
William's E Medium (1X) Life Technologies, Eugene, USA 
Table 2 I Reagents 
Materials and Methods 
17 
 
3.1.3 Technical equipment 
Device Producer 
BD FACS Canto II BD Biosciences 
ChemiDoc™ Touch Imaging System Bio-Rad Laboratories GmbH 
E plate 16 well ACEA Biosciences 
Ficoll-PaqueTM PLUS density gradient 
medium and PLUS solution 
GE Healthcare 
Leica Dmil microscope Leica Microsystems 
Leica TCS SP8 confocal laser scanning 
microscope 
Leica Microsystems 
Millipore Express® PLUS membrane filter Merck Millipore 
Nanodrop® Spectrophotometer PEQLAB Biotechnologie GmbH 
Orion II microplate Luminometer Berthold Detection Systems GmbH 
Primus 25 advanced® Thermocycler PEQLAB Biotechnologie GmbH 
QuantStudio™ 3 Real-Time PCR System Applied Biosystems 
RTCA device ACEA Biosciences 
Seahorse XFe96 Analyzer Agilent Technologies 
SpectraFluor PlusTM Tecan 
Table 3 I Technical equipment 
3.2 Cell culture 
3.2.1 Cell culture buffers and solutions 
PBS (pH 7.4)    Trypsin/EDTA (T/E)   
NaCl 132.2 mM  Trypsin 0.05 % 
Na2HPO4 10.4 mM  EDTA 0.02 % 
KH2PO4 3.2 mM  PBS   
H2O      
     
PBS+Ca2+/Mg2+ (pH 
7.4) 
  
 
Thaw, plate and general 
medium (HepaRG™ cells) 
  
NaCl 137 mM 
 
HepaRG™ Thaw, Plate, & 
General Purpose Medium 
Supplement 
1 bottle 
KCl 2.68 mM  GlutaMAXTM Supplement 5 mL 
Na2HPO4 8.10 mM  William's E Medium (1X) 500 mL 
KH2PO4 1.47 mM    
MgCl2 0.25 mM    
H2O      
     
Materials and Methods 
18 
 
Growth medium    
 
Maintenance and 
differentiation medium 
(HepaRG™ cells) 
  
DMEM/RPMI 1640 500 mL 
 
HepaRG™ 
Maintenance/Metabolism 
Medium Supplement (5X) 
1 bottle 
FCSgold 50 mL  GlutaMAXTM Supplement 5 mL 
   William's E Medium (1X) 500 mL 
     
Freezing medium  
(HUH7 cells) 
  
 
Collagen G   
DMEM/RPMI 1640 70 %  Collagen G 0.001 % 
FCSgold 50 mL  PBS   
DMSO 10 %    
Table 4 I Cell culture buffers and solutions 
3.2.2 Cell lines 
HepG2, HEK293 (ACC 305) and MCF7 cells were obtained from German Research 
Centre of Biological Material (DSMZ). HCT-15 cells were purchased from ATCC. HUH7 
cells were obtained from Japanese Collection of Research Bioresources (JCRB). RIL175 
cells were kindly provided by Prof. Simon Rothenfußer (Center of Integrated Protein 
Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Internal 
Medicine IV, Klinikum der Universität München, Munich, Germany). T24 cells were 
obtained from Dr. B. Mayer (Surgical Clinic, LMU, Munich). MDA-MB-231 cells were 
purchased from Cell Line Service Eppelheim. Vincristine-resistant (VCR-R) CEM cells 
were a kind gift from Prof. Maria Kavallaris (University of New South Wales, Australia). 
VCR-R CEM cells that are mainly resistant to vincristine, but also cross-resistant to a 
variety of other antitumor agents, were generated and described by Haber and 
coworkers70. Sorafenib-resistant HUH7 cells were generated by Maximilian Ardelt and 
Martina Meßner (Prof. Pachmayr, PMU Salzburg).  
HepG2, HUH7, MCF7, MDA-MB-231, RIL175 and T24 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM), supplemented with fetal calf serum (FCS, 10 %, PAA 
Laboratories). HCT-15 and VCR-R CEM cells were cultured in RPMI 1640, supplemented 
with fetal calf serum (FCS, 10 %).  
Human umbilical vein endothelial cells (HUVECs) were purchased from Promocell and 
cultivated with ECGM Kit enhanced (PELO Biotech) supplemented with 10% (FCS) and 
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1% penicillin/streptomycin/amphotericin B (all purchased from PAN Biotech). HUVECs 
were cultured for a maximum of six passages.   
Between thawing and seeding, HepaRG® cells were cultivated in thaw, plate and general 
medium. For differentiation, HepaRG® cells were seeded in 6 well plates at a density of 
0.5 × 106 cells per well in 2 mL of maintenance and differentiation medium for 7 days. 
Maintenance and differentiation medium was exchanged twice per week.  
All cells were cultured at 37 °C at constant humidity with 5% CO2. Before seeding of 
adherent cells, all culture flasks, multiwell plates and dishes were coated with collagen G 
(0.001 % in PBS). 
PBMCs were isolated and cultured as described in 3.24.  
3.2.3 Passaging 
When cells nearly reached confluency, they were split 1:2-1:10 and sub-cultured in 75 cm2 
culture flasks or seeded in multiwell plates or dishes for further experimental use. For 
passaging, culture medium was aspired, cells were washed with pre-warmed PBS and 
detached by incubation with pre-warmed trypsin/ethylenediaminetetraacetic acid (EDTA) 
(T/E) solution for 3-5 min at 37 °C. Thereafter, culture medium was added to stop tryptic 
digestion and T/E solution was removed by centrifugation (1000 rpm, 5 min, 20 °C) and 
addition of new culture medium.  
3.2.4 Freezing and thawing 
Before freezing, cells were cultured to reach confluency in a 150 cm2 flask. Washing and 
cell detachment was conducted as described in 3.2.3. After centrifugation (1000 rpm, 
5 min, 20 °C), cells were re-suspended in ice-cold freezing medium and transferred into 
cryovials at a cell density of 3 × 106 cells per 1.5 mL aliquot. Following an initial storage at 
- 80 °C for at least 24 h, cryovials were transferred into liquid nitrogen tanks (- 196 °C) for 
long-term storage.  
For thawing, the cryovial content was mixed with pre-warmed culture medium. After DMSO 
removal by centrifugation (1000 rpm, 5 min, 20 °C), the cell pellet was re-suspended in 
culture medium and initially transferred into a 25 cm2 flask for 24 h before cells were 
cultured in a 75 cm2 flask.  
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3.3 Apoptosis assays 
VCR-R CEM cells were seeded at a density of 0.125 × 106 cells per well of a 24 well plate 
and incubated for 4 h at 37 °C. Treatment was performed with the indicated concentrations 
for 48 h. Apoptosis was determined by propidium iodide staining as described before 
(Nicoletti et al.) on a BD FACS Canto II (BD Biosciences). Briefly, cell suspensions were 
transferred into pre-cooled FACS tubes, centrifuged for 5 min at 400 g, washed with an 
equal volume of ice-cold PBS, centrifuged again for 5 min at 400 g, and resuspended in 
250 µL ice-cold hypotonic fluorochrome solution (Table 5). Cells were kept in the dark at 
4 °C for at least 30 min prior to flow cytometric analysis.  
Hypotonic fluorochrome 
solution (HFS) 
 
sodium citrate 0.1 % (w/v) 
Triton X-100 0.1 % (v/v) 
propidium iodide 50 µg/ml 
H2O  
Table 5 I Composition of the hypotonic fluorochrome solution.   
3.4 Calcein-AM retention assay 
Calcein-AM is a P-gp substrate and can be actively transported from the plasma 
membrane by P-gp. Once it has entered the cytosol, it is cleaved by cellular esterases and 
becomes fluorescent. Thus, calcein-AM can be used to monitor P-gp activity. The protocol 
was adapted from Robey and coworkers34. VCR-R CEM cells were seeded at a density of 
0.3 × 106 cells per 1 mL per well of a 12 well plate and incubated for 4 h at 37°C. 
Subsequently, calcein-AM (Biomol) (200 nM) and the potential P-gp inhibitors were added 
and incubated for 30 min at 37 °C. After incubation, cells were centrifuged (400 g, 5 min), 
washed with PBS and resuspended in 0.5 mL RPMI 1640 without phenol red (PAN 
Biotech) containing the respective concentration of the P-gp inhibitor. Following a 60 min 
incubation time at 37 °C, calcein fluorescence was analyzed by flow cytometry on a BD 
FACS Canto II (BD Biosciences) and fluorescence intensities were normalized to the 
DMSO control using FlowJo 7.6 (BD Biosciences). 
3.5 Cellular uptake assay 
Cellular uptake of tetrandrine, SG-005 and SG-094 were determined by HPLC-DAD. 
RIL175 WT and HUVECs were incubated with these compounds at 2 and 10 µM. RIL175 
WT and HUVEC cells were seeded at a density of 0.3 × 106 cells per well of a 6-well plate 
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and allowed to adhere overnight. Cells were treated with 2 and 10 µM of the respective 
compounds for 75 min. Before trypsinization with 2X T/E, cells were washed twice with 
PBS (2 mL). For normalization, cells were counted using a ViCell XR cell counter 
(Beckman). After harvesting, cell pellets were centrifuged (table centrifuge, 13,000 rpm, 
5 min, 4 °C), washed with ice-cold PBS (1 mL), centrifuged (table centrifuge, 13,000 rpm, 
5 min, 4 °C) and resuspended in 50 µL acetonitrile. For cell lysis by bead beating, glass 
beads (acid-washed, Sigma Aldrich) were added and cell lysis was conducted by shaking 
on an orbital shaker at 4 °C for at least 30 min. Reaction mixtures were centrifuged again 
(table centrifuge, 13,000 rpm, 5 min, 4 °C). The supernatants (40 µL) were subjected to 
analytical HPLC analysis, which was performed by Anna Niedrig and Christoph Müller 
(Prof. Bracher, LMU Munich). The supernatant was analyzed by HPLC-DAD using an 
Agilent Series 1100 HPLC system (Agilent Technologies) consisting of a quaternary pump 
system (G1311 A QuatPump), an autosampler (G1329 A ALS), a column oven (G1316 A 
ColComp) and a UV-DAD detector (G1315 A DAD). Chromatographic separation was 
carried out with an Agilent Zorbax Eclipse Plus C18 (150 × 4.6 mm, i.d. 5.0 µm) column 
(Agilent Technologies) and a mobile phase of methanol and water (adjusted with 1 M 
sodium hydroxide solution to pH 9) 80:20 (v/v). The total run time was 18 min with an 
isocratic flow rate at 1.2 mL/min, and an injection volume of 10 µL. The column oven was 
set at 30 °C. The UV detection wavelength was set at 210 nm. Data analysis and 
instrument control was carried out with Agilent ChemStation® software Rev. B04.02 
(Agilent Technologies). The retention time of tetrandrine was 4.5 min, of SG-005 was 
10.4 min, and of SG-094 10.0 min. The concentration of each compound was determined 
according to an external standard calibration. 
3.6 CYP3A4 P450-GloTM assay 
Metabolic activity of CYP3A4-EGFP was confirmed using a CYP3A4 P450-GloTM assay 
(Promega, Madison, USA). HepG2 cells were seeded at a density of 0.75 × 106 cells per 
well into a 24 well plate and allowed to adhere overnight. On the following day, cells were 
transfected with either pcDNA3-CYP3A4-EGFP or pcDNA3-EGFP using the 
LipofectamineTM 3000 (Invitrogen, Waltham, USA) transfection reagent according to the 
manufacturer’s instructions. On the subsequent day, cells were incubated with luciferin-
IPA (3 µM) in the presence or absence of ketoconazole (Santa Cruz biotechnology, Dallas, 
USA) (10 µM) for 60 min. The non-lytic method was used as described by the 
manufacturer. Briefly, 150 µL of each well were transferred into to a plate suitable for 
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luminescence measurement. Luminescence at 560 nm was recorded with an Orion II 
Microplate Luminometer (Berthold Detection Systems). 
3.7 Endolysosomal patch clamp method 
All endolysosomal patch clamp experiments were conducted by Yu-Kai Chao (Prof. 
Grimm, LMU Munich) with the aim to either confirm genetic TPC2 knockout or to quantify 
the inhibitory potential of TPC2 blockers. For confirmation of loss of channel function in 
RIL175 cells, whole endolysosomal patch clamp recordings were conducted using 
modified conventional patch clamp. RIL175 cells were treated with YM201636 (800 nM) 
for at least 2 h. Intact endolysosomes were isolated and current recordings and data 
analysis were performed as described before71. For confirmation of loss of channel 
function in VCR-R CEM cells, cells were immobilized on microscope cover slips in a 24 
well plate using Corning® Cell-TakTM Cell and Tissue Adhesive (Corning) according to the 
absorption method protocol provided by the manufacturer. Briefly, approximately 
3.5 μg/cm² (7 μg/well) Cell-Tak™ reagent were diluted in 250 μl 0.1 M bicarbonate buffer 
pH 8 per well. Prior to immobilization, cells were treated with 1 μM vacuolin-1 (Sigma 
Aldrich) overnight in order to enlarge lysosomes and 50,000 cells/well were seeded. For 
determination of the inhibitory effect of benzylisoquinolines on TPC2, human TPC2 (C-
terminally fused to YFP) was transiently transfected into HEK293 cells TurboFect 
Transfection Reagent (Thermo Fisher). Isolation of intact endolysosomes from HEK293 
cells after vacuolin treatment for at least 2 h, current recordings and data analysis were 
performed as described previously4. 10 µM of each inhibitor and 1 µM of PI(3,5)P2 were 
applied. Inhibition percentage was calculated as follows: 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 (%) =
 100 % − 
current (PI(3,5)P2 + inhibitor
current (PI(3,5)P2)
 ×  100 %.  
3.8 Fura-2 Ca2+ imaging 
Single cell Ca2+ imaging experiments were performed by Susanne Gerndt (Prof. Bracher, 
LMU Munich) using Fura-2. HEK293 stably expressing TPC2L11A/L12A –RFP6 were cultured 
at 37 °C with 5 % of CO2 in Dulbecco’s modified Eagle medium (Thermo Fisher), 
supplemented with 10 % fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL 
streptomycin. Cells were plated onto poly-L-lysine (Sigma Aldrich)-coated glass coverslips 
and grown for 2-3 days. For Ca2+ imaging experiments, cells were loaded for 1 h at room 
temperature with Fura-2 AM (4.0 µM) and 0.005 % (v/v) pluronic acid (both from Thermo 
Fisher) in HEPES-buffered solution 1 (HBS1) comprising 138 mM NaCl, 6 mM KCl, 2 mM 
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MgCl2, 2 mM CaCl2, 10 mM HEPES, and 5.5 mM D-glucose (adjusted to pH 7.4 with 
NaOH). After loading, cells were washed in HBS, and mounted in an imaging chamber. 
All recordings were performed in HBS1. Calcium imaging was performed using a Leica 
DMi8 live cell microscope. Fura-2 was excited at 340 nm/380 nm. Emitted fluorescence 
was captured using 515 nm long-pass filter. Compounds were pre diluted in DMSO and 
stored as 10 mM stock solutions not exceeding three months. Working solutions were 
prepared directly before using by dilution with HBS. 
3.9 Fluo-4 Ca2+ imaging 
Fluo-4 based calcium imaging experiments were performed by Nicole Urban (Prof. 
Schäfer, Leipzig University) using a custom-made fluorescence imaging plate reader built 
into a robotic liquid handling station (Freedom Evo 150, Tecan, Männedorf, Switzerland). 
HEK293 stably expressing TPC2L11A/L12A –RFP6 were cultured at 37 °C with 5 % of CO2 in 
Dulbecco’s modified Eagle medium (Thermo Fisher), supplemented with 10 % fetal calf 
serum (Biochrom, Berlin, Germany), 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL 
streptomycin, and 400-800 µg/mL G418. Cells were seeded on black-walled, clear-bottom 
384-well plates (Greiner, Germany) and incubated with Fluo-4 AM (4 µM; Life 
Technologies, Eugene, OR) for 30 minutes at 37 °C, washed and resuspended in HEPES-
buffered solution 2 (HBS2) comprising 132 mM NaCl, 6 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, 10 mM HEPES, and 5.5 mM D-glucose (adjusted to pH 7.4 with NaOH). For 
concentration-effect experiments cells were sequentially stimulated with different 
concentrations of inhibitor (0.1 to 100 µM) and the novel TPC2 activators TPC2-A1-N and 
TPC2-A1-P6 (10 µM each). Concentration-effect relationships were plotted using 
GraphPad Prism 5 and fitted to the Hill equation. 
3.10 FLIM-FRET imaging 
A Förster resonance energy transfer (FRET)-based fluorescent ATP probe, named GO-
ATeam, was recently developed by Nakano et and coworkers72 for ATP imaging in single 
living cells, in which the ε subunit of the bacterial F0F1-ATP synthase is sandwiched 
between a green fluorescent protein (GFP, cp173-mEGFP) and an orange fluorescent 
protein (OFP, mKOκ) that are used as a FRET pair72. Specific binding of ATP to the ε 
subunit 13 in GO-ATeam induces the conformational change of the ε subunit from 
extended to retracted form, and thereby FRET efficiency in GO-ATeam increases, 
enabling the monitoring of ATP concentrations in living cells at a subcellular spatial 
resolution72. The use of the current GO-ATeam probe72 offers several advantages over 
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the originally developed ATeams73. Specifically, the signal is more stable against 
acidification, which allows ATP imaging inside acidic intracellular compartments72. Also, 
the GO-ATeam longer excitation wavelength is much less phototoxic to cells, making the 
probe suitable for longer times of observation72. The dynamics of intracellular ATP levels 
in RIL175 hepatocellular carcinoma cells transfected with the GO-ATeam probe were 
successfully visualized. In these experiments, higher ATP levels correspond to higher 
FRET efficiency as defined by the differences in the lifetime of the GO-ATeam probe. 
Furthermore, sequential false colour Heatmap images for each time point showing the 
distribution of ATP, via FRET efficiency, inside the cells were generated. Specifically, two 
separate data sets comparing the differences in ATP levels were collected, one between 
RIL175 WT and RIL175 TPC2 KO cells and the other between SG-005 pre-treated or non-
treated RIL175 WT cells. For that purpose, RIL175 WT and TPC2 KO cells were seeded 
at different densities ranging from 0.5 to 2 × 104 cells per well of ibidi 8 well µ-slides with 
glass bottoms (ibidi) and incubated overnight. Before imaging, cells were supplemented 
with new DMEM (PAN Biotech), supplemented with 10 % fetal calf serum (FCS) (PAA 
Laboratories). To determine the influence of SG-005 on ATP levels, RIL175 WT cells were 
treated with SG-005 (2 µM) or vehicle for 1 h prior to imaging. For the comparison of 
RIL175 WT and TPC2 KO cells, cells were left untreated. FLIM (fluorescence lifetime 
imaging)-FRET measurements were performed by Themistoklis Zisis (Prof. Vollmar, LMU 
Munich) on a Leica TCS SP8 SMD microscope combined with a Picoquant LSM Upgrade 
Kit using a 470 pulse laser at 40 MHz frequency and a time-correlated single-photon 
counting (TCSPC) approach (SI). For all measurements, a 63× Zeiss water immersion 
lens was used. A complete FLIM image of single cells was recorded until an average of 
1000 photon counts per pixel was collected. The fluorescence decay curve was calculated 
from the recorded FLIM image that was then analyzed by deconvolution fit using the 
instrument response function (IRF). This process was repeated for twelve different 
timepoints (0, 10, 20, 30, 35, 40, 45, 60, 75, 90, 105 and 120 min) with 5 mM of 2-deoxy-
D-glucose (2-DG) (Sigma Aldrich) being added after the 30 min timepoint measurement. 
Data acquisition and analysis was performed using the Picoquant SymPhoTime 64 (V2.1). 
In control experiments, the fluorescence decay time of the donor in absence of the 
acceptor (τD) was determined by applying a single-exponential decay function. For the 
FRET samples, a bi-exponential fit function was assumed. Here, the first time component 
was fixed according to τD previously obtained from the control experiments and reflecting 
the non-interacting donor fraction and the second time component τDA was freely fitted 
reflecting the donor fraction interacting with the acceptor. The quality of the fit was 
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assessed by randomly distributed residuals and by low χR2 values. From the interacting 
fraction, the FRET efficiency (E) was calculated according to: 𝐸 = 1 −
𝜏𝐷𝐴
𝜏𝐷
. 
3.11 Generation of a RIL175 TPC2 knockout cell line using CRISPR-Cas9 
3.11.1 sgRNA design and cloning of constructs 
The knockout of TPCN2 in murine RIL175 cells with the CRISPR-Cas9 system was 
conducted as described earlier74, 75. As a strategy, we aimed to delete exon 2 of TPCN2 
after having sequenced the region of interest (TPCN2 sequencing primer: 5’-
CCACATTTACCTCATGACATCC-3’). As a template, genomic DNA from RIL175 WT cells 
which was isolated using the QuickExtractTM DNA Extraction Solution (Lucigen) according 
to the manufacturer’s instructions was used. Then, single guide RNAs (sgRNAs) were 
designed as described previously76. Three sgRNAs upstream (5’) of exon 2 (Table 6) were 
used for cloning into the eCas9(1.1)-2A-Puro backbone (cloned by introducing the T2A 
puromycin resistance cassette from PX549 into eSpCas9(1.1) via FseI and NotI; both 
plasmids were a gift from Feng Zhang, addgene plasmids #62988 and #71814, 
respectively). Similarly, two sgRNAs downstream (3’) of exon 2 (Table 6) were designed 
to be cloned into the eSpCas9_2A_Blasti plasmid (provided by Lars König, Klinikum der 
Universität München, Munich, Germany). 
Name Sequence (5’-3’) 
5’ TPC2_676/rev_top CACCGTCTACTAACAGGGCACGTGC 
5’ TPC2_676/rev_bottom AAACGCACGTGCCCTGTTAGTAGAC 
5’ TPC2_794/rev_top CACCGTAGAGGCAGCGCTAGTCCA 
5’ TPC2_794/rev_bottom AAACTGGACTAGCGCTGCCTCTAC 
5’ TPC2_857/rev_top CACCGCCGGGCCAGAGTCCCAATC 
5’ TPC2_857/rev_bottom AAACGATTGGGACTCTGGCCCGGC 
3’ TPC2_237/fw_top CACCGACAGTCTTAGCCCGTGCCAA 
3’ TPC2_237/fw_bottom AAACTTGGCACGGGCTAAGACTGTC 
3’ TPC2_386/rev_top CACCGCTGTACCAGCACACTACATG 
3’ TPC2_386/rev_bottom AAACCATGTAGTGTGCTGGTACAGC 
Table 6 I sgRNA sequences/cloning oligomers 
Before cloning, oligomers were annealed using a PCR cycler (5 min at 95 °C, ramp down 
to 25 °C) and diluted (1:100 in RNase-free H2O) (Table 7).   
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Reagent Volume [µl] 
sgRNA_top (100 µM) 1 
sgRNA_botom (100 µM) 1 
T4 ligation buffer 1 
RNase-free H2O 7 
Table 7 I Oligo annealing reaction mix. 
For insertion of the annealed oligos into the respective Cas9 plasmid, the Cas9 plasmids 
were digested using FastDigest (FD) Bpil (Thermo Fisher) for 30 min at 37 °C (Table 8).  
Reagent Volume [µl] 
Cas9 plasmid (150 ng) x 
FD Buffer colorless (10X) 1.5 
FD Bpil 1 
RNase-free H2O ad 15 
Table 8 I Digestion of Cas9 plasmids. 
Annealed oligos and digested Cas9 plasmids were ligated using the T4 DNA ligase 
(Thermo Fisher) for 30 min at room temperature (Table 9).  
Reagent Volume [µl] 
digested Cas9 plasmid  10 
annealed oligos (1:100 dilution) 2 
T4 ligation buffer (10X) 2 
T4 DNA ligase 1 
RNase-free H2O 5 
Table 9 I Ligation of annealed oligos and Cas9 plasmids. 
Non-ligated plasmid was removed using the PlasmidSafe ATP-dependent DNase 
(Lucigen) by incubation for 30 min at 37 °C and for 30 min at 70 °C (Table 10).   
Reagent Volume [µl] 
Ligation reaction 11 
PlasmidSafe buffer (10X) 1.5 
ATP (25 mM) 0.6 
PlasmidSafe Exonuclease 1 
H2O ad 15  
Table 10 I Components used for digestion of non-ligated plasmid.  
Materials and Methods 
27 
 
Subsequently, the constructs were transformed into competent DH5α-E. coli (prepared in-
house) (3-10 µL construct per 100 µL E. coli). After addition of plasmid DNA, E. coli were 
first kept on ice for 10 min before being heat-shocked at 42 °C for 45 s and returned to ice 
for 2 min. Bacterial suspensions were then plated on agar plates containing ampicillin and 
incubated overnight at 37 °C. On the next day, 3-5 colonies were picked per plasmid and 
amplified in 5 mL LB(+) medium containing 100 µg/ml ampicillin. Then plasmids were 
prepared using the QIAGEN Plasmid Miniprep and Maxiprep Kits (QIAGEN) according to 
the manufacturer’s instructions. Correct insertions were confirmed by restriction digestion 
and by Sanger sequencing starting from the U6 promotor.  
3.11.2 Transfection and evaluation of genome targeting efficiency 
Before being transfected with the respective plasmids, RIL175 WT cells were cultured in 
6 well plates to a confluence of 60-70 %. Subsequently, RIL175 WT cells were transfected 
with three pairs of sgRNAs using LipofectamineTM 3000 (Invitrogen) transfection reagent 
according to the manufacturer’s instructions (7.5 µL LipofectamineTM 3000 reagent). 24 h 
later, selection was performed with puromycin (2 µg/mL) and blasticidin S (6 µg/mL) for 
72 h. After removal of puromycin and blasticidin S, cells were allowed to recover until 
reaching sufficient confluency. By applying the T7 DNA Endonuclease I assay (New 
England Biolabs), the sgRNA pair with the highest editing efficiency was determined (5’ 
TPC2_676/rev and 3’ TPC2_237/fw, data not shown) according to the manufacturer’s 
instructions (primers used for PCR: TPC2_5’_T7_FW: 5’-ATTCTGGCTGAACAGGAGGC-
3’, TPC2_5’_T7_RV: 5’-ACAGACAGCACAGCCTCATC-3’, TPC2_3’_T7_FW: 5’-
ACACATGAAGCCAGCTCTCC-3’, TPC2_3’_T7_RV: 5’-GTCTCTCCACATCTCGCTCG-
3’,) and used for subsequent single cell dilution and clonal expansion. For single cell 
dilution, cells were detached, cell aggregates were separated with a cell strainer and 
adjusted to a cell density of 0.6 cells/well before being seeded into 96 well plates. 
Subsequently, cells were transferred into 24 well plates for upscaling before isolation of 
DNA. 
3.11.3 Single cell dilution, clonal expansion and knockout verification 
Successful exon 2 deletion was confirmed by standard PCR (Thermo Scientific Phusion 
Green Hot Start II High-Fidelity Polymerase, Thermo Fisher), agarose gel analysis 
(peqGOLD agarose, universal, VWR International) and sequencing (Table 11).  
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Name FW primer (5’-3’) RV primer (5’-3’) 
TPC2 within ex2 AGGGTCTCTGGCTGCAGACA ACCTAGCACAGGGTAGCCCA 
TPC2 spanning 
ex2 
GGTGTTGTAGCTTGGCTAGGT AGCATCCATGCGGTGGTA 
TPC2 sequencing CCACATTTACCTCATGACATCC - 
Table 11 I Primers used for PCR analysis of exon 2 deletion.  
3.11.4 Off-target screening 
The ten predicted off-target sequences present in exons or introns with the highest cutting 
frequency determination (CFD) scores according to the CRISPOR TEFOR in silico tool76 
for each sgRNA were amplified by PCR (Thermo Scientific Phusion Green Hot Start II 
High-Fidelity Polymerase, Thermo Fisher or Q5® High-Fidelity DNA Polymerase, New 
England Biolabs), analyzed by Sanger sequencing and compared with the WT control. 
The investigated off-targets, sequences and the used primer pairs and polymerases are 
listed in Supplementary Table 1 and Supplementary Table 2. Cloning oligos and 
sequencing services were provided by Eurofins Genomics. Primers were purchased from 
Metabion. 
3.12 Generation of a VCR-R CEM TPC2 knockout cell line using CRISPR-Cas9 
An InDel mutation was introduced near the human TPC2 M484L SNP77 in VCR-R CEM 
cells. In silico design and cloning into the eCas9(1.1)-2A-Puro plasmid were performed as 
described in 3.11.1 (Table 12).  
Name Sequence (5’-3’) 
sgRNA3_top CACCGACCCCAGCAACGTGTTTGAC 
sgRNA3_bottom AAACGTCAAACACGTTGCTGGGGTC 
Table 12 I hTPC2 sgRNA top and bottom sequences. 
VCR-R CEM cells were transfected with the plasmid construct using nucleofection (Amaxa 
Nucleofector Kit C, VACA-1004, Lonza) using the program X-005 and 6 µg of the plasmid 
construct according to the manufacturer’s instructions. To increase transfection efficiency, 
a 10 min post-incubation step at room temperature was included. Selection was performed 
with puromycin (2.5 µg/ml) for 72 h. After a recovery of 5 days, single cell dilution and 
clonal expansion was performed as described in 3.11.3. Standard PCR (Thermo Scientific 
Phusion Green Hot Start II High-Fidelity Polymerase, Thermo Fisher), agarose gel 
analysis (peqGOLD agarose, universal, VWR International) and sequencing were 
performed to detect InDel mutations (Table 13).  
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Target FW primer (5’-3’) RV primer (5’-3’) 
hTPC2_PCR TCGGCCACTACTACTTTGAC GTAGAAACCCAGCCTCCTAA 
hTPC2 
sequencing 
TCGGCCACTACTACTTTGAC - 
Table 13 I Primers used to detect InDels.  
The screening for potential off-targets is described in Franz Geisslinger’s Master Thesis 
(Prof. Vollmar, LMU Munich).  
3.13 In vivo experiments 
All animal experiments were performed by Carina Ortler and Kerstin Loske (Prof. Vollmar, 
LMU Munich), and approved by the District Government of Upper Bavaria, in accordance 
with institutional guidelines and the German Animal Welfare. C57Bl/6-Tyr mice could be 
used as RIL175 cells originate from them. To enable in vivo bioluminescence imaging of 
RIL175 cells that contain a stable luciferase knock-in, the albino phenotype was 
necessary. 
Dissemination assay. 20 C57Bl/6-Tyr mice (Envigo), female, 6 weeks old, were used for 
intravenous injection of either 2 × 105 RIL175 WT or TPC2 KO cells into the tail vein. 
Bioluminescence imaging using the IVIS Lumina system (PerkinElmer) was conducted on 
day 3 after intraperitoneal injection of 6 mg/mL luciferin per mouse. Previously, mice were 
put under anesthesia with 3 % isoflurane in oxygen. Imaging of mice was performed in 
ventrodorsal position and mice were kept under narcosis with 2 % isoflurane in oxygen. 
Hypothermia was prevented by a heating plate (37°C). The tumor signal per defined region 
of interest was calculated as photons/second/cm2 (total flux/area) using the Living Image 
4.4 software (Perkin Elmer).  
Dose-finding test. Initially, for determination of the doses of SG-005 and SG-094, 12 
female C57Bl/6-Tyr mice (Envigo), 6 weeks old, were used. SG-005 was applied at 38 
nmol/kg and 57 nmol/kg and SG-094 at 59 nmol/kg and 90 nmol/kg daily on three 
consecutive days. Compounds were dissolved in a solvent consisting of 5 % DMSO, 10 % 
solutol and 85 % PBS and they were injected intraperitoneally (100 µL injection volume). 
Due to the known toxicity problems of tetrandrine in the literature, the compound was not 
used in vivo.  
Ectoptic tumor model. 40 C57Bl/6-Tyr mice (Envigo), female, 5 weeks old, were injected 
with either 2 × 106 RIL175 WT or TPC2 KO cells into the flank. Treatment of mice with 
vehicle control, SG-005 (57 nmol/kg) or SG-094 (90 nmol/kg) was performed on day 0, 2, 
4, 7 and 9 after implantation of cells. Compounds were dissolved as described for the 
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dose-finding test. Tumor volumes were measured by caliper on day 4, 7, 9 and 10 and 
calculated with the formula π/6 × L × W × H. Bioluminescence imaging was performed on 
day 2, 4, 7 and 10 after implantation of cells following intraperitoneal injection of 6 mg/mL 
luciferin per mouse. Anesthesia, narcosis and calculation of tumor signal per defined 
region were performed as described for the dissemination assay. Tumors were resected 
and stored at -80 °C.  
Immunoblotting of tumors. For Western blot analysis, 100 µl RIPA buffer (3.19, Table 
17) without additives were added per 10 mg of tumor tissue derived from the ectopic tumor 
model. Samples were homogenized using a potter homogenizer (Carl Roth) on ice. Then, 
samples were centrifuged (table centrifuge, 14,000 rpm, 10 min, 4 °C) and supernatants 
were isolated for determination of protein concentration as determined in 3.19. For 
dephosphorylation, 50 µl FastAPTM Thermosensitive Alkaline Phosphatase (1 U/µL) 
(Thermo Fisher) and 10 µL 10X FastAPTM buffer (Thermo Fisher) were used per 20 µg 
protein. The reaction mixtures were incubated for 1 h at 37 °C before dephosphorylation 
was stopped by addition of 20 µL 5X sample buffer (3.19, Table 17) and heat denaturation 
for 5 min at 95 °C. Gel electrophoresis and immunoblotting were performed as described 
in chapter 3.19.     
3.14 Lysosomal uptake assay 
Lysosomal uptake of tetrandrine, SG-005 and SG-094 was determined by LysoTracker-
RedTM DND-99 (Thermo Fisher) staining and flow cytometry as described previously50. 
Briefly, RIL175 WT, RIL175 TPC2 KO and HUVEC cells were seeded at a density of 
0.06 × 106 cells per well of a 24-well plate and allowed to adhere overnight. On the 
subsequent day, cells were treated with 2 and 10 µM of the respective compounds (or with 
10 nM of the V-ATPase inhibitor concanamycin, Santa Cruz Biotechnology) for 60 min. 
LysoTracker-RedTM DND-99 (25 nM) was present during the last 15 min. Fluorescence 
was determined on a BD FACS Canto II (BD Biosciences) and fluorescence intensities 
were normalized to the DMSO control using FlowJo 7.6 (BD Biosciences). 
3.15 Mitochondrial mass 
To determine mitochondrial mass, RIL175 WT cells were seeded at a density of 0.1 × 106 
cells per well of a 24-well plate and allowed to adhere overnight. Cells were either treated 
with the respective compounds for 1 h or for 24 h at the indicated concentrations. After 
detachment with 2X T/E, cells were incubated with 250 µL MitoTracker™ Green FM 
(Thermo Fisher) in DMEM (PAN Biotech) without supplements for 3 min at 37 °C. 
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Subsequently, medium was discarded and cells were resuspended in 250 µL PBS and 
analyzed by flow cytometry. Forward versus side scatter (FSC vs. SSC) gating was used 
to exclude cell debris as shown below using FlowJo 7.6 (BD Biosciences). MitoTracker™ 
Green fluorescence was analyzed in the Alexa Fluor 488-A channel on a FACS Canto II 
(BD Biosciences). 
3.16 Mitochondrial membrane potential  
The cationic dye JC-1 (Thermo Fisher) was used to monitor mitochondrial health and, 
more specifically, to measure mitochondrial membrane potential (ΔΨm). When ΔΨm is 
intact, JC-1 accumulates in mitochondria, yielding a red fluorescence. In contrast, 
mitochondrial depolarization is indicated by a decrease in the red/green fluorescence 
intensity. RIL175 WT cells were seeded at a density of 0.1 × 106 cells per well of a 24-well 
plate and allowed to adhere for at least 6 h. Subsequently, cells were treated for 1 h or 
24 h with the indicated concentrations of the respective compounds. Then, JC-1 (1 µg/mL) 
was added and incubated for 1 h. For 1 h treatment with compounds, staining with JC-1 
was performed simultaneously. Cells were harvested with 2X T/E, washed with PBS and 
resuspended in PBS for flow cytometric analysis on a BD FACS Canto II (BD Biosciences). 
In parallel, compensation samples were prepared using Anti-Mouse Ig, κ/Negative Control 
(FBS) Compensation Particles Set (BD Biosciences) and a BD PE Mouse IgG1, κ/ Isotype 
Control (BD Biosciences #555749) and a BD Alexa Fluor® 488 Mouse IgG1 κ Isotype 
Control (BD Biosciences #557721) as described by the manufacturer. Prior to analysis of 
cellular samples, compensation of spectral overlap was performed on a BD FACS Canto 
II (BD Biosciences) as indicated below. The percentage of PE-A (orange) and of Alexa-
Fluor-488-A positive populations was determined using FlowJo 7.6 (BD Biosciences) as 
shown in Figure 5.  
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Alexa-Fluor-488-stained beads 
 
PE-stained beads 
 
CCCP 100 µM 
 
DMSO 
Figure 5 I Gating for PE-A positive and Alexa-Fluor-488-A positive populations after staining with JC-
1. 
3.17 Molecular cloning of pcDNA3-CYP3A4-EGFP 
The cDNA template was generated by isolation of mRNA from HepaRGTM progenitor cells 
(QIAGEN RNeasy Mini Kit, QIAGEN) and subsequent reverse transcription (High Capacity 
cDNA Reverse Transcription Kit, Applied Biosystems) as described in 3.22. cDNA was 
amplified by PCR (Thermo Scientific Phusion Green Hot Start II High-Fidelity Polymerase, 
Thermo Fisher) (CYP3A4-FW: 5’-ATATATGGTACCGCCACCATGGCTCTCATCCCA-3’, 
CYP3A4-RV: 5’-ATCTCGAGGGCTCCACTTACGGTGCCA-3’). The obtained PCR 
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product was digested using FastDigest (FD) KpnI, FD XhoI and T4 DNA Ligase (all 
purchased from Thermo Fisher) as indicated in Table 14. The digestion reaction mix was 
incubated for 30 min at 37 °C and the reaction was stopped by heat denaturation for 
15 min at 65 °C. 
Reagent Volume [µl] 
CYP3A4 insert 3 
FD Buffer colorless 10X 2 
FD KpnI 1 
FD XhoI 1 
H2O (ad 20 µL) 13 
Table 14 I Restriction digestion mix of CYP3A4 insert. 
The pcDNA3-EGFP vector was a gift from Doug Golenbock (Addgene plasmid #13031; 
http://n2t.net/addgene:13031; RRID:Addgene_13031). The vector was digested and 
dephosphorylated as indicated in Table 15. The digestion reaction mix was incubated for 
30 min at 37 °C and the reaction was stopped by heat denaturation for 15 min at 65 °C. 
Reagent Volume [µl] 
vector (addgene #13031) 1.2 
FD Buffer colorless 10X 2 
FD KpnI 1 
FD XhoI 1 
Fast AP Thermosensitive 
Alkaline Phosphatase 
1 
H2O (ad 20 µL) 14.3 
Table 15 I Simultaneous plasmid vector linearization and dephosphorylation 
Vector and insert digestion reactions were pooled and then purified using the QIAquick 
Gel Extraction Kit (QIAGEN) as indicated by the manufacturer and finally eluted with 26 µL 
RNase-free water. Ligation of linearized, dephosphorylated pcDNA3.1 and CYP3A4 insert 
was performed at a 5:1 insert:vector ratio and 200 ng of vector overnight at room 
temperature as indicated in Table 16.  
Reagent Volume [µl] 
mix of digestion reactions 26 
T4 ligation buffer (10X) 3 
T4 DNA Ligase 1 
H2O (ad 30 µL) 0 
Table 16 I Ligation of linearized, dephosphorylated pcDNA3.1 and CYP3A4 insert.  
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Transformation into competent DH5α-E.coli and preparation of plasmids was conducted 
as described in 3.11.1. Correct insertion of the insert was confirmed by PCR, restriction 
digestion and Sanger sequencing (sequencing primer: hCYP3A4_1_F: 5’- 
GTATGGAAAAGTGTGGGGCT-3’). Sequencing services were provided by Eurofins 
Genomics. Primers were purchased from Metabion. 
3.18 Proliferation assays 
Cellular proliferation of RIL175 WT and TPC2 KO cells was assessed by impedance 
measurement and by CellTraceTM CFSE staining. Cellular proliferation of VCR-R CEM WT 
vs. TPC2 KO cells was quantified by cell counting using trypan blue staining on a ViCell 
XR cell counter (Beckman). Antiproliferative effects of the compounds from the library 
were determined by CellTiter-Blue® assay.  
Impedance measurement. With the xCELLigence RTCA device (ACEA Biosciences), the 
cell index, a dimensionless parameter that is proportional to the cell number, can be 
determined through impedance measurement. RIL175 WT and TPC2 KO cells were 
seeded at a density of 2 × 103 cells per well into an equilibrated 16-well E-plate. Slopes 
were calculated using the xCELLigence RTCA software (ACEA Biosciences) for each cell 
line until reaching the plateau phase using the following equation:  𝑆𝑙𝑜𝑝𝑒 (
1
ℎ
) =
Cell Index−intercept
time (h)
.  
CellTraceTM CFSE staining. Additionally, the CellTraceTM CFSE Cell Proliferation Kit 
(Invitrogen) was used to assess proliferation visually. It relies on a fluorescent CellTraceTM 
reagent that diffuses into cells and binds covalently to intracellular amines. Cell 
proliferation can be followed by flow cytometry for several generations. Labelling of the 
cells was conducted as indicated by the manufacturer using 10 µM CFSE. CFSE 
fluorescence was analyzed directly after labelling and after a 72 h incubation time by flow 
cytometry on a BD FACS Canto II (BD Biosciences). Forward versus side scatter (FSC 
vs. SSC) gating was used to exclude cell debris using FlowJo 7.6 (BD Biosciences). CFSE 
fluorescence was analyzed visually in the FITC-A channel. 
Cell counting with trypan blue staining. Concentration of VCR-R CEM WT and TPC2 
KO cells was adjusted to 0.1 × 106 cells/ml on day 0 and cells were cultured in 75 cm2 
flasks. Cell number and viability were determined every 24 h by trypan blue staining over 
a period of 6 days using a ViCell XR cell counter (Beckman).  
Compound screening by CellTiter-Blue® assay. Antiproliferative effects of compounds 
were determined by CellTiter-Blue® cell viability assay (Promega). Adherent cells were 
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seeded at the indicated cell densities (HCT-15: 3 × 103 cells, HepG2: 5 × 103 cells, 
RIL175: 2 × 103 cells, HUH7: 5 × 103 cells, MDA-MB-231: 5 × 103 cells, MCF7: 5 × 103 
cells, T24: 5 × 103 cells per well) into wells of a 96 well plate and allowed to adhere 
overnight. 4 h after seeding, initial metabolic activity was determined and used as zero 
value. Treatment was performed for 72 h at the indicated concentrations. VCR-R CEM 
cells were seeded at a density of 20 × 103 cells per well of a 96-well plate, incubated for 
4 h before stimulation with the indicated concentrations of compounds for 48 h. 2 h before 
the end of stimulation time, 20 µL CellTiter-Blue® reagent was added to each well and 
fluorescence at 590 nm was detected with a SpectraFluor PlusTM (Tecan). Half-maximal 
inhibitory concentrations (IC50) values were calculated by nonlinear regression using 
GraphPad Prism 8.4.0 software (GraphPad Software). 
3.19 Western Blot analysis 
Western Blot analysis was conducted in order to examine protein levels of interest.  
Impairment of proangiogenic signaling. HUVECs were seeded at a density of 0.5 × 106 
cells per well of a 6-well plate and allowed to adhere overnight. After serum starvation for 
4 h using ECGM medium (PELO Biotech) without supplements, cells were treated with 
vehicle, tetrandrine, SG005 or SG-094 (10 µM) for 1 h. Subsequently, cells were either 
stimulated with VEGF-A165 (0.1 µg/mL) (Peprotech) or left untreated for 15 min before cell 
lysis.  
Blotting of apoptosis markers (VCR-R CEM). VCR-R CEM cells were seeded at a 
density of 2.0 × 106 cells per well of a 6-well plate and incubated for 4 h. Subsequently, 
cells were treated with vincristine (0.1 µM), with or without tetrandrine, SG005 or SG-094 
(1 µM) for 48 h before cell lysis. 
PD-L1 and GRP78 expression after HDAC6 inhibition. T24 cells were seeded at a 
density of 0.8 × 106 cells per well of a 6-well plate and allowed to adhere overnight. Cells 
were treated with KV-46, KV-70 or KV-181 (10 µM) for 48 h before cell lysis. 
Cell lysis and immunoblotting. After cells were washed with ice-cold PBS, 100 µL of 
radioimmunoprecipitation (RIPA) lysis buffer were added and cell lysates were frozen at 
– 80 °C. After the removal of cell debris by centrifugation (14,000 rpm, 10 min, 4 °C), 
protein concentrations were determined by Bradford assay as described previously78. For 
that purpose, 5 µL of protein solution were diluted with 45 µL of H2O. 10 µL of the obtained 
dilutions were mixed with 190 µL of a 1:5 dilution Bradford reagent Roti® Quant (Bio-Rad) 
in water and incubated for 5 min. Absorbance of each sample at 592 nm was determined 
by photometric measurement using a SpectraFluor PlusTM (Tecan) and linear regression 
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was conducted with bovine serum albumin (BSA) dilutions as protein standards. Protein 
concentrations were adjusted with 1X SDS (sodium dodecyl sulfate) sample buffer. 
Proteins were denatured at 95 °C for 5 min after addition of 5X SDS sample buffer. Equal 
amounts of protein were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in electrophoresis buffer (100 V, 21 min then 200 V, 43 min) 
on discontinuous polyacrylamide gels, consisting of a gradient separation (6 -12 %) and a 
stacking gel. Afterwards, proteins were transferred to either nitrocellulose or 
polyvinylidene difluoride (PVDF) membranes that have been equilibrated in 1X tank buffer, 
via tank blotting (100 V, 90 min, 4 °C). After tank blotting, membranes were blocked with 
5 % non-flat dry milk powder in PBS (Blotto) for 2 h. Incubation with the primary antibody 
was performed overnight at 4 °C. After 4 washing steps with TBS-T for 5 min each, the 
secondary, HRP-coupled antibody was added and incubated for 2 h. Following another 4 
washing steps with TBS-T for 5 min each, the membranes were incubated with ECL 
solution and chemiluminescence was detected with a ChemiDoc™ Touch Imaging System 
(Bio-Rad). The bands were assigned by comparison with the Page Ruler™ Plus 
Prestained Protein Ladder (Fermentas). Data processing was performed with the Image 
LabTM software (Bio-Rad).  
RIPA lysis buffer    Separation gel 6-12 %   
Tris/HCl 50 mM  Rotiophorese™ Gel 30 40 - 80 % 
NaCl 150 mM  Tris (pH 8.8) 375 mM 
Nonidet NP-40 1 %  SDS 0.1 % 
Sodium deoxycholate 0.25 %  TEMED 0.1 % 
SDS 0.10 %  APS 0.05 % 
H2O      
added before use:     
Complete®EDTAfree 4 mM    
PMSF 0.5 mM    
activated Na3VO4 2 mM    
     
5X SDS sample buffer    Electophoresis buffer   
Tris/HCl pH 6.8 3.125 M  Tris 4.9 mM 
Glycerol 50 %  Glycine 38 mM 
SDS 5 %  SDS 0.1 % 
DTT 2 %  H2O   
Pryonin Y 0.025 %    
H2O      
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TBS-T (pH 7.6)    Tank buffer   
Tris/HCl 50 mM  Tris base 48 mM 
NaCl 150 mM  Glycine 39 mM 
Tween 20 0.05 %  Methanol 20 % 
   H2O   
Stacking gel       
Rotiophorese™ Gel 30 17 %    
Tris (pH 6.8) 125 mM    
SDS 0.1 %    
TEMED 0.2 %    
APS 0.1 %    
H2O      
Table 17 I Buffers and solutions for Western Blot analysis 
Antigen Product nr.  Provider Dilution In 
BiP/GRP78 610978 BD Biosciences 1:1000 BSA 5 % 
caspase 3, active C8487 Sigma Aldrich 1:1000 BSA 5 % 
hexokinase II (C64G5) 2867 CST 1:1000 BSA 5 % 
PARP 9542 CST 1:1000 BSA 5 % 
PD-L1 (E1L3N®) XP® 13684 CST 1:1000 BSA 5 % 
phospho-Akt (Ser473) 9271 CST 1:1000 BSA 5 % 
phospho-Cofilin (Ser3) 
(77G2) 
3313 CST 1:1000 BSA 5 % 
phospho-eNOS 
(Ser1177) 
9571 CST 1:1000 BSA 5 % 
phospho-p44/p42 
MAPK (Thr202/Tyr204) 
9106 CST 1:1000 BSA 5 % 
phospho-p54/p46 
SAPK/JNK 
(Thr183/Tyr185) 
9251 CST 1:1000 BSA 5 % 
Table 18 I Primary antibodies for Western Blot analysis 
Antigen 
Product 
nr.  
Provider Dilution In 
goat anti-mouse IgG1, 
HRP 
BZL07046 Biozol 1:1000 BSA 5 % 
goat anti-rabbit IgG 
(H+L)-HRP conjugate 
172-1019 Bio-Rad 1:1000 BSA 5 % 
Table 19 I Secondary antibodies for Western Blot analysis 
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3.20 Wound healing assay 
2.5 × 104 RIL175 WT and TPC2 KO cells were seeded into the wells of a 96-well plate. A 
wound was scratched into the cell monolayer with a 96-well scratching device when cells 
reached confluency. PBS (containing Mg2+ and Ca2+) was used to remove detached cells 
and each scratch was examined under a light microscope. After incubation at 37 °C for 
18 h, cells were stained with crystal violet, which was performed by aspiration of medium, 
washing with PBS, fixation with methanol for 10 min and addition of crystal violet solution 
for min. Crystal violet solution was carefully removed and washed with water. The plate 
was dried overnight before images were taken with a LeicaDmil microscope with 4x 
magnification. Cells that were incubated with medium without FCS served as negative 
control. Wound closure was quantified with ImageJ software (NIH) and it was calculated 
with the following equation: Wound closure (%)  =  100% −
wound area (18 h)
wound area (0 h)
 ×  100%.  
3.21 Seahorse XFe96: Metabolic profiling 
3.21.1 Purpose and measurement principle 
In order to investigate differences in glycolysis and oxidative phosphorylation in RIL175 
WT versus (vs.) TPC2 KO cells, the Seahorse Glycolysis Stress Test Kit and the Seahorse 
XFe96 FluxPaks (inc. mini) were used together with the Seahorse XFe96 Analyzer (all from 
Agilent Technologies). The analyzer measures two parameters, Extracellular Acidification 
Rate (ECAR) in mpH/min and Oxygen Consumption Rate (OCR) in pmol/min, 
simultaneously in real-time utilizing dual-florescent biosensors for protons and molecular 
oxygen. For metabolic profiling, cells are glucose-starved first in assay medium without 
glucose and pyruvate for 1 h. As first injection, a saturating concentration of glucose is 
injected. Secondly, oligomycin, which inhibits F1F0-ATP synthase and thereby impairs 
mitochondrial ATP production, is injected and forces the cells to shift their energy 
production towards glycolysis in order to maintain ATP production and thereby energy 
homeostasis. Thirdly, the hexokinase II inhibitor 2-deoxy-D-glucose (2-DG) is injected to 
reveal that the increased ECAR was caused by glycolysis and not by other biochemical 
processes. In order to compare metabolic activities of different cell lines, the OCR/ECAR 
ratio can be used79 or a normalization based on cell number has to be conducted as ECAR 
and OCR reflect both metabolic activity and total cell number.  
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3.21.2 Hydration of the Seahorse XFe96 sensor cartridge 
Each well of the utility plate (Agilent Technologies) was filled with 200 µL sterile H2O and 
the sensors of the Seahorse XFe96 cartridge (Agilent Technologies) were submerged into 
the H2O. The plate was placed in a non-CO2 incubator overnight together with an aliquot 
(20-50 mL) of XF Calibrant (Agilent Technologies). On the next day, H2O was replaced 
with XF Calibrant, followed by 45-60 min of incubation in a non-CO2 incubator prior to the 
assay. 
3.21.3 Coating of the Seahorse XFe96 microplate  
Each well of the XFe96 microplate (Agilent Technologies) was filled with 15 µL of poly-D-
lysine (Sigma-Aldrich) coating solution (Table 20), followed by 5 minutes of incubation at 
room temperature. After incubation, poly-D-lysine solution was discarded and the wells 
were rinsed twice with sterile H2O (100 µL per well). The XFe96 microplate was 
subsequently dried for 2 hours in the laminar flow hood before collagen G coating solution 
(0.001% in PBS, Biochrom) was added. The plate was incubated with collagen G coating 
solution for 30 min at 37 °C prior to seeding of cells 
Poly-D-lysine coating solution   
Poly-D-lysine hydrobromide 5 mg 
H2O (sterile) 50 mL 
Table 20 I Poly-D-lysine coating solution 
3.21.4 Seeding and treatment of cells in the XFe96 microplate 
For comparison of RIL175 WT and TPC2 KO cells, cells were seeded at a density of 
1 × 104 cells per well of the XFe96 microplate plate and allowed to adhere overnight. For 
determining the influence of TPC2 inhibitors, RIL175 WT cells were seeded at a density 
of 2 × 104 cells per well and allowed to adhere for at least 6 h. Cells were either pre-treated 
for 24 h in culture medium or for 1 h in assay medium without glucose as indicated prior 
to the assay.  
3.21.5 Preparation of assay medium 
Assay medium was prepared by dissolving the content of one vial of DMEM 5030-10X1L 
powder (Sigma-Aldrich, Taufkirchen, Germany), 26.7 mL L-Glutamine (Sigma-Aldrich, 
Taufkirchen, Germany) stock solution (150 mM in PBS) and 1.85 g NaCl (Carl Roth, 
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Karlsruhe, Germany) in 950 mL of H2O. Following pH adjustment to 7.35 ± 0.05 at 37 °C, 
the assay medium was diluted ad 1000 mL with H2O and sterile-filtered with a Millipore 
Express® PLUS membrane filter (0.22 µM, Merck Millipore, Darmstadt, Germany).  
Assay medium  
(pH 7.35, 37 °C) 
  
DMEM 5030 powder 1 vial 
L-Glutamine 4 mM 
NaCl 143 mM 
H2O ad 1000 mL 
Table 21 I Seahorse assay medium 
3.21.6 Washing of cells in the XFe96 microplate 
After two washing steps with pre-warmed (37 °C) assay medium (100 µL per well), 175 µL 
of assay medium with or without the respective compounds were added to each well and 
the XFe96 microplate was placed in a non-CO2 incubator for 60 min prior to the assay. 
3.21.7 Loading of the XFe96 sensor cartridge with injection compounds 
The hydrated XFe96 sensor cartridge ports were loaded with 25 µL of each injection 
compound, dissolved in assay medium (Table 22).  
Port solutions for Glycolysis 
Stress Test (standard) 
  
D-Glucose (8X) 80 mM 
Oligomycin (9X) 9 µM 
2-Deoxy-D-glucose (10X) 500 mM 
Assay medium (pH 7.35, 37 °C)  
Table 22 I Port solutions for metabolic profiling 
3.21.8 Seahorse run 
The assay template was designed with Wave 2.6.1 software and the run was performed 
with a Seahorse XFe96 Analyzer (both from Agilent Technologies). Following calibration 
and equilibration, basal measurements of ECAR and OCR in assay medium without 
glucose and pyruvate were performed (4 measurement cycles, 20 min in total). Firstly, D-
glucose was injected (10 mM final well concentration, 4 measurement cycles, 16 min in 
total). Secondly, oligomycin was injected, resulting in final well concentrations of 1 µM (4 
Materials and Methods 
41 
 
measurement cycles, 16 min in total). Thirdly, 2-deoxy-D-glucose (2-DG) was injected, 
giving final well concentrations of 50 mM (6 measurement cycles, 24 min in total).   
3.22 Quantitative real-time PCR analysis 
mRNA was isolated from cell samples using the RNeasy® Mini Kit (250) (QIAGEN, Hilden, 
Germany) as described by the manufacturer. mRNA concentration was subsequently 
determined using a Nanodrop® Spectrophotometer (PEQLAB Biotechnologie, Erlangen, 
Germany). Reverse transcription was performed with the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Waltham, USA) according to the manufacturer’s 
instructions. For the quantitative real-time polymerase chain reaction (qPCR), a 
QuantStudio™ 3 Real-Time PCR System (Applied Biosystems, Waltham, USA) was used. 
Primers were purchased from metabion (Planegg, Germany). They were designed using 
the NCBI database or the ThermoFisher Cloud OligoPerfect tool and the corresponding 
nucleotide codes are listed in Table 23. 100 ng of cDNA (2 µL), 6.25 µL PowerUp™ 
SYBR® Green Master Mix (Applied Biosystems, Waltham, USA), 3.75 µL RNase-free 
water and 0.025 mol of each primer (0.25 µL) were used for each well of the MicroAmp® 
Fast Optical 96-Well Reaction Plate, 0.1 mL (Applied Biosystems, Waltham, USA). The 
∆∆CT method was used to quantify changes in mRNA levels as described earlier80 and 
actin was used as housekeeping gene. Previously, primer efficiency was determined for 
each primer pair using 500 ng, 50 ng and 5 ng of cDNA per well.  
Target Name FW/RV Primer Sequence (5’-3’) 
actin (human) FW Primer CCAACCGCGAGAAGATGA 
actin (human) RV Primer CCAGAGGCGTACAGGGATAG 
actin (mouse) FW Primer CCACCATGTACCCAGGCATT 
actin (mouse) RV Primer AGGGTGTAAAACGGAGCTCA 
CYP3A4 (human) FW Primer GTATGGAAAAGTGTGGGGCT 
CYP3A4 (human) RV Primer GACCATCTCCTTGAGTTTTCCA 
TPC2 ex2 #1 (mouse) FW Primer GAAGAGCAGCCCCTTCTGG 
TPC2 ex2 #1 (mouse) RV Primer GGAGCGGTACTTTATGGCGT 
TPC2 ex2 #2 (mouse) FW Primer GAGCTCTGCATAGACCAGGC 
TPC2 ex2 #2 (mouse) RV Primer GAGCTCTGCATAGACCAGGC 
TPC2 5’ (mouse) FW Primer GAAGAGCAGCCCCTTCTGG 
TPC2 5’ (mouse) RV Primer CCAGCGGTAAAGCCACAATG 
TPC2 (human) FW Primer TGCATTGATCAGGCTGTGGT 
TPC2 (human) RV Primer GAAGCTCAAAGTCCGTTGGC 
Table 23 I Primers with nucleotide codes used for qPCR analysis 
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In some cases, PCR products were analyzed on an agarose gel (peqGOLD agarose, 
universal, VWR International) after quantitative real-time PCR. GeneRuler 1 kb Plus DNA 
Ladder (Thermo Fisher) was used as molecular size marker. GelRed (Biotium) was used 
to detected DNA. 
3.23 Statistical analyses 
All the listed experiments were conducted at least three times unless otherwise indicated 
in the figure legends. The given data are presented as means ± SEM. Statistical 
differences between groups were assessed with a t-test (with or without Welch’s correction 
as indicated) or with an ordinary one-way ANOVA and the indicated multiple comparisons 
test. Statistical analyses were performed with GraphPad Prism software version 8.4.0 
(GraphPad Software). 
3.24 Toxicity assays 
For assessing the toxicity of muraricine, KV compounds as well as with tetrandrine and its 
analogues, several cellular models and approaches were used: HUVECs, PBMCs, 
differentiated HepaRGTM cells without transfection, differentiated HepaRGTM cells with 
transient transfection and HepG2 cells with stable transfection.  
HUVECs. HUVECs were seeded at a density of 10 × 103 cells/well of a 96 well plate and 
allowed to adhere overnight. On the following day, cells were treated with the indicated 
concentrations of the respective compounds for 6 h. Cellular ATP content was quantified 
by CellTiter‐Glo® cell viability assay (Promega). Therefore, 100 µL CellTiter-Glo® reagent 
were added to 200 µL medium in each well. Cell lysis was induced on an orbital shaker 
for 2 min, followed by 10 min incubation at room temperature in the dark. Subsequently, 
contents of each well were transferred to a plate suitable for luminescence measurement. 
Luminescence at 560 nm was recorded with an Orion II Microplate Luminometer (Berthold 
Detection Systems). 
PBMCs. Peripheral blood mononuclear cells (PBMCs) were isolated from anticoagulated 
whole blood from healthy donors by density gradient centrifugation using Ficoll-PaqueTM 
PLUS density gradient medium (GE Healthcare) as described by the manufacturer. Blood 
samples were diluted with the same amount of Hanks balanced salt solution (HBSS) prior 
to application of Ficoll-PaqueTM PLUS solution. Cells were extracted from the PBMC layer 
with syringe and needle. Subsequently, the triple volume of HBSS (Table 24) was added 
to PBMCs. 
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HBSS (pH 7.2)     
CaCl2 1.26 mM MgSO4 x 7 H2O 0.41 mM 
D-glucose 5.56 mM Na2HPO4 0.34 mM 
KCl 5.33 mM NaCl 137.9 mM 
MgCl2 x 6 H2O 0.49 mM NaHCO3 4.17 mM 
KH2PO4 0.44 mM   
H2O    
Table 24 I HBSS buffer. 
The cell suspension was centrifuged and isolated PBMCs were cultivated in RPMI 1640 
supplemented with 20 % FCS and 1 % penicillin/streptomycin (all purchased from PAN 
Biotech). 4 hours after seeding, cells were treated as indicated for 48 h. Cell death was 
analyzed by propidium iodide (5 µg/mL in PBS) staining and flow cytometry using a BD 
FACS Canto II (BD Biosciences). For evaluation, cell debris was excluded and propidium 
iodide positive cells were determined using FlowJo 7.6 (BD Biosciences) as shown in 
Figure 6. Assays with PBMCs were performed by Franz Geisslinger (Master Thesis, Prof. 
Vollmar, LMU Munich. 
  
Figure 6 I Gating strategy used to determine viability of PBMCs. 
Differentiated HepaRGTM cells without transfection. HepaRGTM cells were 
differentiated in Williams’ medium E supplemented with GlutaMAX and HepaRG 
Maintenance/Metabolism Medium Supplement (Maintenance/Metabolism Working 
Medium) (all purchased from Life Technologies) as indicated by the manufacturer. After 
24 h treatment with the respective compound concentrations, cell viability was determined 
by CellTiter-Blue® cell viability assay as described by the manufacturer.  
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Differentiated HepaRGTM cells with transient transfection with pcDNA3-CYP3A4-
EGFP. HepaRGTM cells were differentiated as described above. 16 h prior to stimulation, 
cells were transfected with either pcDNA3-CYP3A4-EGFP or pcDNA3-EGFP using 
LipofectamineTM 3000 (Invitrogen) transfection reagent according to the manufacturer’s 
instructions. Cells were treated as indicated for 24 h. Cell death was assessed by 
propidium iodide (5 µg/mL in PBS; Carl Roth, Karlsruhe, Germany) staining and flow 
cytometry using a BD FACS Canto II (BD Biosciences). Data were analyzed using FlowJo 
7.6 (BD Biosciences). No FSC/SSC gating was performed. Determination of the 
percentage of PI-A positive cells was conducted as stated below. Specific cell death was 
calculated as follows: 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑐𝑒𝑙𝑙 𝑑𝑒𝑎𝑡ℎ (%) =  𝑐𝑒𝑙𝑙 𝑑𝑒𝑎𝑡ℎ (𝑥) % −
 𝑐𝑒𝑙𝑙 𝑑𝑒𝑎𝑡ℎ (𝑐𝑜𝑛𝑡𝑟𝑜𝑙) %.  
HepG2 cells with stable transfection with CYP3A4-EGFP. HepG2 cells were 
transfected with either pcDNA3-CYP3A4-EGFP or pcDNA3-EGFP using LipofectamineTM 
3000 (Invitrogen) transfection reagent according to the manufacturer’s instructions. 
Transfected cells were constantly cultivated in the presence of 0.5 mg/mL G418 (Sigma 
Aldrich, St. Louis, USA) for four weeks. Presence of plasmids was confirmed by PCR 
(pcDNA3-forward: 5’-TACATCAATGGGCGTGGATAG-3’, pcDNA3-reverse: 5’-
AGGAAGGGAAGAAAGCGAAAG-3’). Primers were purchased from metabion. HepG2 
cells stably expressing either CYP3A4-EGFP or pcDNA3-EGFP were seeded at a density 
of 0.1 × 106 cells per well of a 24-well plate and allowed to adhere overnight. Treatment, 
flow cytometry and data analysis were performed as described for HepaRGTM cells. 
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4 Results 
4.1 Part I: Tetrahydroisoquinolines as inhibitors of TPC2 and P-gp 
4.1.1 Functional effects of TPC2 knockout on liver cancer cells 
4.1.1.1 Generation and validation of a TPC2 knockout cell line using CRISPR-Cas9 
To test whether TPC2 is involved in cancer cell proliferation in vitro and tumor growth in 
vivo, the channel was knocked out using the CRISPR-Cas9 system in murine RIL175 
hepatocellular carcinoma (HCC) cells. Successful deletion of exon 2 was confirmed by 
agarose gel analysis, Sanger sequencing of PCR products at DNA level (Supplementary 
Figure 1 a) and quantitative real-time PCR (qPCR) at mRNA level (Supplementary 
Figure 1 b). Furthermore, strongly reduced 5’ mRNA levels indicated the presence of 
nonsense-mediated decay (NMD) as a response to the deletion (Supplementary Figure 
1 c). In accordance with the agarose gel and qPCR analyses, PI(3,5)P2-induced currents 
of enlarged lysosomes obtained from TPC2 knockout (KO) cells were strongly reduced, 
confirming loss of channel function (Figure 7 a,b). All endolysosomal patch clamp 
experiments were conducted by Yu-Kai Chao (Prof. Grimm, Walther Straub Institute of 
Pharmacology and Toxicology, LMU Munich). The ten predicted off-target sequences with 
the highest cutting frequency determination (CFD) scores76 for each sgRNA were 
analyzed by Sanger sequencing and no insertions or deletions were detected for the clone 
of interest as compared with the WT control (Supplementary Table 1, Supplementary 
Table 2). Due to the lack of a suitable antibody, deletion of the protein was not investigated 
by immunoblotting. TPC2 KO cells in fact showed an impaired ability to migrate in vitro 
and to disseminate into the lungs of mice (Figure 7 c,d), both confirming as well as 
extending our knowledge of the effect of TPC2 on tumor cell migration12.  
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Figure 7 I Generation of a TPC2 knockout cell line and validation of loss of channel function by 
migration and dissemination assays. (a,b) Successful loss of TPC2 function was confirmed by measuring 
PI(3,5)P2-evoked TPC2 currents on isolated, enlarged endolysosomes of RIL175 cells. Patch clamp 
experiments were performed by Yu-Kai Chao (Prof. Grimm, LMU Munich).  The endogenous TPC2 inhibitor 
ATP81 and the TRPML1 activator ML-SA16 were used as controls to ensure that TPC2 currents were elicited 
by PI(3,5)P2 and that functional endolysosomes were used for measurements, respectively. 
(a) Representative patch clamp recordings of YM201636-enlarged acidic vesicles of WT and KO cells are 
shown. (b) Statistical analysis of PI(3,5)P2-induced current densities of TPC2 WT versus (vs.) KO cells is 
shown as mean ± SEM of three independent experiments (Two-Way ANOVA, *P < 0.05). (c) Reduced 
migration of TPC2 KO cells was determined using a scratch assay. Wound closure of RIL175 WT and TPC2 
KO cells was determined 18 h after the scratch was performed. Cells were stained with crystal violet. Data are 
expressed as mean ± SEM, performed in triplicate (unpaired t-test with Welch’s correction, *P < 0.05). (d) 
TPC2 KO impairs tumor cell dissemination into the lungs of C57Bl/6-Tyr mice. Images of tumor-bearing mice 
3 days after intravenous injection of RIL-175 WT and TPC2 KO cells are shown. The bar graph displays the 
quantified signal intensities as mean ± SEM of 10 mice per group (n= 10, unpaired t-test with Welch’s 
correction, ***P < 0.001). The dissemination assay was performed by Carina Ortler and Kerstin Schmid (Prof. 
Vollmar, LMU Munich).  
4.1.1.2 TPC2 KO reduces proliferation and prevents tumor growth of HCC cells 
Next, we aimed to investigate if TPC2 affects cell proliferation and tumor growth. Cell 
proliferation in vitro was monitored using real-time impedance measurements (Figure 8 a) 
and staining with the fluorescent dye CFSE (Figure 8 b), which can be used to monitor 
cell divisions. As evident from a reduced slope over a period of four days as well as from 
the presence of two CFSE-positive populations after three days, proliferation of TPC2 KO 
cells was considerably reduced (Figure 8 a,b). Remarkably, TPC2 KO completely 
abrogated tumor growth in an ectopic in vivo model using syngeneic C57Bl/6-Tyr mice 
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(Figure 8 c,d). Similar bioluminescence signals of WT and TPC2 KO tumors on day 2 
ensured equivalent amounts of viable engrafted cells among both arms (Figure 8 c), whilst 
average signal intensity of TPC2 KO tumors was reduced by 99 % on day 10 (P = 0.0006) 
(Figure 8 c,d). Thus, this study emphasizes that interfering with TPC2 as a single target 
is sufficient to suppress tumor growth in vivo.   
 
Figure 8 I TPC2 knockout impairs cancer cell proliferation and tumor growth. (a) Proliferation of RIL175 
WT and TPC2 KO cells is shown as cell index over time from a representative experiment performed in 
triplicate. Statistical analysis of the slope is displayed as mean ± SEM of three independent experiments 
(unpaired t-test with Welch’s correction, **P < 0.01). (b) CFSE stainings of RIL175 WT and TPC2 KO cells are 
presented upon initial staining and after 72 h of incubation in comparison to the corresponding unstained (unst) 
control. Two populations, visible for TPC2 KO cells, indicate a reduced number of cell divisions after 72 h. 
Fluorescence (FITC-A) was detected by flow cytometry. The experiment was performed in triplicate and one 
representative experiment is shown. (c,d) RIL175 WT and TPC2 KO cells were implanted into the flanks of 
C57Bl/6-Tyr mice and TPC2 KO suppressed tumor growth. (c) The bar graph indicates similar levels of viable 
cells among both groups on day 2 (d2) after implantation. The line chart displays bioluminescence signal 
intensities of tumors over time as mean ± SEM (n= 10 for RIL175 TPC2 KO, n= 9 for RIL175 WT, outlier 
identified with Grubbs’ test and α=0.05, unpaired t-test with Welch’s correction, *P < 0.05, **P < 0.01, 
***P < 0.001). (d) Bioluminescence images taken on day 10 are shown. The outlier is marked with an x. One 
excised tumor is exemplarily shown for each group. 
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4.1.1.3 TPC2 KO influences cellular energy metabolism 
To support sustained proliferation, cancers often reprogram their energy metabolism14. As 
a result of the Warburg effect, listed as a cancer hallmark14, cancer cells derive their 
cellular ATP predominantly from glycolysis to fuel their high energy demand, regardless 
of oxygen availability82. The alkaloid dauricine, which we identified as TPC2 inhibitor in 
this study (4.1.2.1, Figure 12 b), is known to suppress glycolysis in HCC cells83. Hence, 
we investigated if TPC2 is implicated in energy metabolism of RIL175 cells. Metabolic 
profiling on a Seahorse Extracellular Flux Analyzer revealed that, following 1 h of glucose 
starvation, TPC2-deficient RIL175 cells displayed a less glycolytic phenotype as indicated 
by an increased OCR/ECAR ratio (OCR: oxygen consumption rate, parameter for 
oxidative phosphorylation; ECAR: extracellular acidification rate, parameter for glycolytic 
activity) (Figure 9 a). This effect was abolished when saturating concentrations of D-
glucose were injected (Figure 9 a). Despite being glucose-dependent, glucose deprivation 
is a common feature of solid tumors due to poor vascularization84, 85, among others, and 
the OCR/ECAR ratio can be used to decipher the reliance of cells on glycolysis or oxidative 
phosphorylation79. To further assess the role of TPC2 in energy metabolism, we applied a 
Förster resonance energy transfer (FRET) biosensor, that consists of a subunit of the 
bacterial F0F1-ATP-synthase and which can be used for real-time visualization of ATP 
levels inside single live cells72. Stressing the glycolytic pathway using the glycolysis 
inhibitor 2-deoxy-D-glucose (2-DG) resulted in a stronger drop of cellular ATP levels in 
WT cells, whereas TPC2 KO cells remained unaffected (Figure 9 b,c). Taken together, 
extracellular flux analysis and FRET live cell imaging indicated that loss of TPC2 function 
promotes a switch towards oxidative phosphorylation in HCC cells in vitro. Increased 
glycolysis, but also decreased mitochondrial function and respiration are hypothesized to 
promote tumor growth86. As TPC2 KO favors the opposite effect, this study suggests that 
the metabolic implication of TPC2 contributes to the reduced proliferation rate in vitro and 
tumor growth in vivo.  
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Figure 9 I TPC2 knockout alters the metabolic phenotype of cancer cells. (a) RIL175 WT and TPC2 KO 
cells were subjected to extracellular flux analysis on a Seahorse device. Metabolic profiling was performed 
after 1 h of glucose starvation to assess basal glycolytic and respiratory activity, which was followed by 
sequential injection of D-glucose (Glc) and oligomycin (oligom.) to determine glycolysis and respiratory activity 
after injection of saturating concentrations of glucose and glycolytic reserve upon inhibition of oxidative 
phosphorylation, respectively. The last injection of the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) served 
as control. The OCR (oxygen consumption rate)/ECAR (extracellular acidification rate) ratio is displayed over 
time as mean ± SEM, performed in triplicate (unpaired t-test with Welch’s correction, *P < 0.05). An increase 
of the OCR/ECAR ratio, indicating a decreased reliance on aerobic glycolysis of TPC2 knockout cells, is 
visible. ATP levels of (b) RIL175 WT and (c) TPC2 KO cells were monitored in real-time using a FRET (Förster 
resonance energy transfer) biosensor before and after injection of 2-DG (5 mM, t = 30 min), suggesting a 
higher dependence on aerobic glycolysis for energy production of WT cells. ATP is sandwiched between the 
FRET pair, consisting of a green fluorescent protein (GFP) and an orange fluorescent protein (OFP), and 
corresponds to higher FRET efficiency (E). FLIM-FRET imaging was performed by Florian Gegenfurtner and 
Themistoklis Zisis (Prof. Vollmar, LMU Munich). Bar graphs, line charts and images from a representative 
experiment performed in triplicate are shown (unpaired t-test with Welch’s correction, *P < 0.05). 
4.1.2 Development and biological investigation of novel cytostatic TPC2 
inhibitors 
4.1.2.1 Screening of a library of (bis)benzyltetrahydroisoquinolines 
After having shown that genetic ablation of the channel is sufficient to induce antitumor 
effects (Figure 8), we aimed to identify pharmacological TPC2 inhibitors, derived from the 
known inhibitor tetrandrine12, 24, with potent anticancer properties. High micromolar 
concentrations of known TPC2 inhibitors, synthetic compounds Ned-19 (≥ 100 µM) and 
natural flavonoid naringenin (≥ 75 µM) were required to inhibit proliferation of RIL175 cells 
(Supplementary Figure 2 a,b). Thus, these compounds were not studied further. Instead, 
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we screened tetrandrine and related compounds, including commercially available 
bisbenzyltetrahydroisoquinoline (BBTHIQ) alkaloids, such as oxyacanthine and 
berbamine (Figure 10 a), and, additionally, a library of synthesized truncated variants 
(Figure 10 b) for their potential to inhibit cancer cell growth and TPC2 function. Hence, 
BBTHIQs bearing two tetrahydroisoquinoline moieties, as well as monomeric 
1-benzyltetrahydroisoquinolines (BTHIQs, simplified tetrandrine congeners) were 
included in the screening. Synthesis of truncated tetrandrine variants (SG compounds, 
Supplementary Figure 3) was performed by Susanne Gerndt (Prof. Bracher, Department 
of Pharmacy, LMU Munich). Some simplified tetrandrine congeners were previously 
probed by Iturriaga-Vásquez et al. for their affinities to α1-adrenergic receptors and L-type 
Ca2+ channels87.  
Firstly, the antiproliferative properties of our compound library were evaluated using 
RIL175 cells. Thereby, numerous molecules with increased potency as compared with 
tetrandrine (half-maximal inhibitory concentration/IC50: 9.1 µM) were identified, including 
truncated variants with IC50 values in the low micromolar range (Figure 10 a,b). To 
analyze structure-activity relationships, different positions of the tetrahydroisoquinoline 
scaffold were modified and the antiproliferative effect was examined. To make a long story 
short, monomeric BTHIQs bearing additional aromatic residues (phenyl or benzyl ethers) 
at both benzenoid rings were found to have outstanding properties. When modifying the 
amino group, antiproliferative activity remained in a similar range (IC50: 2.4-4.8 µM) when 
N-alkyl residues of different lengths (NH (Z3), N-methyl (SG-005, SG-159), N-ethyl (SG-
158) were used, provided that the nitrogen atom retained its basicity. N-Acyl variants lost 
their antiproliferative properties (SG-089, SG-145, IC50: ≥ 33.0 µM). Variations at C-6 and 
C-7 of the isoquinoline unit had only slight effects. In most cases, loss of the aromatic 
substituents (aryl- or benzyl ethers) in C-7 position slightly decreased antiproliferative 
activity (SG-083, SG-127, SG-157, IC50: 7.6-11.0 µM). The same applied if the 1-benzyl 
group was changed into a phenyl group (SG-122 vs. SG-157), whereas shifting a 
benzyloxy residue from position C-7 to C-6 had no influence (Z3 vs. Z5). Furthermore, the 
impact of modifications of the 1-benzyl residue was investigated. Variation of substitution 
patterns, mostly differing in meta or para position, did not markedly affect antiproliferative 
activity (SG-005, SG-159, Z6, Z11, Z13, Z15, Z18, Z20, IC50: 1.2-4.8 µM). Miscellaneous 
diaryl ethers at the 1-benzyl residue were synthesized bearing both electron-donating and 
-releasing substituents, mainly in meta or para position (SG-153, SG-154, SG-155, SG-
161, SG-162, SG-164, SG-165). In most cases, no changes in antiproliferative potency 
were observed (IC50: 3.9-5.6 µM). However, cyano and chlorine substituents slightly (SG-
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164, SG-165, IC50: 8.5-9.1 µM) and the pyridine moiety strongly reduced it (SG-163, IC50: 
22.0 µM). Further, deletion of both benzyl or diaryl ether moieties resulted in significant 
reduction (SG-132, IC50: 11.0 µM) or complete loss of activity (SG-089, SG-121, SG-121-
NP, IC50: > 50 µM). Summarizing, all BTHIQs carrying two aryl or benzyl ether groups and 
a basic amine inhibited proliferation of RIL175 cells to a similar extent or stronger than 
tetrandrine.  
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Figure 10 I Structures of the (bis)benzyltetrahydroisoquinoline library. (a) Bisbenzyltetrahydroisoquinoline 
alkaloids and derivatives, which were applied in enantiopure form, are listed. (b) Structures of monomeric 
1-benzyltetrahydroisoquinolines, consisting of synthesized tetrandrine congeners (SG compounds) and 
substances from other sources (Z compounds), which were used in racemic form, are shown. SG compounds 
were synthesized by Susanne Gerndt (Prof. Bracher, LMU Munich).  
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Thus, the two simplest BTHIQs, SG-005 and SG-094, either bearing two unsubstituted 
benzyl (SG-005) or two phenyl (SG-094) ethers, were subjected to further investigation. 
SG-005 (IC50: 2.4 µM) and SG-094 (IC50: 3.7 µM) both displayed markedly enhanced 
antiproliferative effects against RIL175 cells, compared with tetrandrine (Figure 11 a). 
Furthermore, SG-005 exerted similar or increased antiproliferative potencies against 
various other cancer cell lines, including human hepatocellular carcinoma (HUH7, 
HepG2), human breast cancer (MCF7), human colorectal adenocarcinoma (HCT-15) and 
human vincristine-resistant acute lymphoblastic leukemia (VCR-R CEM) (Figure 11 b-f). 
Except for HUH7 cells (Figure 11 b), SG-094 inhibited proliferation of the other tested 
cancer cell lines to a similar or higher extent than tetrandrine (Figure 11 d-f).   
 
Figure 11 I Effects of tetrandrine and the truncated analogues SG-005 and SG-094 on various cancer 
cell lines. Antiproliferative effects of the respective compounds were assessed by CellTiter-Blue® cell viability 
assays. (a) RIL175, (b) HUH7, (c) MCF7, (d) HCT-15, (e) HepG2 and (f) VCR-R CEM cells. (a-e) Adherent 
cancer cells were treated for 72 h, (f) VCR-R CEM cells were treated for 48 h and IC50 values were calculated 
by nonlinear regression. (a-f) Fluorescence intensities were normalized to vehicle control and are displayed 
as mean ± SEM of three independent experiments. 
By applying the endolysosomal patch clamp technique71 (performed by Yu-Kai Chao, Prof. 
Grimm, LMU Munich), we analyzed their potential to block PI(3,5)P2-elicited TPC2 
currents. Notably, the bis-phenyl ether SG-094 significantly increased the percentage of 
channel inhibition (75 %) as against tetrandrine (54 %), whereas SG-005 was virtually 
equipotent (44 %) with tetrandrine, the related bisbenzylisoquinoline alkaloid 
cepharanthine and the natural seco-analogue dauricine (Figure 12 a,b). The inhibitory 
effect of tetrandrine, SG-005 and SG-094 on TPC2 was further confirmed by single cell 
Ca2+ imaging (Figure 12 c, performed by Susanne Gerndt, Prof. Bracher, LMU Munich). 
As recently shown by Gerndt et al.6, TPC2 inhibitors can be screened by Ca2+ imaging 
taking advantage of a plasma membrane version of TPC2 using the small molecule 
activator TPC2-A1-N. In contrast, SG-132 and SG-145, either lacking both essential 
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aromatic substituents or a basic nitrogen, respectively, were not able to inhibit TPC2 
activation (Figure 12 d).  
To identify potential eutomers, the racemates SG-005 and SG-094 were separated by 
semi-preparative chiral HPLC (Susanne Gerndt, Prof. Bracher, LMU Munich). The 
absolute configuration of the enantiomers was determined using ECD spectra and 
confirmed by computational calculations (performed by Aaron Gerwien, Prof. Dube, LMU 
Munich, data not shown). Notably, Ca2+ imaging revealed that both enantiomers of SG-
005 and SG-094 inhibit TPC2 upon activation (Supplementary Figure 4, performed by 
Nicole Urban, Prof. Schäfer, Leipzig University). Consequently, the racemates were used 
for all following experiments. Due to the strong dependence of channel activation on the 
transfection level, single cell Ca2+ imaging rather represents a qualitative than a 
quantitative approach. Obviously, the presence of a simplified, monomeric BTHIQ 
structure bearing two aryl ethers (the additional phenyl rings most likely mimicking parts 
of the second benzylisoquinoline unit of tetrandrine) appears to be sufficient to induce 
inhibitory effects on TPC2 and cell proliferation, while both effects are at least as strong 
as those of the more complex lead structure tetrandrine. 
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Figure 12 I Identification of novel TPC2 inhibitors. (a) Chemical structures of tetrandrine, SG-005 and SG-
094 are presented. Dispensable substructures for biological activity of tetrandrine are shaded. Benzyl and 
phenyl moieties of SG-005 and SG-094 at the western half of the molecules, respectively, are highlighted in 
purple. (b) The inhibition percentage of several TPC2 blockers is displayed. 10 µM of inhibitors were applied 
upon activation with 1 µM of PI(3,5)P2 on isolated and vacuolin-enlarged endolysosomes from HEK293 cells 
expressing TPC2-EGFP. The bar graph indicates mean ± SEM of at least two independent experiments 
(unpaired t-test, *P < 0.05). Additionally, a representative current density – voltage relation is shown for a 
recording of the most potent TPC2 inhibitor of the study, SG-094. Patch clamp experiments were performed 
by Yu-Kai Chao (Prof. Grimm, LMU Munich). (c) Ca2+ imaging results of tetrandrine, SG-005, SG-094 and a 
DMSO control using the TPC2 activator TPC2-A1-N6 are displayed. For Ca2+ imaging of inhibitors, HEK293 
cells stably expressing TPC2L11A/L12A –RFP6 were used. After applying the inhibitors (10 µM each) and 
monitoring the signal for 400 s, cells were stimulated with the activator TPC2-A1-N (10 µM) and further 
recorded for 400 s. Experiment was performed at least in sextuplicate and statistical analysis of the maximum 
change in Fura-2 ratio for activation is shown (mean ± SEM, unpaired t-test, *P < 0.05, **P < 0.01). 
Representative Ca2+ signals showing the direct comparison of SG-094 (n= 18 single cells) and DMSO (n= 17 
single cells). Means are represented as highlighted lines, while single cell traces of each experiment are 
visualized as shaded lines. (d) Experiments were performed as in (c), investigating SG-132 (n= 4) and SG-
145 (n= 4) as for their potential to inhibit TPC2 in comparison to vehicle control after activation with TPC2-A1-
N (10 µM). Experiment was performed at least in triplicate and statistical analysis of the maximal change in 
Fura-2 ratio (mean ± SEM, unpaired t-test, ns, not significant) is shown. Representative Ca2+ signals depicting 
the mean of SG-132, SG-145 and a DMSO control and stimulation of each with TPC2-A1-N (10 µM) are 
displayed. Ca2+ imaging was performed by Susanne Gerndt (Prof. Bracher, LMU Munich).  
4.1.2.2 Functional characterization of the tetrandrine congeners SG-005 and SG-
094 
As stated above, SG-005 and SG-094 were identified as advanced candidates from the 
screened (B)BTHIQ library in our effort to identify TPC2 blockers with potent anticancer 
properties. Next, we endeavored to characterize these compounds in more detail in a 
cellular setting by validating known biological effects of TPC2 inhibition and by determining 
their cellular and lysosomal uptake and their effects on glucose metabolism, all in direct 
comparison to tetrandrine.  
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Firstly, we wanted to confirm their on-target activities by investigating their capabilities of 
impairing the VEGFR2/NAADP/TPC2/Ca2+ signaling pathway. The involvement of TPC2-
mediated Ca2+ release in neoangiogenesis of endothelial cells was described by others by 
applying anti-TPC2 shRNA13, the NAADP antagonist Ned-1913 and the TPC2 inhibitor 
naringenin15. Impaired TPC2 function reduced VEGF-evoked activation of eNOS, JNK, 
MAPK and AKT13 in human umbilical vein endothelial cells (HUVECs). We used SG-132 
and SG-145, which do not block TPC2 (4.1.2.1, Figure 12 d), as negative controls. 
Western blot analysis revealed that only SG-005 and SG-094 were capable of significantly 
reducing VEGF-induced phosphorylation levels of several downstream targets, including 
eNOS, JNK and AKT, indicating that both molecules also act as TPC2 inhibitors in a 
cellular setting (Figure 13 a,b). As expected, SG-132 or SG-145 did not result in reduced 
phosphorylation of the investigated VEGFR2 downstream targets. Surprisingly, also 
tetrandrine had no effect under the chosen treatment conditions.  
As tetrandrine and SG-005 displayed a similar inhibitory effect on TPC2 in patch clamp 
analysis (4.1.2.1, Figure 12 b), the question arose if they differ in their pharmacokinetic 
properties. Therefore, we investigated the cellular uptake of tetrandrine, SG-005 and SG-
094 by analytical HPLC. Of all three tested compounds, detectable amounts were taken 
up by HUVECs within a 75 min incubation time at both tested concentrations (2 and 10 µM) 
(Supplementary Figure 5 a). Incorporation of SG-005 into HUVECs was slightly higher 
than that of tetrandrine and SG-094 at 2 µM (Supplementary Figure 5 a). For the higher 
concentration (10 µM), which was previously used for western blot analysis of the VEGF-
dependent signaling pathway, however, no significant differences were found 
(Supplementary Figure 5 a). These data indicate that the driver for improved efficacy of 
SG-005 or SG-094 to hinder VEGF-induced phosphorylation of eNOS, JNK and AKT, as 
compared to tetrandrine, is not an altered uptake into the cells. In a next step, we 
determined the uptake of the TPC2 blockers into RIL175 cells. Neither SG-005 nor SG-
094 were internalized to a greater extent at both concentrations, as compared with 
tetrandrine (Supplementary Figure 5 b). Of note, when comparing their uptake into 
primary endothelial and cancerous liver cells, all three molecules of interest showed a 
preference for RIL175 cells vs. HUVECs (Figure 13 c).  
Thereafter, their uptake into lysosomes was examined by their propensity to diminish 
fluorescence of LysoTrackerTM Red, as shown by others for basic compounds50, 88. 
Interestingly, reduction of LysoTrackerTM Red fluorescence by SG-005 and SG-094 was 
larger than that caused by tetrandrine in HUVECs and RIL175 cells, indicating stronger 
accumulation of the new synthetic compounds in acidic vesicles (Figure 13 d,e). This 
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decrease was similarly observed in RIL175 TPC2 KO cells (Supplementary Figure 6). 
Taken together, analysis of VEGFR2 downstream targets suggested improved on-target 
activity on TPC2 for the tetrandrine congeners SG-005 and SG-094. While initial cellular 
uptake does not markedly differ, accumulation of SG-005 and SG-094 in their intended 
cellular target organelles is enhanced compared to tetrandrine.  
 
 
Figure 13 I SG-005 and SG-094 impair VEGFR2 downstream signaling and are preferably taken up by 
cancer vs. endothelial cells. (a,b) Only SG-005 and SG-094 impair phosphorylation of VEGFR2 downstream 
targets. (a) After serum starvation for 4 h, HUVECs were pre-treated with 10 µM of the TPC2 inhibitors 
tetrandrine, SG-005 and SG-094 or with the non-TPC2 inhibitors SG-132 and SG-145 (chemical structures 
are shown) before stimulation with VEGF-A165 (0.1 µg/mL) for 15 min. Phosphorylated proteins were analyzed 
by western blotting. The experiment was performed in triplicate and a representative experiment is shown. tet, 
tetrandrine. (b) Quantitative evaluation of protein levels from (a) is shown. Proteins of interest were normalized 
to whole lane protein and are presented as percentage relative to vehicle control. The bar graphs indicate 
mean ± SEM of three independent experiments (One-Way ANOVA followed by Dunnett’s multiple comparison 
test, *P < 0.05, **P < 0.01, ns, not significant). (c) Tetrandrine, SG-005 and SG-094 are preferably taken up 
by RIL175 cells. The amount of incorporated compounds within 75 min was determined by analytical HPLC 
and was normalized to cell number. Bar graphs indicate mean ± SEM from three independent experiments 
(unpaired t-test with Welch’s correction, **P < 0.01, ***P < 0.001, ****P < 0.0001). (d,e) Reduction of 
LysoTrackerTM Red fluorescence indicates lysosomal uptake of tetrandrine, SG-005 and SG-094 into (d) 
RIL175 WT cells and (e) HUVECs within 60 min. (d,e) Geometric means of fluorescence intensity (gMFI) were 
determined by flow cytometry and normalized to DMSO control. Concanamycin A (ConcA, 10 nM) served as 
control. Bar graphs indicate mean ± SEM of three independent experiments (One-Way ANOVA followed by 
Tukey’s multiple comparison test, *P < 0.05, **P < 0.01, ****P < 0.0001, ns, not significant). 
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Next, we aimed to test the inhibitors for their implications on glucose metabolism, which 
we identified as one pathway that is altered as a result of TPC2 deficiency (4.1.1.3, Figure 
9). Metabolic profiling revealed that, upon short-term pre-treatment (1 h) with low 
micromolar doses of tetrandrine, SG-005 and SG-094, a shift towards higher oxygen 
consumption after glucose starvation occurred (Figure 14 a). Applying higher 
concentrations of tetrandrine (10-50 µM, 1 h) and extending treatment duration (24 h) also 
caused a metabolic shift towards lower glycolysis, whereas the opposite effect was 
observed for SG-005 and SG-094 (Supplementary Figure 7 a,b). We partly linked this to 
a non-TPC2-related impairment of mitochondrial function, indicated by mitochondrial 
membrane depolarization, which was most evident after SG-005 treatment 
(Supplementary Figure 7 c). Loss of mitochondrial membrane potential results in a 
decoupling of the respiratory chain89, whereas cytosolic glycolysis is likely to remain 
unaffected. Additionally, strong compensatory upregulation of mitochondrial mass was 
detected for longer incubation times and high micromolar doses of SG-005 and SG-094 
(Supplementary Figure 7 d), a phenomenon described in the literature as a response to 
mitochondrial dysfunction90. To further decipher the effects of pharmacological TPC2 
inhibition on cellular energy metabolism, ATP levels were visualized by FRET-based live 
cell monitoring. As observed for genetic TPC2 ablation, SG-005-treated (2 µM, 1 h) 
RIL175 cells were less susceptible to inhibition of the glycolytic pathway (Figure 14 c). In 
contrast, ATP levels in untreated WT cells were significantly decreased after addition of 
2-DG (Figure 14 b), suggesting a stronger dependence on glycolysis for energy 
production. Consequently, pharmacological inhibition of TPC2 can lead to a metabolic shift 
towards a less glycolytic phenotype. 
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Figure 14 I I Tetrandrine, SG-005 and SG-094 affect energy metabolism of RIL175 cells. (a) Tetrandrine, 
SG-005 and SG-094 pre-treatments (1, 2 and 5 µM) increase OCR/ECAR ratios of RIL175 WT cells after 
glucose starvation. Metabolic profiling was performed as described for Figure 9 a. The OCR/ECAR ratios are 
displayed over time as mean ± SEM, performed in triplicate and statistical analyses are shown for 2 µM 
(repeated measures ANOVA followed by Dunnett’s multiple comparison test, *P < 0.05, **P < 0.01). (b,c) 
Real-time monitoring of ATP levels in RIL175 WT cells after pre-treatment with (b) DMSO or (c) SG-005 (2 µM) 
as described in Figure 9 b,c. (b,c) Bar graphs, line charts and images from a representative experiment 
performed in triplicate are shown (unpaired t-test with Welch’s correction, ***P < 0.001, ns, not significant). E, 
FRET efficiency. 
4.1.2.3 SG-005 and SG-094 are less toxic to non-cancerous cells than tetrandrine 
Tetrandrine treatment can be harmful to lungs27 and liver28, 91, 92, 93 in vivo, which was 
related to metabolic activation by CYP enzymes27, 92, 94 or mitochondrial pathways93. As 
we sought to cope with this drawback by simplification to the relevant pharmacophores, 
we probed tetrandrine and its congeners SG-005 and SG-094 for their toxic effect on the 
non-cancerous hepatic stem cell line HepaRGTM. Firstly, HepaRGTM progenitor cells, 
which possess various characteristics of primary human hepatocytes95, were exposed to 
24 h treatment to assess acute toxicity. Tetrandrine treatment caused the strongest 
decrease of cell viability at 10 and 20 µM (10 µM: 88 % viability, 20 µM: 63 % viability), 
compared with SG-005 (10 µM: 104 % viability, 20 µM: 93 % viability) and SG-094 (10 µM: 
104 % viability, 20 µM: 98 % viability) (Figure 15 a). Secondly, differentiated HepaRGTM 
cells were used after seven days in culture, characterized by peak levels of CYP 
activities96, 97. Following treatment with 10 µM, tetrandrine induced a stronger effect on cell 
viability (63 %), as compared with SG-005 (84 %) and SG-094 (90 %), whereas 20 µM 
caused similar cytotoxicities (61-72 % viability) (Figure 15 b). Toxicity was also probed 
against peripheral blood mononuclear cells (PBMCs). At 10 µM, the strongest impact on 
cell viability was observed for tetrandrine (86 %) in comparison to the congeners (SG-005: 
92 %, SG-094: 95 %) (Figure 15 c). Following treatment with 20 µM, SG-094 had the least 
influence on cell viability (91 %) (Figure 15 c). To study whether the observed elevated 
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toxicity of tetrandrine to non-cancerous liver cells is primarily caused by metabolic 
toxification through CYP3A4-mediated oxidation, as proposed by others27, HepaRGTM 
cells were transiently transfected with CYP3A4-EGFP following seven days of culture. 
CYP3A4 overexpression did not increase cell death for any of the tested 
benzylisoquinolines (Figure 15 d). In line with the cell viability assays, tetrandrine 
triggered the highest specific cell death (10 %) of HepaRGTM cells, whilst SG-005 had a 
smaller and SG-094 had no effect (Figure 15 d). Additionally, toxicity to transgenic HepG2 
cells, a cancerous model cell line for recombinant CYP overexpression and hepatotoxicity 
studies98, 99, 100, 101, was evaluated. Both stable (Figure 15 e) and transient overexpression 
(Figure 15 f) of CYP3A4-EGFP did not significantly affect cell death following treatment 
with the three compounds (Figure 15 e,f). Likewise, combination with the CYP3A4 
inhibitor ketoconazole (KCZ)99 had no protective effect against cell death (Figure 15 e,f), 
suggesting that metabolic activation by CYP3A4 is not a primary cause of the increased 
cytotoxicity of tetrandrine in vitro. Metabolic toxification of tetrandrine by CYP3A4 was 
investigated in more detail in chapter 4.1.4. In accordance with the enhanced 
antiproliferative potency of SG-005 against cancerous HepG2 cells (4.1.2.1, Figure 11 e), 
cell death induction was most evident upon SG-005 treatment (Figure 15 e,f). Together, 
our data highlight decreased toxicities of the tetrandrine congeners SG-005 and SG-094 
to non-cancerous liver and blood cells, which is most likely not primarily related to reduced 
susceptibility to toxification by CYP3A4. Thus, removal of substructures from tetrandrine 
slightly (SG-005) or substantially (SG-094) improves the toxicity prolife for healthy cells.   
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Figure 15 I Evaluation of toxicity of tetrandrine, SG-005 and SG-094. (a-d) Toxicity of tetrandrine, SG-005 
and SG-094 to non-cancerous cells was probed by treating (a) HepaRG progenitor, (b) differentiated HepaRG 
and (c) peripheral blood mononuclear cells (PBMCs) with 10 µM and 20 µM of the corresponding compound 
for 24 h. (a,b) Cell viability was assessed by CellTiter-Blue® cell viability assay and was normalized to vehicle 
control. Bar graphs indicate mean ± SEM of three independent experiments (One-Way ANOVA followed by 
Tukey’s multiple comparison test, *P < 0.05, **P < 0.01). (c) Cell viability was quantified by propidium iodide 
staining and flow cytometry after treatment of peripheral blood mononuclear cells (PBMCs) with 10 µM and 
20 µM of the corresponding compound for 48 h. Bar graphs indicate mean ± SEM of three different donors 
(One-Way ANOVA followed by Tukey’s multiple comparison test, **P < 0.01, ***P < 0.001). PBMCs were 
isolated, cultivated and treated by Franz Geisslinger (Master Thesis). (d) Differentiated HepaRG cells were 
transfected with CYP3A4-EGFP or an empty vector control using LipofectamineTM 3000 reagent before 
treatment with 10 µM of tetrandrine, SG-005 and SG-094 for 24 h. Specific cell death was assessed by 
propidium iodide staining and flow cytometry. (e,f) HepG2 cells (e) stably or (f) transiently expressing CYP3A4-
EGFP or an empty vector control were treated with 10 µM of tetrandrine, SG-005 and SG-094 alone or in 
combination with the CYP3A4 inhibitor ketoconazole (KCZ) for 24 h. (e,f)  Cell death was assessed by 
propidium iodide staining and flow cytometry. Data in (d-f) are displayed as mean ± SEM of three independent 
experiments (One-Way ANOVA followed by Tukey’s multiple comparison test, ns, not significant). 
4.1.2.4 SG-094 reduces tumor growth in a murine HCC model 
Apart from the outlined toxicity issues, in vivo use of tetrandrine is limited due to its poor 
solubility and some authors describe the need for dissolving it in acidified solutions before 
dosage24, 27, 102, 103. Hence, the tetrandrine congeners SG-005 and SG-094 were evaluated 
for their therapeutic potential in an ectopic mouse model using C57Bl/6-Tyr mice and 
RIL175 HCC cells. Dosing was adapted from a published dose of 100 mg/kg bodyweight 
(161 nmol/kg) for tetrandrine27 and adjusted by their reduced IC50 values, plus a second 
regimen with a 50 % higher dose (SG-005: 38 nmol/kg and 57 nmol/kg, SG-094: 
59 nmol/kg and 90 nmol/kg). As mouse weight remained constant among all groups over 
the initial dose-finding period (Supplementary Figure 8) and no solubility issues without 
acidification of the injection solutions occurred, SG-005 was finally administered 
intraperitoneally (i.p.) at 57 nmol/kg and SG-094 at 90 nmol/kg every 2-3 days over a 10-
day timescale (Figure 16 a-d). Due to the known toxicity problems, tetrandrine was not 
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used in vivo. To exclude effects of SG-005 or SG-094 treatment on accumulation of D-
luciferin in the engrafted tumors related to altered blood supply, tumor volume was 
measured simultaneously using a caliper (Figure 16 b) in addition to bioluminescence 
imaging (Figure 16 a,d). Notably, 10 days post engraftment of RIL175 cells, average 
bioluminescence signals in the SG-094 arm were decreased by 42 % (not significant) 
(Figure 16 a,d) and average tumor volume in the SG-094 arm  was decreased by 33 % 
(significant) (Figure 16 b). Concurrently, no weight loss (Figure 16 c) or changes in health 
or behavior of the mice were observed and no acidification of the injection solution was 
required. In contrast, the administered dose of SG-005 was not sufficient to markedly 
suppress tumor growth (Figure 16 a,b). 
 
Figure 16 I SG-094 reduces tumor growth in vivo. (a-d) RIL175 WT cells were implanted into the flanks of 
C57Bl/6-Tyr mice. SG-005 and SG-094 were administered intraperitoneally (i.p.) at 57 nmol/kg and at 90 
nmol/kg, respectively, every 2-3 days over a 10-d period, starting on the day of implantation. Line graphs 
indicate (a) bioluminescence signal intensities and (b) tumor volumes over time. (a,b) Engrafted tumors 
derived from TPC2 KO cells are displayed as dashed line for comparison. (a) Data are presented as mean ± 
SEM (n= 9 for WT PBS/DMSO, n= 10 for other treatment arms, outlier identified with Grubbs’ test and α= 0.05, 
One-Way ANOVA followed by Dunnett’s multiple comparison test, ns, not significant). (b) Data are presented 
as mean ± SEM (n= 9 for SG-094, n= 10 for other treatment arms, outlier identified with Grubbs’ test and 
α= 0.05, One-Way ANOVA followed by Dunnett’s multiple comparison test, *P < 0.05). (c) Mouse weight from 
(a,b) is shown over time as mean ± SEM (n= 10). (d) Bioluminescence images taken on day 10 are shown. 
The outlier is marked with an x. One excised tumor is exemplarily shown for each group. 
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4.1.3 TPC2 knockout or inhibition impairs phosphorylation of Akt and 
hexokinase II in vivo 
As shown above, TPC2 KO and inhibition favor oxidative phosphorylation instead of 
glycolysis (Figure 9, Figure 14). Hexokinase II (HK II) has a key role in regulating 
glycolytic flux in cancer82 and, thus, we investigated whether the enzyme is involved in the 
observed metabolic switch. Apart from transcriptional activation82, glycolysis can be 
regulated by phosphorylation of HK II, resulting in increased protein stability and 
mitochondrial binding, which in turn promotes glycolysis, proliferation and cell survival of 
cancer cells as well as tumor growth104. By immunoblotting, two bands were detected for 
HK II, of which the upper one was assigned to the phosphorylated form by comparison 
with the lysate after dephosphorylation (Figure 17 a,b). Levels of phosphorylated HK II 
were strongly reduced in tumors formed by TPC2 KO cells. Translocation and 
phosphorylation of HK II can be facilitated by growth factors via PI3K-AKT signaling105, 106, 
a pathway that can be impaired by TPC2 knockdown or inhibition (Figure 13 a,b and 
literature13, 107). Indeed, protein levels of p-AKT were reduced in tumors from SG-094-
treated mice and from TPC2 KO tumors (Figure 17 a,b). We propose that TPC2 affects 
important metabolic circuits in cancer cells by posttranslational modification of HK II via 
reduced AKT signaling and thus provide important information on mechanistic pathways 
linking TPC2 and cellular metabolism. 
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Figure 17 I TPC2 knockout reduces phosphorylation of Akt and hexokinase II in vivo. (a,b) C57Bl/6-Tyr 
mice were implanted with RIL175 WT or RIL175 TPC2 KO cells and treated as described for Figure 8 and 
Figure 16. Protein levels of p-Akt (Ser473) and hexokinase II in the tumors were analyzed by western blotting. 
(a) Except for the TPC2 KO tumors, two bands were detected for hexokinase II, which converged into one 
band after dephosphorylation of the protein lysates with calf intestinal phosphatase (CIP), indicating that the 
upper band is the phosphoprotein. P-Cofilin (Ser3) served as control for the dephosphorylation reaction. (b) 
Quantitative evaluation of protein levels from (a) in the absence of CIP is shown. Proteins of interest were 
normalized to whole lane protein and are presented as percentage relative to vehicle control. The experiment 
was performed in triplicate and the bar graphs indicate mean ± SEM (One-Way ANOVA followed by Dunnett’s 
multiple comparison test). 
4.1.4 Tetrandrine toxicity is independent of CYP3A4 expression in vitro 
Several studies in the literature suggest that the hepatotoxicity and pulmonary toxicity of 
tetrandrine27, 94 (4.1.2.3) and related bisbenzylisoquinoline alkaloids, such as dauricine108 
and berbamine109, is partly caused by metabolic activation by CYP3A4 and CYP3A5. More 
specifically, the authors proposed that through CYP3A4/5 oxidation, electrophilic 
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metabolites (para-quinone methides) are generated (Figure 18), which they considered 
as major cause for cytotoxicity in vitro and pulmonary or hepatic damage in mice or rats27, 
94, 108, 109.  
 
Figure 18 I Postulated metabolic activation and toxification of tetrandrine, dauricine and berbamine, 
according to Jin et al.27, Jin et al.108 and Sun et al.109. Following oxidative O-demethylation by Cytochrome 
P450 (P450s) enzymes (not specified in more detail), CYP3A4 and CYP3A5 are hypothesized to equally 
oxidize the phenol to form a para-quinone methide, which is prone to attack bio-nucleophiles (Nuc). The 
phenols dauricine and berbamine do not require the demethylation step.  
In a combined medicinal chemistry and cell biology approach we evaluated if a reduction 
of the discussed CYP3A4-mediated toxicity of tetrandrine can be achieved by replacing or 
eliminating the hypothesized metabolically instable 12-methoxy group. We designed 
analogues of tetrandrine, in which this methoxy group is either deleted (RMS1-2) or 
replaced by metabolically stable trifluoromethoxy (RMS3-4) or chlorine substituents 
(RMS9-10) (Figure 19). Further, we replaced the methoxybenzyl residue by a 
thienylmethyl (RMS5-6) and by a non-aromatic butylidene unit (RMS7-8). Chemical 
synthesis was conducted by Ramona Schütz (Prof. Bracher, LMU Munich). Subsequently, 
the effects of the obtained tetrandrine analogues RMS1-RMS10 on HepaRGTM and HepG2 
cells, with or without overexpression of CYP3A4, were investigated.   
 
Figure 19 I Chemical structures of RMS1-RMS10. Various tetrandrine analogues (RMS1-RMS10) 
containing metabolically stable substituents were synthesized by Ramona Schütz (Prof. Bracher, LMU 
Munich). 
To start with, differentiated HepaRGTM cells having high P450 activity96, 97, were treated 
with 10 and 20 µM of tetrandrine and RMS1-10. Unlike expected, none of the new 
compounds was less toxic to HepaRGTM cells than tetrandrine at 10 µM (Figure 20 a). In 
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contrast, RMS4 and RMS10 slightly, but RMS2 strongly decreased cell viability. Similarly, 
at 20 µM, RMS2, RMS4 and RMS10 were significantly more toxic to HepaRGTM cells than 
tetrandrine (Figure 20 b). Of note, 20 µM of RMS6 and RMS7 were significantly less toxic 
than tetrandrine, whereas toxic effects of the other compounds did not substantially differ 
from those of tetrandrine (Figure 20 b). It should be noted that, depending on the 
substituent at C-12 of ring C, oxidation to a para-quinone methide cannot be excluded for 
12-unsubstituted compounds RMS1/RMS2 (via initial CYP-mediated ring hydroxylation), 
whereas in trifluoromethoxy compounds RMS3/RMS4 and chloro compounds 
RMS9/RMS10 oxidation processes are prevented by metabolically stable substituents.  
To specifically determine the influence of CYP3A4 activity on toxicity in vitro, CYP3A4 with 
a C-terminal EGFP tag was cloned (CYP3A4-EGFP) and its physiological function was 
successfully validated by conversion of a proluminogenic CYP3A4 substrate in transiently 
transfected HepG2 cells, which was strongly reduced by the CYP3A4 inhibitor 
ketoconazole99 (Supplementary Figure 9 a). Of note, treatment of CYP3A4 
overexpressing HepaRGTM cells with respective compounds did not significantly increase 
cell death (Figure 20 c). As observed for the non-transfected HepaRGTM cells, RMS2 still 
had the strongest effect on cell viability.  
Next, transgenic HepG2 cells, a liver cancer cell line frequently used for recombinant 
expression of CYP enzymes and hepatotoxicity studies98, 99, 101, were generated. Stable 
transfection and overexpression of CYP3A4 were confirmed by PCR methods 
(Supplementary Figure 9 b,c). Again, no correlation between the level of cellular 
CYP3A4 expression and cytotoxicity was observed (Figure 20 d). Interestingly, most 
tetrandrine analogues (RMS1, RMS2, RMS3, RMS4, RMS5, RMS9, RMS10) exerted 
generally increased cytotoxicities against cancerous HepG2 cells, mostly independent of 
their stereochemistry, in comparison to tetrandrine (Figure 20 d). Surprisingly, the 
diastereomers RMS9 and RMS10 slightly, while RMS5 and RMS6 substantially differed in 
their cytotoxic potencies. Of note, RMS3 and RMS5 influenced cell viability of HepaRGTM 
cells similarly to tetrandrine (Figure 20 a,b), but they exerted strongly increased 
cytotoxicites to cancerous HepG2 cells (Figure 20 d).  
To exclude that the observed similar cytotoxic effects on vector and CYP3A4-EGFP 
transfected cells were caused by insufficient initial demethylation that is required for 
tetrandrine for being oxidized to a putatively toxic para-quinone methide (Figure 18), 
related alkaloids berbamine and dauricine were also tested. Both alkaloids bear a para-
hydroxybenzyl moiety at the region of interest (Figure 10 a, Figure 18), which theoretically 
can be oxidized directly by CYP3A4 to a para-quinone methide with no need for previous 
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O-demethylation. Similarly, for both berbamine and dauricine, cell death was not 
significantly increased by cellular CYP3A4 overexpression (Figure 20 d).  
Taken together, the toxicity of tetrandrine was not considerably decreased or even 
increased by variation of the para-methoxybenzyl moiety in several cellular models. 
However, no influence of the level of cellular CYP3A4 expression was found. 
Consequently, we conclude that the proposed CYP3A4-mediated generation of a para-
quinone methide110 does not substantially contribute to the hepatotoxicity of tetrandrine. 
This piece of work is intended to be published in the European Journal of Medicinal 
Chemistry (Elsevier) (accepted).  
 
Figure 20 I I Evaluation of toxicity of tetrandrine and the tetrandrine analogues RMS1-RMS10. (a,b) 
Toxicity of tetrandrine, SG-005 and SG-094 to non-cancerous cells was probed by treating differentiated 
HepaRG cells with (a) 10 µM and (b) 20 µM of the corresponding compound for 24 h. (a,b) Cell viability was 
assessed by CellTiter-Blue® cell viability assay and was normalized to vehicle control. Bar graphs indicate 
mean ± SEM of three independent experiments (One-Way ANOVA followed by Dunnett’s multiple comparison 
test, *P < 0.05, **P < 0.01, ***P < 0.001). (c) Differentiated HepaRG cells were transfected with CYP3A4-
EGFP or an empty vector control using LipofectamineTM 3000 reagent before treatment with 10 µM of 
tetrandrine or RMS1-RMS10 for 24 h. (d) HepG2 cells stably expressing CYP3A4-EGFP or an empty vector 
control were treated with 15 µM of berbamine, dauricine, tetrandrine, or RMS1-RMS10 for 24 h. (c,d) Specific 
cell death was assessed by propidium iodide staining and flow cytometry. Bar graphs indicate means ± SEM 
of three independent experiments (One-Way ANOVA followed by Tukey’s multiple comparison test, ns, not 
significant). 
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4.1.5 TPC2 blockers also act as P-gp inhibitors and vice versa 
4.1.5.1 Simplified tetrandrine congeners inhibit P-gp 
Apart from TPC2 inhibition, numerous other biological activities and molecular targets are 
described for tetrandrine111. By inhibiting the efflux pump P-gp, it was shown to sensitize 
resistant tumor cells to cytostatics33 and, thus, it has entered early phase clinical studies 
under the brand name CBT-1®34, 35. Therefore, we investigated the influence of the 
tetrandrine congeners SG-005 and SG-094 on the accumulation of the P-gp model 
substrate calcein-AM (Figure 21 a) in vincristine-resistant CEM (VCR-R CEM) cells, 
leukemia cells that overexpress P-gp70. Similar to tetrandrine and the positive control 
verapamil, SG-005 and SG-094 dose-dependently increased calcein fluorescence, 
suggesting that they act as direct P-gp inhibitors (Figure 21 b). Accordingly, combination 
of the P-gp substrate VCR with tetrandrine, SG-005 and SG-094 sensitized VCR-R CEM 
cells towards VCR when analyzing proliferation (Figure 21 c) and cell death dose-
response curves (Figure 21 d). Additionally, immunoblotting confirmed enhanced 
apoptosis, indicated by cleavage of poly (ADP-ribose) polymerase (PARP) and activation 
of caspase 3 (Figure 21 d). Consequently, tetrandrine and its simplified congeners SG-
005 and SG-094 share TPC2 and P-gp as mutual targets. 
 
Figure 21 I Tetrandrine, SG-005 and SG-094 inhibit P-gp and sensitize VCR-R CEM cells to VCR. (a) 
Scheme illustrating the calcein-AM retention assay. (b) Retention of the P-gp model substrate calcein-AM in 
vincristine-resistant CEM (VCR-R CEM) cells was determined by flow cytometry. Cells were incubated with 
calcein-AM, in presence or absence of increasing concentrations of tetrandrine, SG-005, SG-094 and the 
positive control verapamil (vera) (0.1, 1, 10 µM). Bar graph displays means ± SEM of three independent 
experiments (One-Way ANOVA followed by Tukey’s multiple comparison test, ns, not significant, **P < 0.01, 
***P < 0.001). (c,d) Dose-response curves of VCR-R CEM cells, treated with VCR alone or in combination 
with 1 µM of tetrandrine, SG-005 and SG-094 for 48 h are shown. (c) Antiproliferative effects were determined 
by CellTiter-Blue® cell viability assay and (d) cell death was assessed by propidium iodide staining and flow 
cytometry. (e) Cleavage of PARP and activation of caspase 3 in VCR-R CEM cells, treated with either VCR 
(100 nM) alone or in combination with tetrandrine, SG-005 or SG-094 (1 µM) were analyzed by western 
blotting.  
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4.1.5.2 Third generation P-gp inhibitor elacridar is a potent TPC2 blocker 
As the newly identified TPC2 blockers, SG-005 and SG-094, were found to also inhibit P-
gp (4.1.5.1), we investigated whether elacridar, a third generation P-gp and BCRP (breast 
cancer resistance protein) inhibitor that was co-administered with topotecan and 
doxorubicin in clinical phase I trials41, 42, is a TPC2 antagonist. Elacridar bears a 
tetrahydroisoquinoline moiety, but, unlike all bisbenzylisoquinolines and truncated variants 
that were used in this study, elacridar lacks the 1-benzyl or 1-phenyl substituent and a 
chiral center (Figure 22 a). Of note, elacridar strongly reduced PI(3,5)P2-evoked TPC2 
currents in TPC2-EGFP-transfected HEK293 cells (Figure 22 b). When compared with 
tetrandrine, elacridar treatment led to a significantly increased channel inhibition (75 % vs. 
54 %) (Figure 22 c). Hence, the effect of elacridar on cancer cell proliferation was 
investigated. While colon adenocarcinoma cells (HCT-15) were barely affected, elacridar 
moderately inhibited proliferation of hepatocellular carcinoma (HepG2, IC50: 17.1 µM) and 
bladder carcinoma (T24, IC50: 24.6 µM) cells (Figure 22 d). Thus, an extensively 
investigated P-gp inhibitor with minimal side effects in humans41 could be repurposed as 
a potent TPC2 blocker with moderate antiproliferative properties. Further, due to the low 
structural similarities with known TPC2 antagonists, elacridar was identified as new 
chemical lead structure.  
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Figure 22 I Elacridar is a potent TPC2 antagonist and a moderate inhibitor of cancer cell proliferation. 
(a) The chemical structure of elacridar is shown. (b,c) 10 µM of tetrandrine or elacridar were applied upon 
activation with 1 µM of PI(3,5)P2 on isolated and vacuolin-enlarged endolysosomes from HEK293 cells 
expressing TPC2-EGFP. (b) Elacridar strongly blocks PI(3,5)P2-elicited TPC2 currents. Bar graph presents 
means ± SEM of at least three independent experiments (One-Way ANOVA followed by Tukey’s multiple 
comparison test, *P < 0.05, ***P < 0.001). (c) The inhibition percentage of tetrandrine and elacridar is 
displayed. The bar graph indicates means ± SEM of at least two independent experiments (unpaired t-test, 
*P < 0.05). Patch clamp experiments were performed by Yu-Kai Chao (Prof. Grimm, LMU Munich). (d) 
Antiproliferative effects of elacridar on colorectal adenocarcinoma (HCT-15), hepatocellular carcinoma 
(HepG2) and bladder carcinoma (T24) cell lines were determined by CellTiter-Blue® assay. Cells were 
incubated with for 72 h and proliferation is shown as percentage of vehicle control. Line graphs display 
means ± SEM of three independent experiments. 
4.1.6 TPC2 function impacts chemoresistance of P-gp overexpressing cells 
As outlined in chapter 4.1.5, there is a clear overlap between pharmacological TPC2 and 
P-gp inhibitors. Since Al-Akra and coworkers46, among others, recently suggested that P-
gp can be trafficked to the endolysosomal system to promote the lysosomal safe house 
effect, we investigated whether or not there is a functional connection between TPC2 and 
P-gp. As RIL175 cells failed to markedly retain calcein-AM via P-gp (Supplementary 
Figure 10 a), P-gp overexpressing VCR-R CEM cells70 were chosen as capable model to 
study the implication of TPC2 in P-gp-mediated drug resistance. Firstly, elevated TPC2 
mRNA expression in VCR-R CEM cells in comparison to parental, non-resistant CCRF 
CEM cells was determined by qPCR, indicating that TPC2 plays a role in multidrug 
resistance (Figure 23 a). Secondly, we aimed to delete TPC2 in VCR-R CEM cells using 
CRISPR-Cas9 and a single sgRNA approach. An InDel (insertion or deletion of bases) in 
exon 16 (thymidine insertion) was detected by Sanger sequencing (Supplementary 
Figure 10 b), leading to a pre-mature stop codon (Supplementary Figure 10 c). 5’ mRNA 
levels were decreased by ∼82 %, suggesting NMD as a response to the InDel formation 
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(Supplementary Figure 10 d). In patch clamp experiments, PI(3,5)P2-elicited currents of 
enlarged lysosomes obtained from TPC2 KO cells were decreased, suggesting loss of 
channel function (Supplementary Figure 10 e). All seven predicted off-target sequences 
for each sgRNA were analyzed by Sanger sequencing and no InDels were found for the 
investigated clone (Master Thesis Franz Geisslinger, data not shown). Theoretically, 
despite the presence of NMD and the observed reduced channel activation by PI(3,5)P2, 
a minimal residual PI(3,5)P2 activity cannot be fully excluded as the binding site of the 
phosphoinositide is located to an earlier exon. Therefore, it remains to be verified if the 
described thymidine insertion leads to a successful KO or a stable knockdown, e.g. by 
additional recordings of channel currents upon activation with synthetic TPC2 activators6. 
Nonetheless, TPC2-deficient cells are referred to as KO cells in this work and they were 
studied further. In agreement with the impact of loss of TPC2 function in RIL175 cells, 
proliferation of TPC2-deficient VCR-R CEM cells was strongly impaired, as evident by 
counting of cell numbers over time (Figure 23 b) and an increase in doubling time from 
23 h to 31 h (Figure 23 c). Notably, TPC2 KO led to an increased sensitivity towards VCR-
induced apoptosis (WT EC50: 3.0 µM, KO EC50: 1.7 µM, Figure 23 d). Likewise, they were 
more responsive to VCR treatment than their WT counterpart, as evident by a reduced 
IC50 value (WT IC50: 3.3 µM, KO IC50: 1.6 µM) in a cell proliferation assay (Figure 23 e). 
Thus, these data indicate that interfering with TPC2 function reduces proliferation not only 
of solid cancer cells, but also of leukemic cells, and that it contributes to the reversal of P-
gp-mediated drug resistance.  
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Figure 23 I Loss of TPC2 function decreased proliferation of VCR-R CEM cells and sensitized them to 
VCR treatment. (a) Increased mRNA expression of TPC2 in VCR-R CEM WT vs. non-resistant, parental 
CCRF CEM cells was detected by qPCR. (b,c) Counting of cells over 144 h indicated reduced proliferation 
rate of VCR-R CEM TPC2 KO vs. WT cells. (c) Calculation of the doubling time from (b). (a-c) Bar and line 
graphs display means ± SEM of three independent experiments (unpaired t-test with Welch’s correction, 
*P < 0.05, **P < 0.01). (d,e) TPC2-deficient cells are more sensitive towards vincristine (VCR). (d) Apoptosis 
of VCR-R CEM WT vs. KO cells was quantified by propidium iodide staining and flow cytometry following 48 h 
of VCR treatment. (e) The impact of VCR treatment on proliferation of VCR-R CEM WT and KO cells was 
assessed by CellTiter-Blue® assay. Cells were incubated with VCR for 72 h and proliferation is shown as 
percentage of vehicle control. (d,e) Line graphs display means ± SEM of three independent experiments. 
(a-e) Experiments were conducted by Franz Geisslinger (Master Thesis).  
4.1.7 Combination with benzylisoquinolines is beneficial in sorafenib-resistant 
hepatocellular carcinoma cells 
Since genetic TPC2 KO and pharmacological TPC2/P-gp inhibition successfully sensitized 
VCR-R CEM cells to VCR (4.1.5, 4.1.6), tetrandrine, SG-005 and SG-094 were 
investigated in another cell model, sorafenib-resistant HUH7 cells. The orally administered 
multi-kinase inhibitor sorafenib was the first worldwide approved systemic therapy for 
unresectable HCC112. However, resistance to sorafenib remains a problem to date and, 
therefore, Meßner et al. (Prof. Pachmayr, PMU Salzburg) have generated sorafenib-
resistant HUH7 cells (HUH7-R) which tolerate clinically relevant peak concentrations of 
sorafenib (8.5–15.7 µM113). As we have described earlier, those HUH7-R cells are broadly 
cross-resistant to various other cytostatic and cytotoxic agents, which is independent of 
P-gp activity114. Characterization of HUH-R cells has revealed, among others, a higher 
glycolytic phenotype, increased lysosomal volume and elevated cytosolic Ca2+ levels in 
comparison to HUH7 WT114. This invited us to test if a combination treatment with 
tetrandrine, SG-005 or SG-094 was able to reverse resistance of HUH-R cells to sorafenib. 
Notably, low micromolar concentrations of all three tested compounds were able to 
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considerably reduce HUH-R cell growth in combination with 10 µM sorafenib (Figure 
24 a). SG-005 (IC50: 0.7 µM) and SG-094 (IC50: 2.1 µM) achieved significant reduction of 
cell proliferation at lower concentrations than tetrandrine (IC50: 5.8 µM), while SG-005 
showed the most potent effect (Figure 24 b,c). Real-time impedance measurements were 
performed by Martina Meßner (Prof. Pachmayr, PMU Salzburg). Whether or not this effect 
is predominantly mediated by TPC2 inhibition remains to be elucidated by gene silencing 
or knockout experiments.  
 
Figure 24 I Combination of sorafenib with tetrandrine, SG-005 and SG-094 re-sensitized sorafenib-
resistant HUH7 (HUH7-R) cells. (a-c) Proliferation of HUH7-R cells, treated with sorafenib (10 µM) and 
increasing concentrations of tetrandrine, SG-005 and SG-094, was observed by real-time impedance 
measurements. Experiments and data analysis were conducted by Martina Meßner (Prof. Pachmayr, PMU 
Salzburg). (a) Cell growth of HUH7-R cells is shown as cell index over time as means ± SEM of three 
independent experiments. Cell index was normalized to the treatment start. (b) The dose-dependent inhibition 
of growth rate by increasing concentrations of tetrandrine, SG-005 and SG-094 is displayed (One-Way 
ANOVA followed by Dunnett’s multiple comparison test, *P < 0.05). (c) Dose-response curves, calculated from 
(a,b), are shown.  
4.1.8 Biological characterization of the isoquinoline-benzylisoquinoline alkaloid 
muraricine 
Based on the findings of this work, it is clearly obvious that bisbenzylisoquinolines and 
analogues thereof are highly interesting molecules. Thus, the discovery and 
characterization of novel bisbenzylisoquinolines can help to decipher their structure-
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activity relationships and related targets. Recently, a novel bisbenzylisoquinoline alkaloid, 
muraricine, was isolated from Berberis vulgaris (Berberidaceae) by Hostalkova and 
colleagues115. In this seco-bisbenzylisoquinoline, a diaryl ether bridge connecting two 
isoquinoline units is still present, and formally one benzyl unit is lost (Figure 25 a). 
Therefore, muraricine can be regarded as an isoquinoline-benzylisoquinoline alkaloid and, 
based on analogy with related alkaloids, (R) configuration was postulated115. Apart from 
moderate butylcholinesterase inhibition in first investigations115, no pharmacological 
effects are known to date, which prompted us to investigate if rac-muraricine (muraricine), 
obtained by racemic total synthesis (performed by Ramona Schütz, Prof. Bracher, LMU 
Munich) possesses antiproliferative, toxic, TPC2 inhibitory, and multidrug resistance 
reversing properties116. Unlike the reference compound tetrandrine, muraricine showed 
only very low antiproliferative effects and no cytotoxic activity (Figure 25 b). Due to the 
known toxic effects of tetrandrine and other bisbenzylisoquinoline alkaloids, as outlined in 
chapters 4.1.2.3 and 4.1.4, we investigated whether muraricine was toxic to non-
cancerous cells. For that purpose, HUVECs were treated with 10, 20 and 50 µM for 6 h 
and cell viability was assessed by quantifying intracellular ATP content. As expected, 
tetrandrine strongly and dose-dependently affected viability of HUVECs (Figure 25 c). In 
contrast, no significant toxicity to endothelial cells was observed upon muraricine 
treatment (Figure 25 c). In line with the observations from the screening of truncated 
tetrandrine analogues (4.1.2.1), removal of a second aromatic residue led to loss of 
inhibitory activity at TPC2, when subjected to single cell Ca2+ imaging (Figure 25 d,e).  
Results 
76 
 
 
Figure 25 I Weak antiproliferative, toxic and TPC2 inhibitory potential of muraricine. (a) Chemical 
structures of tetrandrine and rac-muraricine (muraricine) are shown. (b) Antiproliferative effects of muraricine 
on hepatocellular carcinoma (HepG2), colorectal adenocarcinoma (HCT-15) and bladder carcinoma (T24) cell 
lines were determined by CellTiter-Blue® assay. Cells were incubated with the respective concentrations for 
72 h and proliferation is shown as percentage of vehicle control after subtraction of the zero value. Tetrandrine 
served as control. Line graphs display means ± SEM of three independent experiments. (c) Acute toxicity to 
non-cancerous human umbilical vein endothelial cells (HUVECs) is shown. Cells were treated for 6 h with 
muraricine and tetrandrine (10, 20, 50 µM) for 6 h. Cell viability was determined by quantifying cellular ATP 
content applying a CellTiter-Glo® cell viability assay and is displayed as percentage of vehicle control as 
means ± SEM of three independent experiments (One-Way ANOVA followed by Tukey’s multiple comparison 
test,  **P < 0.01, ***P < 0.001). (d) Ca2+ imaging results of muraricine, tetrandrine and a DMSO control using 
the TPC2 activator TPC2-A1-N. Representative Ca2+ signals recorded from HEK293 cells stably expressing 
TPC2L11A/L12A–RFP. After applying muraricine (10 µM, n= 19 single cells), tetrandrine (1, 10 µM, n= 17 single 
cells) or DMSO (0.1 % in HBS, n= 16 single cells) and monitoring the signal for 400 s, cells were stimulated 
with TPC2-A1-N (10 µM) and further recorded for 400 s. (e) Statistical analysis of the maximal change in Fura-
2 ratio is displayed as mean ± SEM of at least two independent experiments (unpaired t-test, ns, not 
significant). Ca2+ imaging was performed by Susanne Gerndt (Prof. Bracher, LMU Munich).  
As pointed out, muraricine does not cause direct antitumor effects. Hence, we aimed to 
evaluate its potential as add-on in combination therapy. As inhibition of P-gp could be 
shown for the seco-analogues of tetrandrine, SG-005 and SG-094 (4.1.5.1), we 
investigated the influence of muraricine on the accumulation of the P-gp model substrate 
calcein-AM in VCR-R CEM cells. We found a dose-dependent increase of calcein 
fluorescence (Figure 26 a,b). Although the inhibition of P-gp-mediated calcein-AM efflux 
was weaker than that of the known inhibitor verapamil (Figure 26 a,b), P-gp could be 
identified as target of muraricine. Verapamil was used as positive control since the 
treatment did not affect cell viability under the chosen conditions. To test if a combination 
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of vincristine with muraricine provides a therapeutic benefit, apoptosis of VCR-R CEM 
cells was evaluated. For both tested concentrations of vincristine (0.1 and 1 µM), 
significantly increased apoptosis rates were detected when it was combined with non-toxic 
concentrations of muraricine (25 µM) (Figure 26 c). Taken together, these results 
demonstrate that muraricine represents a non-toxic seco-analogue of tetrandrine without 
direct effects on TPC2 or cancer cell proliferation, but with the potential to overcome drug 
resistance in cancer. This work was published in the journal Archiv der Pharmazie (Wiley‐
VCH Verlag GmbH & Co. KGaA on behalf of Deutsche Pharmazeutische Gesellschaft) in 
2020116.  
 
Figure 26 I Muraricine inhibits P-pg and provides a therapeutic benefit in combination therapy. (a,b) 
Retention of the P-gp model substrate calcein-AM in vincristine-resistant CEM (VCR-R CEM) cells was 
determined by flow cytometry. Cells were incubated with calcein-AM, in presence or absence of increasing 
concentrations of muraricine and the positive control verapamil (1, 10, 20, 50 µM). (a) Histograms of cell 
populations are shown. The experiment was performed in triplicate and one representative experiment is 
shown. (b) Quantification and statistical analysis of data from (a,b). Bar graph displays means ± SEM of three 
independent experiments (One-Way ANOVA followed by Tukey’s multiple comparison test, ns, not significant, 
**P < 0.01, ***P < 0.001). (c) The Percentage of apoptotic cells is shown. VCR-R CEM cells were treated with 
vincristine (VCR, 0.1 and 1 µM) with or without muraricine (25 µM) for 48 h. Apoptotic cells were quantified by 
propidium iodide staining and flow cytometry. Bar graph displays means ± SEM of three independent 
experiments (One-Way ANOVA followed by Tukey’s multiple comparison test, ns, not significant, *P < 0.05, 
***P < 0.001). 
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4.1.9 Part I: Summary 
Here, we describe that genetic TPC2 knockout using CRISPR-Cas9 reduces cell 
proliferation in vitro and effectively suppresses tumor growth in vivo, suggesting that this 
lysosomal ion channel represents a suitable target for cancer therapy. Mechanistically, we 
could show that TPC2 deficiency alters the metabolic phenotype, rendering a lower 
dependency on glycolysis, the main energy-yielding pathway of solid cancers. By 
combining chemical synthesis and state-of-the-art functional testing systems, we 
succeeded in generating novel, tetrandrine-derived TPC2 inhibitors that inhibit TPC2 
currents with either equal (SG-005) or even higher potency (SG-094) than tetrandrine. 
Further, both new molecules display an enhanced potency to inhibit proliferation of several 
cancer cell lines and to impair phosphorylation of angiogenesis related VEGFR2 
downstream targets in endothelial cells. Importantly, reduced toxicity of both simplified 
analogues to liver and blood cells was observed and, thus, one major disadvantage of 
tetrandrine has been overcome. Along this line, SG-094 was well-tolerated and 
successfully reduced tumor growth in a mouse model, thereby representing the first 
described TPC2 inhibitor with antitumor efficacy in vivo. 
Additionally, the advanced candidates SG-005 and SG-094 also inhibited the drug efflux 
pump P-gp, a major cause of multidrug resistance, similarly to tetrandrine. Consequently, 
combination of vincristine with either tetrandrine, SG-005 or SG-094 successfully re-
sensitized drug-resistant leukemia cells. Considering their favorable toxicity profile, SG-
005 and SG-094 represent promising choices to modulate P-gp, for which no approved 
treatment options are available to date. The well described P-gp inhibitor elacridar, in turn, 
was identified as potent TPC2 blocker, revealing that TPC2 and P-gp have structural 
similarities. In addition to the fact that P-gp and TPC2 share mutual pharmacological 
inhibitors, we could also show that TPC2 deficiency sensitized drug-resistant leukemia 
cells towards vincristine, thus influencing chemoresistance.  
Furthermore, we discovered P-gp as pharmacological target of the recently described 
isoquinoline-benzylisoquinoline alkaloid muraricine. Significantly increased apoptosis 
rates were observed in combination with vincristine while no acute cytotoxicity to healthy 
human cells (HUVEC) in concentrations higher than required for reversing 
chemoresistance was detected.  
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Lastly, SG-005 and SG-094 successfully sensitized sorafenib-resistant liver cancer cells 
to sorafenib in a P-gp-independent manner, providing the basis for studying the exact 
underlying mechanisms.  
4.2 Part II: Phenothiazine-based benzhydroxamic acids as inhibitors of HDAC6 
4.2.1 Functional characterization of the HDAC6 inhibitors KV-46, KV-70 and KV-
181 
HDAC6 represents a unique isoenzyme among HDACs as it is predominantly localized in 
the cytoplasm and therefore mainly deacetylates non-histone proteins such as α-tubulin54 
and the HSP90 chaperone55. Defective regulation of HDAC6 activity is associated with a 
variety of human diseases and high expression seems to play a crucial role in the 
pathogenesis of cancer60. By preparation and systemic variation of phenothiazines and 
their analogues containing a benzhydroxamic acid moiety as zinc-binding group (ZBG) 
(synthesis performed by Katharina Vögerl, Prof. Bracher, LMU Munich), we identified KV-
46, KV-70 and KV-181 as potent HDAC6 inhibitors (Figure 27)117. In a biochemical in vitro 
assay (conducted by the group of Prof. Jung, University of Freiburg), their inhibitory 
activities against human HDAC1 and HDAC6 were evaluated. The lead structure KV-46 
already showed very impressive HDAC6 inhibition (IC50 = 22 nM) and a selectivity factor 
(SF) of 231 over HDAC1, thus comparing favorably with the data obtained for tubastatin 
A (IC50 = 30 nM, SF = 64), a known selective HDAC6 inhibitor (Figure 27). The 
incorporation of one or two nitrogen atoms into the phenothiazine scaffold (KV-70, KV-
181) even enhanced the potency for HDAC6. Strikingly, KV-70, bearing an 1-
azaphenothiazine scaffold, attained a very high level of potency and selectivity 
(IC50 = 5 nM, SF = 538)117.  
 
Figure 27 I Chemical structures of the novel HDAC6 inhibitors KV-46, KV-70 and KV-181 (synthesized 
by Katharina Vögerl, Prof. Bracher, LMU Munich) and the known HDAC6 inhibitor tubastatin A. The 
IC50 value indicates their inhibitory activity, as determined by in vitro testing on recombinant human HDAC6. 
The selectivity factor is a measure for their selectivity for HDAC6 over HDAC1. In vitro testing on HDAC6 and 
HDAC1 was performed by the group of Prof. Jung, University of Freiburg.  
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HDAC6 is a crucial regulator of gene expression and transcription in cancer and several 
HDAC6 inhibitors are currently investigated in clinical studies as potential tumor 
therapeutics53. Likewise, we aimed to investigate the effects of KV-70 and KV-181 on 
different cancer cells. The lead structure KV-46 and the pan-HDAC inhibitor vorinostat 
were used as reference compounds. Firstly, cell viability assays indicated that KV46, KV-
70 and KV-181 inhibited proliferation of HUH7 (hepatocellular carcinoma), MDA-MB-231 
(breast adenocarcinoma) and T24 (bladder carcinoma) cells at concentrations of 10 and/or 
100 µM after 72 h of incubation (Figure 28 a). Vorinostat treatment generally resulted in 
stronger antiproliferative effects, with IC50 values in the low micromolar range (HUH7: 
1.2 µM, MDA-MB-231: 2.8 µM, T24: 2.4 µM). Secondly, cytotoxic effects on cancer cells 
were analyzed by measurement of apoptotic cell death. In accordance with 
antiproliferative effects, the highest apoptosis rates of all tested HDAC inhibitors were 
observed after treatment of MDA-MB-231 breast cancer and T24 bladder cancer cells with 
vorinostat for 48 h (Figure 28 b). These findings further emphasize that KV-46, KV-70 and 
KV-181 are selective HDAC6 inhibitors and their application as single treatment only 
causes minor anticancer activity, which is in line with the low clinical activity of selective 
HDAC6 inhibitors53.  
Furthermore, toxicity of the HDAC inhibitors to non-malignant cells was assessed using 
HepaRGTM cells. Toxicity and unfavorable tolerability associated with pan-HDAC inhibitor 
therapy118 remain key unmet needs that have driven the development of specific HDAC6 
inhibitors. Viability of HepaRGTM cells after 24 h of treatment was not significantly reduced 
even at 100 µM concentrations of KV-46 and KV-70, whereas application of vorinostat and 
KV-181 slightly decreased cell viability at the highest tested concentration to around 80 % 
(Figure 28 c).   
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Figure 28 I Effects of HDAC6 inhibitors on proliferation and apoptosis of cancer cells and cell viability 
of non-cancerous liver cells. The pan HDAC-inhibitor vorinostat served as control. (a) Antiproliferative 
effects on HUH7, T24 and MDA-MB-231 cells were assessed by CellTiter-Blue® cell viability assay. Cells were 
treated with vorinostat, KV-46, KV-70 and KV-181 for 72 h. Proliferation is shown as percentage of vehicle 
control. (b) The percentage of apoptotic cells is shown. T24 and MDA-MB-231 cells were treated with the 
respective compounds (1 and 10 µM) 48 h. Apoptotic cells were quantified by propidium iodide staining and 
flow cytometry. (c) Toxicity was probed by treating HepaRG progenitor cells with vorinostat, KV-46, KV-70 
and KV-181 for 24 h. Cell viability was assessed by CellTiter-Blue® cell viability assay and was normalized to 
vehicle control. (a-c) Bar graphs display means ± SEM experiments performed in triplicate (One-Way ANOVA 
followed by Tukey’s multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). 
4.2.2 Influence of HDAC6 inhibition on immune checkpoints and unfolded protein 
response 
The limited anticancer activity of specific HDAC6 inhibitors is sought to be overcome by 
combination strategies, e.g. with immunotherapeutic agents like lenalidomide119 or anti- 
programmed death receptor ligand-1 (PD-L1) antibodies120 or, alternatively, with the 
proteasome inhibitor bortezomib121, 122. Based on that, we hypothesized that KV-46, KV-
70 and KV-181 might alter critical cancer-related pathways, namely immune checkpoints 
and unfolded protein response (UPR). Hence, we checked the influence of specific 
HDAC6 inhibition on PD-L1 and endoplasmatic reticulum chaperone BiP (GRP78). 
Interestingly, western blot analyses of bladder carcinoma lysates revealed that 
pharmacologic HDAC inhibition caused a clear upregulation of PD-L1 (Figure 29 a) and 
a slight increase in GRP78 protein level (Figure 29 b). Since a combination of HDAC6 
inhibition and bortezomib is known to strongly enhance induction of GRP78 and 
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synergistically reduce cell viability121, we tested the influence of simultaneous exposure of 
KV-46, KV-70 and KV-181 and bortezomib on cell proliferation by impedance 
measurements. However, we could not prove a synergism of KV-46, KV-70 and KV-181 
and bortezomib at the tested concentrations (Figure 29 c), which we related to the narrow 
therapeutic window of bortezomib in our setting (Figure 29 d). Taken together, KV-46, 
KV-70 and KV-181 alter protein levels of PD-L1 and GRP78, providing the rationale for 
their future investigation in combination therapies. This piece of work was published in the 
Journal of Medicinal Chemistry (American Chemical Society) in 2019117.  
 
Figure 29 I Alteration of expression of immune checkpoint and unfolded protein response protein 
markers upon HDAC6 inhibition provide the rationale for combination regimens. (a,b) Influence of 
vorinostat, KV-46, KV-70 and KV-171 treatment (48 h) on protein expression of (a) programmed death 
receptor ligand-1 (PD-L1) and (b) endoplasmatic reticulum chaperone BiP (GRP78) in T24 cells. (c) No 
synergism of KV-46, KV-70 and KV-171 (1 µM) with bortezomib (BTZ) could be found by analysing 
proliferation of T24 cells with impedance measurements. (d) A CellTiter-Blue® cell viability assay shows the 
narrow therapeutic window of bortezomib after 72 h of treatment. (c) Graph displays mean and (d) bar graph 
displays means ± SEM of experiments performed in triplicate.   
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4.2.3 Part II: Summary 
With the second part of this project, inhibitors of another cancer-relevant target, HDAC6, 
were investigated. Together with collaborators, the group of Prof. Bracher developed 
HDAC6-specific inhibitors, currently a hot topic in clinical trials, namely the phenothiazine-
based benzhydroxamic acids KV-46, KV-70 and KV-181. Biological characterization 
revealed that all three molecules were relatively non-toxic to non-malignant, hepatocyte-
like cells, they moderately inhibited proliferation of different cancer cell lines and barely 
caused apoptosis. In contrast, the pan-HDAC inhibitor vorinostat impaired proliferation 
and induced apoptosis to a greater extent. These observations are in line with the low 
clinical efficacy of specific HDAC6 vs. pan-HDAC inhibition, providing the rationale for 
combination regimens. In that respect, we detected an upregulation of protein markers of 
the unfolded protein response and immune checkpoints, namely GRP78 and PD-L1, upon 
exposure of bladder cancer cells to KV-46, KV-70 and KV-181.   
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5 Discussion 
5.1 Discussion part I 
5.1.1 Validation of two-pore channel 2 as target for cancer therapy and 
development of synthetically accessible inhibitors 
Inevitably, the identification of novel, druggable targets represents a key step for the 
improvement of tumor therapy. Analysis of differentially expressed gene signatures 
revealed that high gene expression of TPCN2 acts as negative predictive value for post-
operative biochemical recurrence in prostate cancer patients after radical prostatectomy8. 
Moreover, TPC2 was shown to be involved in neoangiogenesis13, 15 as well as migration 
and metastasis formation12, providing incentive for further investigation of its role in cancer.  
Our findings clearly illustrate that TPC2 is a cancer driver as genetic ablation of the 
channel reduced proliferation of liver cancer cells in vitro and effectively halted tumor 
growth in an ectopic mouse model. This, in turn, highlights the need for the development 
of suitable TPC2 inhibitors as potential anticancer drugs. Apart from induction of blood 
vessel formation and activation of invasion and metastasis, chronic proliferation 
doubtlessly represents a key hallmark capability that enables tumor growth14.  
In addition to the frequent dysregulation of cellular proliferation, cancer cells often 
reprogram their energy metabolism in order to fuel extensive cell division14. We unraveled 
that TPC2 influences glucose utilization of liver cancer cells for energy production. 
Mechanistically, TPC2 knockout led to reduced phosphorylation of HK II, a key mediator 
of glycolytic flux, which can be regulated transcriptionally82 or by posttranslational 
modification104, 106. Thus, our work expands the number of cancer hallmarks14 that are 
affected by TPC2. Normal cells convert glucose to pyruvate in the cytosol by glycolysis, 
then further oxidize it to carbon dioxide in mitochondria. Many cancer cells, however, 
preferentially use glycolysis for ATP production, despite the presence of oxygen, a 
phenomenon that is termed aerobic glycolysis or Warburg effect82. Upon loss of TPC2 
function or pharmacological inhibition of this channel, extracellular flux analyses and 
FRET-based live cell monitoring indicated a switch towards lower glycolysis and, hence, 
metabolic reprogramming of liver cancer cells was partly reversed. Although glycolysis 
produces substantially less ATP per mol glucose than mitochondrial oxidative 
phosphorylation14, it is hypothesized that it represents a distinct growth advantage and 
seems to be linked to tumor aggressiveness82. On the one hand, constantly upregulated 
glycolysis provides faster ATP production and metabolic intermediates for biosynthesis of 
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macromolecules required for rapid proliferation and it enables the adaption to hypoxic 
conditions that frequently occur in tumor regions. On the other hand, elevated export of 
the glycolytic waste products lactic acid and hydroxonium ions into the extracellular space 
can facilitate invasion through acidification of the tumor microenvironment82. Several 
preclinical and early phase clinical studies showed efficacy of disrupting glycolytic energy 
metabolism of cancer cells. However, direct inhibition of the glycolytic pathway can cause 
severe toxicity123. By targeting TPC2, we present an alternative approach to indirectly 
interfere with aerobic glycolysis.  
Importantly, we have underlined that TPC2 is a druggable target as novel small molecule 
blockers, SG-005 and SG-094, with antiproliferative activity have been developed in the 
course of this investigation. Taking into consideration that TPC2 KO mice are viable13, 48, 
81, 107, our study suggests that pharmacological interference with TPC2 function is sufficient 
to induce antitumor effects while it can generally be tolerated by mammalian organisms. 
Besides, preferential uptake of the blockers into cancer cells could contribute to the 
observed tumor selectivity.  
Further, the tetrandrine congeners are superior to other known TPC2 inhibitors, naringenin 
and Ned-19, concerning the impairment of proangiogenic signaling and inhibition of cancer 
cell proliferation. Naringenin and Ned-19 were mechanistically studied by others with 
respect to the involvement of TPC2 in VEGF-induced angiogenesis, which is necessary 
for vascularization of solid tumors13, 15. In detail, knockdown of TPC2 using shRNA 
abolished capillary-like tube formation of HUVECs in vitro and vessel formation was 
abrogated in TPC2 KO, but not in TPC1 KO mice, suggesting an isoform-specific role for 
TPC213. This effect was mimicked by treatment with Ned-19 and, mechanistically, it 
reduced Ca2+-evoked phosphorylation of eNOS, JNK, MAPK and AKT, although high 
micromolar doses (100 µM) were required13. Similarly, 500 µM of naringenin were applied 
to prevent VEGF-induced vessel formation15. Of note, we could show that 1 h of pre-
treatment with a far lower concentration of SG-005 and SG-094 (10 µM each) was 
sufficient to impair phosphorylation of VEGFR2 downstream targets, whereas tetrandrine 
did not show an effect. Thus, an improved on-target effect of truncated tetrandrine 
analogues SG-005 and SG-094 was found in intact whole cells, which we partly linked to 
enforced accumulation in lysosomes. 
Additionally, we tested the tetrandrine congeners as well as known TPC2 inhibitors for 
their antiproliferative activities on cancer cells. In line with the reported requirement of high 
concentrations (at ≥ 50 µM) for the impairment of VEGF-induced vessel formation, as well 
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as migration12 and proliferation of tumor cells124, 125, Ned-19 and naringenin displayed 
weak antiproliferative effects on RIL175 cells, starting at high micromolar concentrations 
(at ≥ 75 µM). Instead, we chose tetrandrine as lead molecule as it could successfully inhibit 
migration of invasive cancer cells (at ≤ 15 µM)12 and reduce Ebola virus infection of HeLa 
cells (at ≤ 2 µM)24 via TPC inhibition at low micromolar concentrations. Though tetrandrine 
also considerably inhibited proliferation of RIL175 cells (IC50: 9.1 µM), antiproliferative 
effects were markedly enhanced for SG-005 and SG-094 (IC50: 2.4 and 3.7 µM).  
Moreover, tetrandrine has serious deficiencies, which include its rather moderate inhibition 
of TPC2 (54 % at 10 µM in our setting), its structural complexity and its pulmonary and 
hepatic toxicity27, 28, 91, 92, 93. To cope with these limitations, we have synthesized and 
screened various analogues (other bisbenzylisoquinoline alkaloids and synthetic 
derivatives thereof, truncated analogues, mainly substituted 1-BTHIQs) of the lead 
molecule by cell proliferation assays, calcium imaging and endolysosomal patch clamp. 
Apart from enabling chemical accessibility, structural simplification was proven to be an 
effective strategy to overcome drawbacks of natural compounds, with respect to drug-
likeness and potency126. Exemplarily, structurally simpler analogues of trabectedin127 and 
gambogic acid128 led to equal or stronger antitumor activity, depending on the cell line, 
while the mode of action remained the same. Here, we demonstrate that the rigid, 
macrocyclic BBTHIQ structure of tetrandrine can be reduced to less complex BTHIQ 
scaffold, in case additional aromatic residues (no less than two aryl or benzyl ethers) are 
introduced. These crucial additional aromatic residues most likely mimic the two 
benzenoid rings of the second benzylisoquinoline moiety of the parent compound 
tetrandrine and their flexibility should enable them to adapt to the binding site of the target 
protein. In comparison to the very complex synthetic routes to tetrandrine29, 30, SG-005 
and SG-094 are accessible via a short and inexpensive synthesis. Moreover, simplification 
resulted in similar (SG-005: 44 % at 10 µM) or even enhanced inhibition (SG-094: 75 % 
at 10 µM) of PI(3,5)-P2-evoked TPC2 currents and, as stated before, to comparable or 
stronger antiproliferative properties against several cancer cell lines. This even applied to 
leukemic cells which display a multidrug resistant phenotype (VCR-R CEM)70. 
Concurrently, toxicity to non-cancerous liver cells and PBMCs was markedly reduced for 
SG-094 and slightly reduced for SG-005. Since SG-005 was more toxic to PBMCs than 
SG-094, a lower dose was applied in the ectopic mouse model, but this dose was not 
sufficient to translate the antiproliferative in vitro potency into in vivo efficacy. 
Nevertheless, due to the enhanced on-target effect on TPC2 and the improved toxicity 
profile versus tetrandrine, as outlined above, SG-005 might have the potential to treat 
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other conditions that are connected to TPC2, such as cardiac dysfunction and viral 
infections7, 25, 26. The other optimized tetrandrine congener, SG-094, successfully 
managed to reduce tumor growth in vivo at tolerated doses and thereby represents a 
promising drug candidate for cancer therapy.  
Taken together, we could show that interfering with TPC2 function reduces cancer cell 
proliferation, alters cellular energy metabolism and prevents tumor growth. Additionally, 
we have added easily accessible, potent inhibitors with favorable drug-likeness to the 
limited panel of currently available direct TPC2 blockers. 
5.1.2 Tetrandrine toxicity is independent of cellular CYP3A4 expression 
Tetrandrine has diverse pharmacological activities111, but, as outlined above, its clinical 
application is limited by its toxicity27, 28, 91, 92, 94. Five diastereomeric pairs of novel 
analogues of tetrandrine and its natural diastereomer isotetrandrine, respectively, were 
synthesized and biologically evaluated with respect to their toxicity in the course of this 
investigation. The design of these new analogues was driven by the published hypothesis 
that one particular structural element, the methoxy group at C-12 in para-position to a 
benzylic methylene group, is responsible for toxicity due to its susceptibility to undergo 
enzymatic oxidation to a reactive (toxic) para-quinone methide, which in turn can react 
with bio-nucleophiles27. The shape of the new compounds was intended to prevent this 
oxidative toxification process. Although all the analogues lack the putative problematic 
structure motif, no significant decrease of toxicity could be observed without a concurrent 
reduction of anticancer activity. Compounds RMS2, RMS4 and RMS8 were found to be 
even more toxic to healthy cells than tetrandrine. Moreover, CYP3A4 overexpression in 
two cellular models that are established for recombinant hepatotoxicity studies suggested 
that the propagated mechanism of CYP3A4-mediated toxification involving the para-
quinone methide is no primary cause for the cytotoxicity of tetrandrine and related 
(bis)benzylisoquinoline alkaloids.  
To decipher the correlation between the structure of quinone methides and their liver 
toxicity, Thompson and coworkers129 investigated the toxicity of a series of 4-alkyl-2-
methoxyphenols using an in vitro hepatotoxicity model. Although all tested molecules were 
converted into quinone methides, only little correlation between the rate of quinone 
methide formation in microsomes and relative toxicities of the alkylphenols was found129. 
It was suggested that primarily the reactivity of the quinone methides being formed and 
their stability towards solvolysis are the determining factors for their toxicity. These findings 
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support the results of a former in vivo study130 which observed differences in the toxicities 
of 2-methoxy-quinone methides that could be explained by their relative reactivities131. 
Thus, formation of quinone methides does not necessarily lead to toxicity in vitro and in 
vivo. 
Not only the comparison of tetrandrine with the analogues RMS1-RMS10 that lack the 
putative problematic structure motif, but also our study performed with the isoquinoline-
benzylisoquinoline muraricine suggest that enzymatic oxidation to a para-quinone methide 
is not the primary cause for in vitro toxicity. Tetrandrine strongly and dose-dependently 
reduced cell viability of HUVECs within a 6 h treatment period, whereas muraricine did not 
show an effect. Muraricine contains a para-hydroxybenzyl moiety and could theoretically 
be oxidized to a (toxic) para-quinone methide by CYP3A4 without the need for previous 
O-demethylation. Since HUVECs express various CYP enzymes, including CYP3A132, but 
no cytotoxic effect even at micromolar high doses of muraricine (50 µM) was observed, 
this finding further contradicts the hypothesis of CYP3A4-mediated toxification of 
tetrandrine and related alkaloids.  
For tetrandrine, other proposed mechanisms might play a more substantial role in toxicity, 
such as the generation of ROS by CYP2E192 or the proposed interaction with p38α MAPK, 
a promotor of inflammatory processes in the liver91, or additional effects that remain to be 
elucidated. 
5.1.3 TPC2, tetrahydroisoquinolines and chemoresistance 
As outlined in chapter 5.1.1, the simplified tetrandrine congeners SG-005 and SG-094 are 
superior to their parental molecule regarding inhibitory on-target effects on TPC2 in a 
cellular setting and the toxicity profile. Additionally, we could show that SG-005 and SG-
094 inhibit the efflux transporter P-gp and thus successfully reversed chemoresistance of 
VCR-R CEM cells to vincristine. P-gp facilitates the efflux of cytostatic drugs and thereby 
represents a major cause of treatment failure and resistance to common cancer 
therapeutics37. As no clinically approved treatment options are available so far, there is a 
high unmet need for identifying novel safe and efficacous P-gp inhibitors. Inhibition of P-
gp ist mostly described for macrocyclic bisbenzylisoquinolines like tetrandrine, which even 
advanced into early phase clinical trials34, 35, and related alkaloids37, but also for some 
seco-analogues, such as sanguinarine133 and chelidonine134. Considering their reduced 
toxicity to non-malignant hepatocytes and PBMCs, in comparison to tetrandrine, the seco-
analogues SG-005 and SG-094 might represent novel safe and effective options to 
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reverse multidrug resistance in cancer. Furthermore, since tetrandrine, SG-005 and SG-
094 inhibit both TPC2 and P-gp, structural similarities between the binding pockets on 
both proteins must be present. The three-dimensional structure of P-gp has been resolved 
and numerous, structurally diverse inhibitors are known37, 38, which could aid to identify 
new lead structures for TPC2 blockers.  
In contrast to tetrandrine, SG-005 and SG-094, muraricine was not capable of blocking 
TPC2 currents in Ca2+ imaging experiments nor had significant antiproliferative or 
cytotoxic effects on cancer or endothelial cells. Muraricine lacks a second aryl or benzyl 
ether being essential for TPC2 inhibition, which is in line with the conclusions drawn from 
the screening of simplified tetrandrine congeners. Aside from moderate 
butylcholinesterase inhibition that was found upon initial investigations115, no 
pharmacological activities of muraricine were known. We could show that muraricine 
moderatly inhibits P-gp and sensitizes drug-resistant leukemia cells to vincristine at a 
concentration that can be tolerated by non-malignant cells, albeit significantly higher 
concentrations (25 µM) were necessary than for tetrandrine, SG-005 and SG-094 (1 µM). 
Based on our synthetic approach, systematic structure variations of muraricine can be part 
of future drug design projects, as there is a high clinical need for P-gp inhibitors for the 
treatment of chemoresistant tumors.   
The other way around, we tested elacridar, representative for third-generation P-gp 
inhibitors, for its ability to block TPC2. Indeed, patch clamp experiments revealed that it 
reduced TPC2 currents to a stronger extent than tetrandrine, challenging the widely 
accepted view on elacridar specifically acting on efflux pumps39. Although elacridar bears 
a tetrahydroisoquinoline moiety, the acridone substituent and the lack of the 1-benzyl or 
1-phenyl substituent substantially differentiate it from tetrandrine and analogues thereof. 
Consequently, elacridar might also represent a new lead structure for further optimization 
of TPC2 inhibitors. Thinking one step ahead, this further provides the basis for 
investigating other third-generation inhibitors, such as tariquidar, laniquidar and 
zosuquidar, which could potentially be repurposed as TPC2 inhibitors for tumor therapy 
and beyond. The molecules of this class have a known and favorable safety profile, when 
applied as monotherapy, which could simplify translatability into clinical practice. For 
instance, toxicity of three doses of zosuquidar 500 mg peroral (p.o.) was minimal135 and 
adverse events of elacridar 400 mg p.o. twice daily were limited to occasional somnolence 
and gastrointestinal complaints41. However, when compared to SG-005 and SG-094, far 
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higher concentrations of elacridar were necessary to achieve direct anticancer effects. 
Hence, it remains to be determined if such plasma levels can be achieved with elacridar.   
Interestingly, TPC2 and P-gp or, more generally, chemoresistance, not only share 
common small molecule modulators, they also seem to be functionally connected. We 
found that TPC2 mRNA levels were elevated in P-gp overexpressing VCR-R CEM cells in 
comparison to their non-resistant, parental counterpart and that TPC2 KO slightly 
sensitized VCR-R CEM cells to VCR, suggesting that TPC2 affects chemoresistance. 
Since recent works of others45, 46 pointed out that P-gp is not only localized to the plasma 
membrane, but can also be relocated to the lysosome to tremendously enhance lysosomal 
sequestration of chemotherapeutics, it will be of great relevance to study if TPC2 affects 
cellular localization of P-gp and thereby sensitizes resistant cells to cytostatic agents. 
Targeting of lysosomal proteins, such as the V-ATPase and the acid sphingomyelinase, 
was proven to be a successful strategy to overcome multidrug resistance. Specifically, V-
ATPase knockdown sensitized doxorubicin-resistant MCF-7 cells to doxorubicin and 
vincristine49. Targeting acid sphingomyelinase, a lipase responsible for lysosomal 
hydrolysis of sphingomyelin, was proven to be another effective strategy to successfully 
treat multidrug resistant tumors, by disrupting lysosomal membrane integrity and thereby 
achieving cancer-specific cytotoxicity50. 
Additionally, the TPC2 blockers tetrandrine, SG-005 and SG-094, significantly enhanced 
the response of sorafenib-resistant liver tumor cells to sorafenib. The broad cross-
resistance of those HUH7-R cells was previously found to be independent of the multidrug 
resistance machinery. Instead, a shift towards a higher glycolytic phenotype, elevated 
cytosolic Ca2+ levels and increased lysosomal volume were observed, among others, 
when compared to the sensitive WT counterpart114. Since these characteristics can 
potentially be influenced by modulating TPC2 function, we tested the ability of tetrandrine 
and its congeners SG-005 and SG-094 to provide a therapeutic benefit. As this was the 
case, it remains to be clarified by using genetic knockdown/knockout models if blocking 
TPC2 is the main reason for the sensitization or if e.g. the basicity and potentially related 
lysosomotropic effects play a more important role.  
Taken together, novel seco-analogues of tetrandrine, SG-005, SG-094 and muraricine 
were found to be either chemosensitizers and/or inhibitors of P-gp, thus aiding the search 
for effective multidrug resistance modulators. Further, first hints for TPC2 being a 
contributor to drug resistance were provided and a dual mode of action of TPC2 and P-gp 
antagonists was established.   
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5.2 Discussion part II 
In contrast to most other HDACs, HDAC6 is primarily located in the cytoplasm and also 
deacetylates various non-histone substrates, such as cortactin56 and α-tubulin62. Thereby, 
it is involved in cellular processes, including proliferation and motility57, and it has gained 
great interest as target in tumor therapy53. By developing the HDAC6 inhibitors KV-46, KV-
70 and KV-181 with superior potency and specificity compared with the known HDAC6 
inhibitor tubastatin A, we have addressed the high need for the identification of HDAC6-
specific inhibitors53. By variation of the phenothiazine-based capping motif, KV-70 could 
be developed as the most potent (IC50: 5 nM) and isoenzyme-specific (SF of 538 over 
HDAC1) HDAC6 inhibitor of our study. As expected, antiproliferative effects of KV-46, KV-
70 and KV-181 on several cancer cell lines were lower in comparison to those of the pan-
HDAC inhibitor vorinostat. Likewise, induction of apoptosis was strongly reduced, which 
is in line with a study conducted by Woan et al.136, who observed decreased proliferation 
without induction of apoptosis upon HDAC6 knockdown in melanoma cells. Further, 
viability of non-cancerous HepaRGTM cells was hardly or not at all impaired upon exposure 
to KV-46, KV-70 and KV-181, indicating low toxicity of the compounds. Undesired toxicity 
of pan-HDAC inhibition caused by indiscriminate modulation of various HDAC isoenzymes 
limits its clinical use and, thus, the usage of more selective HDAC inhibitors is sought to 
improve patient prognosis to a greater extent53.  
The limited efficacy of specific HDAC6 inhibition alone in both preclinical and clinical 
setting has driven studies on combination regimens, mainly with proteasome inhibitors66, 
68, 121, 122 and immunomodulatory agents136, 137, 138. Interestingly, we found that HDAC6 
inhibition by KV-46, KV-70 and KV-181, as well as pan-HDAC modulation by vorinostat, 
increased protein expression of GRP78, a marker for the activation of the unfolded protein 
response (UPR). The UPR is responsible for detection of misfolded proteins and the 
control of their disposal. Misfolded proteins can either be eliminated via the proteasome 
or the aggresome. Simultaneous blockade of the two main garbage-disposal systems, 
namely the proteasome by proteasome inhibitors and the aggresome by HDAC inhibitors, 
can synergistically increase cytotoxicity139. In this context, Amengual et al.121 detected 
increased GRP78 expression following treatment of lymphoma cells with ricolinostat, an 
effect that was enhanced by the proteasome inhibitor bortezomib. Later, Li and 
coworkers140 detected elevated GRP78 protein levels after exposure of colon cancer cells 
to tubastatin A. Although we could not show a synergistic effect with bortezomib due to its 
narrow therapeutic window, our results further extend the knowledge about the impact on 
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HDAC6 inhibition on UPR and proposes KV46, KV70 and KV-181 as candidates for 
combination studies with proteasome inhibitors.  
Moreover, our data could help to decipher the interaction of HDAC6 and PD-L1 in cancer, 
which is still debated. In our study, both pan-HDAC (vorinostat) and HDAC6 inhibition (KV-
46, KV-70, KV-181) increased PD-L1 protein levels in T24 bladder cancer cells. Woods et 
al.141 could show that class I and pan-HDAC inhibition (panobinostat, entinostat, 
MGCD0103) enhances antitumor immunity by upregulating PD-L1 expression in a panel 
of melanoma cell lines in vitro and in vivo, Lienlaf and coworkers137, on the other hand, 
found a reduction of PD-L1 protein level after HDAC6 inhibition (tubastatin A and 
nexturastat A) in melanoma cells. They reported that HDAC6 is essential for cytokine-
mediated expression control of PD-L1. Yet, Woan et al.136 could not detect alterations in 
PD-L1 protein level after pharmacologic (tubastatin A and nexturastat A) or shRNA 
knockdown of HDAC6 activity in both human and murine melanoma cell lines. It is 
therefore obvious that more research has to be performed to clarify the role of HDAC6 in 
PD-L1 regulation. Although several HDAC6-selective inhibitors are available, inhibition of 
other HDACs can lead to opposing effects, depending on the concentration of the inhibitor 
and incubation times. Unfortunately, studies on stable HDAC6 knockout cells and the 
influence on PD-L1 expression are lacking to date. Adding still more complexity to the 
question, the regulation might also be tissue specific as tumors of different origin display 
distinct immunogenicity142. Therefore, HDAC6 inhibition can cause an upregulation of PD-
L1 in bladder cancer, as reported in our study, and at the same time an unchanged 
expression or a downregulation in melanoma as reported by Woan et al.136 and by Lienlaf 
et al.137, respectively.  
Taken together, the novel potent and selective HDAC6 inhibitors KV-46, KV-70 and KV-
181 were developed and our findings confirm the rationale for combining them with anti-
PD1/anti-PD-L1 antibodies and proteasome inhibitors. 
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7 Appendix 
7.1 Supplementary Information 
7.1.1 Supplementary Figures 
 
Supplementary Figure 1 I Generation of a TPC2 knockout cell line. (a) Agarose gel analysis of RIL175 
CRISPR clones is shown. For the upper gel, primers spanning exon 2 (ex 2), and for the lower gel, primers 
binding within the excised exon 2 sequence, were used for PCR. The clone 1D1, later referred to as TPC2 
knockout (KO) und used for all further experiments, is highlighted. The lower panel displays a two-sequence 
alignment of the WT and the deleted genomic region for the clone 1D1, which is highlighted in yellow. (b) 
Absence of the deleted mRNA region in TPC2 KO cells was confirmed by quantitative real-time PCR (qPCR) 
using two different primer pairs. The bar graph displays the quantified mRNA amount, which was subsequently 
analyzed on an agarose gel. Actin served as control. nd, not determined. (c) Strongly reduced 5’ mRNA levels 
indicated the presence of nonsense-mediated decay (NMD) as a response to the deletion. qPCR was 
performed as described in (b), but a primer pair consisting of a forward primer binding to the 5’ end and a 
reverse primer binding outside of the deleted region of TPC2 mRNA was used. Data are expressed as mean 
± SEM, performed in duplicate (unpaired t-test with Welch’s correction, *P < 0.05). 
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Supplementary Figure 2 I Weak antiproliferative effects of Ned-19 and naringenin. Antiproliferative effects of 
(a) Ned-19 and (b) naringenin on RIL175 WT cells were assessed by CellTiter-Blue® cell viability assays. 
(a,b) Fluorescence intensities were normalized to vehicle control and are displayed as mean ± SEM of three 
independent experiments. 
 
 
Supplementary Figure 3 I Synthesis of truncated analogs of tetrandrine. (i) Acyl-Pictet Spengler reaction: 
phenylethyl amides of type I, enol ethers of type II, TFA, 4 Å molecular sieves, CH2Cl2, 0 °C → rt, 18-90 h. (ii) 
Reduction: Carbamates of type III, LiAlH4, THF, reflux, 3-20 h. Subsequent construction of diaryl ethers from 
tetrahydroisoquinolines of type IV with one or two free phenolic groups was achieved by Chan-Evans-Lam 
coupling with the appropriate arylboronic acids and Cu(OAc)2 catalyst under alkaline dry conditions. Synthesis 
of tetrandrine congeners (SG compounds) was performed by Susanne Gerndt (Prof. Bracher, LMU Munich).  
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Supplementary Figure 4 I Enantiomerically pure (S)-SG-005, (R)-SG-005, (S)-SG-094 and (R)-SG-094 
have inhibitory effects on TPC2, as determined by Fluo-4 based Ca2+ imaging. (a-f) After separation of 
the racemic mixtures SG-005 and SG-094 by semi-preparative chiral HPLC, inhibitory effects of the 
enantiomers and racemates were probed by Fluo-4 based Ca2+ imaging. Therefore, cells were sequentially 
treated with SG-005, (S)-SG-005, (R)-SG-005, SG-094, (S)-SG-094, (R)-SG-094 and the TPC2 activators 
(a,d) TPC2-A1-P or (b,e) TPC2-A1-N1. Line graphs show means ± SEM of at least three independent 
experiments. Experiments were performed by Nicole Urban (Prof. Schäfer, Leipzig University).  
 
 
Supplementary Figure 5 I Uptake of tetrandrine, SG-005 and SG-094 into HUVECs and RIL175 cells. The 
amount of incorporated compounds within 75 min into (a) HUVECs and (b) RIL175 cells was determined by 
analytical HPLC and was normalized to cell number. (a,b) Bar graphs indicate means ± SEM from three 
independent experiments (One-Way ANOVA followed by Tukey’s multiple comparison test, *P < 0.05, ns, not 
significant). 
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Supplementary Figure 6 I Lysosomal uptake of tetrandrine, SG-005 and SG-094 into RIL175 TPC2 KO 
cells. Reduction of LysoTrackerTM Red fluorescence indicates uptake of tetrandrine, SG-005 and SG-
094 into acidic vesicles of RIL175 TPC2 KO cells within 60 min. Geometric means of fluorescence intensity 
(gMFI) were determined by flow cytometry and normalized to DMSO control. Concanamycin A (ConcA, 10 nM) 
served as control. Bar graphs indicate mean ± SEM of two independent experiments (One-Way ANOVA 
followed by Tukey’s multiple comparison test, ****P < 0.0001). 
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Supplementary Figure 7 I Effects of high-dose and long-term treatment with tetrandrine, SG-005 and SG-
094 on metabolic parameters and mitochondria. (a,b) Metabolic profiling was performed as described for 
Figure 14. Tetrandrine, SG-005 and SG-094 (a) high-dose pre-treatment (10, 20 and 50 µM) for 1 h and (b) 
low-dose pre-treatment (1, 5 and 10 µM) for 24 h and their influences on OCR/ECAR ratios of RIL175 WT 
cells after glucose starvation are shown. The OCR/ECAR ratios are displayed over time as mean ± SEM, 
performed in triplicate. (c,d) RIL175 WT cells were treated with the indicated concentrations of tetrandrine, 
SG-005 and SG-094 for 1 h or 24 h, respectively, (c) before staining with JC-1 (1 µg/mL). Loss of mitochondrial 
membrane potential was quantified by determining the percentage of green fluorescent JC-1 monomers by 
flow cytometric analysis. The mitochondrial uncoupler CCCP (100 µM) served as control. Data are shown as 
mean ± SEM of two independent experiments (One-Way ANOVA followed by Dunnett’s multiple comparison 
test, *P < 0.05). (d) Mitochondrial mass was determined by MitoTrackerTM Green FM staining and flow 
cytometry. Data are displayed as geometric mean of fluorescence intensity (gMFI) relative to vehicle control 
as mean ± SEM of at least three independent experiments (One-Way ANOVA followed by Dunnett’s multiple 
comparison test, *P < 0.05, **P < 0.01, ***P < 0.001). 
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Supplementary Figure 8 I Mouse weight during the dose-finding test for SG-005 and SG-094. C57Bl/6-
Tyr mice were treated with the indicated doses of SG-005 and SG-094 (i.p.) on three consecutive days. Mouse 
weight was observed and is displayed as mean ± SEM of three mice per group. 
 
 
Supplementary Figure 9 I Confirmation of CYP3A4-EGFP activity and presence in transfected HepG2 
cells. (a) HepG2 cells were transiently transfected with pcDNA3-CYP3A4-EGFP or empty vector control and 
CYP3A4 activity was confirmed with a luminescence-based P450-GloTM assay in presence or absence of the 
CYP3A4 inhibitor ketoconazole (KCZ, 10 µM). Experiment was performed in duplicates (Two-Way ANOVA 
followed by Sidak’s multiple comparison test, ****P < 0.0001). (b) Presence of pcDNA3-CYP3A4-EGFP or 
empty vector control in stably transfected HepG2 cells was confirmed by PCR and subsequent agarose gel 
analysis. (c) Overexpression of CYP3A4 mRNA in stably transfected HepG2 cells was confirmed by qPCR. 
Experiment was performed in triplicate (unpaired t-test with Welch’s correction, ***P < 0.001). 
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Supplementary Figure 10 I Utilization of VCR-R CEM cells as model cell line to study the influence of 
TPC2 on P-gp-mediated drug resistance. (a) Calcein-AM retention is low in RIL175 WT cells, as determined 
by flow cytometry. Cells were incubated with calcein-AM (ctrl), in presence or absence of increasing 
concentrations of the respective P-gp inhibitors (0.1, 1, 10 µM). Bar graph displays means ± SEM of three 
independent experiments. (b) A thymidine insertion in the VCR-R CEM TPC2 KO clone was detected by 
Sanger sequencing. (c) The thymidine insertion led to a premature stop codon, indicated by an asterisk. (d) 
Significantly reduced 5’ mRNA levels, detected by qPCR, indicate the presence of nonsense-mediated decay 
(NMD) as a response to the insertion. Data are expressed as mean ± SEM, performed in triplicate (unpaired 
t-test with Welch’s correction, **P < 0.01). (e) PI(3,5)P2-evoked TPC2 currents were reduced in vacuolin-
enlarged TPC2 KO cells, compared with the WT control. Patch clamp recordings were performed by Yu-Kai 
Chao (Prof. Grimm, LMU Munich).    
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7.1.2 Supplementary Tables 
C
F
D
 s
c
o
re
 
g
e
n
e
 
TPC
2 
geno
type 
PCR: forward 
primer (5'-3') 
PCR: reverse 
primer (5'-3') 
sequencing 
primer (5'-3') 
potential off-target:  
Sanger sequencing 
(5'-3') 
polym
erase 
0
.4
9
  
K
a
t7
  
WT 
CCCAAAGTTCA
GTGAGGCCT 
CACCTGTACTCA
GCAGACCG 
CCCAAAGTTCAG
TGAGGCCT 
CCAGCACTTGCCC
ACTTGGTAGT 
Phusio
n 
KO 
CCAGCACTTGCCC
ACTTGGTAGT 
Phusio
n 
 
0
.4
0
  
S
h
3
p
x
d
2
a
  
WT 
TCACACACACA
CACAGCACT 
GGGCCCCTTTC
ATACCTGAC 
TCACACACACAC
ACAGCACT 
TCTACAGACAAGG
CACGTTCGGG 
Phusio
n 
KO 
TCTACAGACAAGG
CACGTTCGGG 
Phusio
n 
 
0
.3
5
  
C
lin
t1
  
WT 
TGCTTCCTTTCA
TCCCCGAC 
GCAGGTAAGGT
ACAGGCAGG 
TGCTTCCTTTCAT
CCCCGAC 
TCTGCTAACAGGA
CACAAGCAGG 
Phusio
n 
KO 
TCTGCTAACAGGA
CACAAGCAGG 
Phusio
n 
 
0
.3
5
  
S
p
1
0
0
  
WT 
TGGGTACTCAG
GACCTCTGG 
CTGGCTGTCCT
GGAACTCAC 
ATATGGGTACTC
AGGACCTCTG 
CCAGAACGTGTCC
TGTTAATAAA 
Q5 
KO 
CCAGAACGTGTCC
TGTTAATAAA 
Q5 
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TPC
2 
geno
type 
PCR: forward 
primer (5'-3') 
PCR: reverse 
primer (5'-3') 
sequencing 
primer (5'-3') 
potential off-target:  
Sanger sequencing 
(5'-3') 
polym
erase 
 
0
.3
3
  
G
m
7
5
9
2
  
WT 
TCTGTGTACCAC
TTGTGCCC 
CATCTCGCCAG
CCCACTTTT 
GGGAATCGAACT
CAGGACCT 
CCAGAATGTGTCC
TGTTAATAAA 
Q5 
KO 
CCAGAATGTGTCC
TGTTAATAAA 
Q5 
 
0
.3
2
  
4
9
3
0
5
1
9
G
0
4
R
ik
  WT 
CGGAGCGGCTT
AGTCCTAAG 
TGGCTGCTTTTC
CAGAGGAC 
CGGAGCGGCTTA
GTCCTAAG 
TCTACCCACTAGA
CACGTGCAGG 
Phusio
n 
 
KO 
TCTACCCACTAGA
CACGTGCAGG 
Phusio
n 
 
0
.2
9
  
R
a
lb
p
1
  
WT 
TGTGGGCAGAG
TAGGAGTGT 
ATGAGCAACCA
TTCCCCAGG 
TGTGGGCAGAGT
AGGAGTGT 
CCAGCACGTGTGC
TGCTGGTAAA 
Phusio
n 
KO 
CCAGCACGTGTGC
TGCTGGTAAA 
Phusio
n 
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TPC
2 
geno
type 
PCR: forward 
primer (5'-3') 
PCR: reverse 
primer (5'-3') 
sequencing 
primer (5'-3') 
potential off-target:  
Sanger sequencing 
(5'-3') 
polym
erase 
 
0
.2
9
  
2
6
1
0
5
0
7
B
1
1
R
ik
  
WT 
CTCTCTGGTCC
AGGCACTTG 
CCTTGAGGGAG
TTGAGGCAG 
CCTTGAGGGAGT
TGAGGCAG 
CCCGCACTTGCCC
TTTTCCTAGT 
Phusio
n 
KO 
CCCGCACTTGCCC
TTTTCCTAGT 
Phusio
n 
 
0
.2
8
  
W
n
t4
  
WT 
CGGAGGTGTGG
ATTAGCCTC 
GAGGCTGACCA
TCCTTGCTT 
CGGAGGTGTGGA
TTAGCCTC 
TCTAGAAACTGGG
CACAAGCTGG 
Phusio
n 
KO 
TCTAGAAACTGGG
CACAAGCTGG 
Phusio
n 
 
0
.2
7
  
G
m
1
7
4
9
5
  
WT 
GCTGCTCCCAT
CAATTTGCTC 
GATTCCAAGTG
GTGCCTGGA 
GATTCCAAGTGG
TGCCTGGA 
CCAGCACTTGCCC
TGCTTGTGGA 
Q5 
KO 
CCAGCACTTGCCC
TGCTTGTGGA 
Q5 
 
Supplementary Table 1 I CRISPR-Cas9 off-target screening. The ten predicted off-target sequences present 
in exons or introns with the highest CFD scores for the 5' sgRNA were amplified by PCR and analyzed by 
Sanger sequencing. The investigated off-targets, sequences and the used primer pairs and polymerases are 
shown. 
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C
F
D
 s
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g
e
n
e
 
TPC2 
geno
type 
PCR: forward 
primer (5'-3') 
PCR: reverse 
primer  (5'-3') 
sequencing 
primer  (5'-3') 
potential off-target:  
Sanger sequencing 
(5'-3') 
polym
erase 
0
.5
1
  
F
a
rs
2
  
WT GCTGATGGCTG
GAAGGAACT 
CTGCCCAAATCT
CCCACCAT 
GCTGATGGCTG
GAAGGAACT 
ATAGCCTTAGACC
ATGCCAAGGG 
Phusio
n 
KO ATAGCCTTAGACC
ATGCCAAGGG 
Phusio
n 
 
0
.3
9
  
T
tn
  
WT GGGTCTGATGG
TTCACTGGG 
GTACGAGTTCCG
AGTGAGGG 
GGGTCTGATGG
TTCACTGGG 
CCTTTGGTACGTT
CTAAGACTTT 
Phusio
n 
KO CCTTTGGTACGTT
CTAAGACTTT 
Phusio
n 
 
0
.3
3
  
C
e
p
1
2
0
  
WT TCTTGCTGTCTG
TGTGGCTT 
GACGCGCTGTG
CTCATTAAG 
GACGCGCTGTG
CTCATTAAG 
CCATTAGCACAGG
ATAAGACTAT 
Phusio
n 
KO CCATTAGCACAGG
ATAAGACTAT 
Phusio
n 
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C
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TPC2 
geno
type 
PCR: forward 
primer (5'-3') 
PCR: reverse 
primer  (5'-3') 
sequencing 
primer  (5'-3') 
potential off-target:  
Sanger sequencing 
(5'-3') 
polym
erase 
0
.2
9
  
R
3
h
c
c
1
l  
WT CTCTGATGGTGT
GCCTGGTT 
CCTGCCACTTCA
GCACCTTA 
CTCTGATGGTGT
GCCTGGTT 
ACGATCTTAGCCT
GTGCCAGAGG 
Phusio
n 
KO ACGATCTTAGCCT
GTGCCAGAGG 
Phusio
n 
 
0
.2
4
  
P
x
n
  
WT AGCGCTGTAGA
AGGGACCTA 
ACTGCTCATCTC
TCCCTGGT 
AGCGCTGTAGA
AGGGACCTA 
CCCTTGGCACGGT
CTCAGCCAGT 
Phusio
n 
KO CCCTTGGCACGGT
CTCAGCCAGT 
Phusio
n 
 
0
.2
0
  
T
ia
m
1
  
WT GCCCAAGGTGT
GTTTGCATT 
GTGGCTCAATG
GCTTCTCCT 
GCCCAAGGTGT
GTTTGCATT 
ACAGACCTAGCCC
GTGCCATTGG 
Phusio
n 
 KO ACAGACCTAGCCC
GTGCCATTGG 
Phusio
n 
 
0
.1
8
  
N
u
tf2
  
WT GCCTCGTGGGA
CTTTACCTC 
GATGGATGACCT
GAGGTGCC 
GCCTCGTGGGA
CTTTACCTC 
CCTATGGCACTGG
CTTAGACTGT 
Phusio
n 
KO CCTATGGCACTGG
CTTAGACTGT 
Phusio
n 
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n
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TPC2 
geno
type 
PCR: forward 
primer (5'-3') 
PCR: reverse 
primer  (5'-3') 
sequencing 
primer  (5'-3') 
potential off-target:  
Sanger sequencing 
(5'-3') 
polym
erase 
 
0
.1
5
  
P
lc
b
1
  
WT GCAGGGCACAT
AGAGATGGG 
TGACATCTTCCA
GAGGTGCTC 
GCAGGGCACAT
AGAGATGGG 
CCCATGTCATGGG
CTCAGACTGT 
Phusio
n 
KO CCCATGTCATGGG
CTCAGACTGT 
Phusio
n 
 
0
.1
3
  
T
e
a
d
1
  
WT CTCGCCTCTTTC
TAGCTGGG 
GAACCAGGCGG
AGGGTTAAA 
CTCGCCTCTTTC
TAGCTGGG 
AAAGTGTTAGCTT
GTGCCAAGGG 
Phusio
n 
KO AAAGTGTTAGCTT
GTGCCAAGGG 
Phusio
n 
 
0
.1
1
  
G
s
a
p
  
WT GGGCTTCACTG
CAGAACTCT 
CACACACTGCC
GTCTTACCT 
GGGCTTCACTG
CAGAACTCT 
CCTTTGACATGGG
CCAACACTGT 
Phusio
n 
KO CCTTTGACATGGG
CCAACACTGT 
Phusio
n 
 
Supplementary Table 2 I CRISPR-Cas9 off-target screening. The ten predicted off-target sequences present 
in exons or introns with the highest CFD scores for the 3' sgRNA were amplified by PCR and analyzed by 
Sanger sequencing. The investigated off-targets, sequences and the used primer pairs and polymerases are 
shown.   
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7.2 Abbreviations 
Abbreviation Term 
2-DG 2-deoxy-D-glucose 
ANOVA Analysis of variance between groups 
APS Ammonium persulfate 
ATP Adenoside 5'-triphosphate 
BBTHIQ bisbenzyltetrahydroisoquinoline 
BCRP Breast cancer resistance protein 
BSA Bovine serum albumin 
BTHIQ benzyltetrahydroisoquinoline 
cDNA Complementary DNA 
CFD Cutting Frequency Determination 
CFSE Carboxyfluorescein succinimidyl ester 
CoV Coronavirus 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CYP Cytochrome P450 enzyme 
DMEM  Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTE Dithioerythritol  
DTT 1,4-dithiothreitol  
EC50 Half-maximal effective concentration 
ECAR Extracellular Acidification Rate  
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EL endolysosomal 
eNOS Endothelial Nitric Acid Synthase 
ERK Extracellular signal-regulated kinase 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FLIM Fluorescence lifetime imaging 
FRET Förster resonance energy transfer 
GFP Green fluorescent protein 
gMFI Geometric mean of fluorescence intensity 
GRP78 Endoplasmatic reticulum chaperone BiP  
HAT Histone acetylase 
HCC Hepatocellular carcinoma 
HDAC Histone deacetylase 
HK II Hexokinase II 
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Abbreviation Term 
HPLC High Performance Liquid Chromatography 
HSP90 Heat shock protein 90 
HUH-R  Sorafenib-resistant HUH7 cells 
HUVECs Human Umbilical Vein Endothelial Cells 
IC50 half-maximal inhibitory concentration 
InDel Insertion or deletion of bases in the genome 
JNK c-Jun N-terminal kinase 
KCZ Ketoconazole 
KO Knockout 
MAPK Mitogen-activated protein kinase 
MDR Multidrug resistance 
MERS Middle East Respiratory Syndrome 
min Minute 
mRNA Messenger RNA 
NAADP Nicotinic acid adenine dinucleotide phosphate 
nd Not determined 
NMD Nonsense-mediated decay 
ns Not significant 
OCR Oxygen Consumption Rate 
OFP Orange fluorescent protein 
OXPHOS Oxidative phosphorylation 
PAGE polyacrylamide gel electrophoresis 
PARP Poly (ADP-ribose) polymerase 
PARP Poly (ADP-ribose) polymerase  
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PD-1 Programmed death receptor-1 
PD-L1 Programmed death receptor ligand-1 
P-gp P-glycoprotein 
PI(3,5)P2 Phosphatidylinositol 3,5-bisphosphate 
qPCR Quantitative real-time PCR 
rac Racemic 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
SARS Severe Acute Respiratory Syndrome 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
Ser  Serine 
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Abbreviation Term 
SERM Selective estrogen receptor modulator  
sgRNA Single guide RNA 
shRNA Short hairpin RNA 
T/E Trypsin/ethylenediaminetetraacetic acid  
TEMED Tetramethylethylenediamine 
tet Tetrandrine  
TPC Two-pore channel 
Tris Tris(hydroxymethyl)aminomethane 
UPR Unfolded protein response 
V-ATPase Vacuolar ATPase 
VCR Vincristine 
VCR-R Vincristine-resistant 
VEGF-A Vascular endothelial growth factor A 
VEGFR2 Vascular endothelial growth factor receptor 2 
WT Wildtype 
XF Extracellular Flux 
ZBG Zinc-binding group 
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